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Hepatocellular carcinoma (HCC) is the 5th most common cancer 
worldwide with an annual global mortality of ~700,000. HCC is a very 
complex disease and the role of miRNAs in HCC is not fully understood. In 
this study, we profiled miRNA expression in tumor versus paired adjacent 
non-tumor tissues from 100 HCC patients and identified a miRNA signature 
of 66 significantly (FDR<0.000) differentially expressed miRNAs associated 
with HCC. We subsequently characterized let-7a down-regulation and miR-
224 up-regulation. We demonstrated that hepatitis B virus X protein (HBx) 
down-regulates let-7a and let-7a negatively regulates cell proliferation through 
targeting Signal Transduction and Activator of Transcription 3 (STAT3). The 
HBx-let-7-STAT3 pathway supports cell proliferation in HBx-expressing cells. 
Additionally, we demonstrated that over-expression of miR-224 increases cell 
proliferation by targeting SMAD family member 4 (SMAD4) and sensitizes 
cells to apoptotic cell death by targeting Apoptotis Inhibitor 5 (API5). We 
observed statistically significant (p<0.05) inverse correlation between let-7a & 
STAT3, miR-224 & SMAD4 and miR-224 & API5 in HCC patients, 
demonstrating the clinical relevance of our observation. Therefore, our work 
contributed to the identification of miRNA deregulation in HCC and the 
understanding of the functional relevance of two such miRNA deregulations 
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CHAPTER 1: INTRODUCTION  
1.1 Hepatocellular carcinoma 
1.1.1 HCC epidemiology 
Hepatocellular carcinoma (HCC) is the primary cancer of the liver 
which is the fifth most common cancer among men worldwide and eighth 
among women (Figure 1.1.1) [1]. The distribution of HCC shows significant 
geographical variation. More than 80% of HCC cases occur in Asia and sub-
Saharan Africa while its incidence is relatively low but steadily rising in Japan, 
UK, Germany and USA over the past two decades (Figure 1.1.2) [2]. HCC is 
almost always lethal, with less than six months of survival time upon 
diagnosis and a median five year survival rate of 5-9 %. With more than 
700,000 deaths annually, HCC is ranked the third leading cause of cancer-
related deaths worldwide [3], posing a serious health and economic burden to 
the affected individuals and the countries. 
1.1.2 HCC etiology 
 HCC is a very heterogeneous disease with many etiologic factors. 
Table 1.1.2 summarizes the many viral and environmental factors associated 
with HCC. Chronic hepatitis viral infection with hepatitis B virus (HBV) 
and/or hepatitis C virus (HCV) is the dominant risk factor for HCC 
carcinogenesis. The impact of hepatitis virus infection on HCC varies greatly 
from region to region. HBV is implicated in approximately 80 % of HCC 
cases in Asia and sub-Saharan Africa where HBV infection is endemic and 10-




Figure 1.1.1 The incidence and mortality of the top ten most common 
cancers worldwide. Cancer incidence and mortality in more-developed and 
less-developed countries are plotted as bar charts and ranked according to 
overall incidence in males (top) and females (bottom) population. The liver 
cancer incidence in males and females are boxed in red.          







infection, which infects 2-3 million people each year, is particularly implicated 
in HCC in the more developed countries such as Japan and the USA. 
Worldwide, the proportion of HCC attributable to chronic hepatitis is about 
55 % for HBV and 30 % for HCV [3]. This is conservative estimate, as it only 
accounts for cases with detectable HBV surface antigen (HBsAg) in the blood 
stream and excludes cases with occult HBV infection, where there is persistent 
viral DNA with no release of HBsAg in the blood stream. Therefore, the 
overall contribution of hepatitis viral infection to HCC may be close to 90 %.  
1.1.3 HBV and HCC 
There are an estimated 400 million chronic HBV carriers worldwide, 
making HBV the single most important causal factor of HCC. 
HBV has a relaxed circular, partially double-stranded DNA genome of 
approximately 3.2 kilobase pairs (bp) in size (Figure 1.1.3). The HBV genome 
comprises four overlapping open reading frames (ORFs) in the minus DNA 
strand of the virus. These ORFs encode viral peptides including: the viral 
envelope (pre-S/S), the viral nucleocapsid or core (pre-core/core), viral 
polymerase and the X protein (HBx) [5].  
The mechanism of HBV in contributing to HCC is still not fully 
understood. Our current knowledge suggests that at least three overlapping 
mechanisms may be involved in HBV-associated HCC.  First, persistent HBV 
infection induces oxidative stress damage in hepatocytes, resulting in 
significant cell death and compensatory cell proliferation. This creates a 
deregulated and inflammatory environment in which the transformed cells will 





Figure 1.1.2 Incidence of liver cancer worldwide 2002. HBV is particularly 
prevalent in Asia and sub-Saharan Africa, as highlighted in intense red color. 




Table 1.1.2 Major etiologic factors associated with HCC. 
Major Etiologic Factors 
Hepatitis B virus infection  





























decreased sensitivity to apoptosis signals, favoring tumorigenesis. Second, 
even though HBV does not contain an integrase gene, the integration of HBV 
genome into host genome is still very frequently observed in HCC patients 
who are chronic HBV carriers.  Such integration events create opportunities 
for insertional mutagenesis to occur and this can potentially activate cellular 
proto-oncogenes to oncogenes or inactivate cellular tumor suppressor genes, in 
the vicinity of the integration point. Previous small scale studies have not 
identified any consensus HBV integration sites in the human genome. Third, 
the expression of HBV encoded proteins such as HBx has a significant impact 
on the host cellular gene expression and pathways. The HBx gene is the most 
common viral open reading frame integrated into the genome of HCC patients 
and the HBx protein is often found to be selectively over-expressed in the 
tumors of HCC [6-8].  HBx lacks a DNA binding domain and is widely 
believed to function as a promiscuous trans-co-activator by interacting with 
various cellular factors to deregulate many host genes such as tumor 
suppressor p53 (TP53) and v-myc myelocytomatosis viral oncogene homolog 
(avian) (c-Myc). HBx is also reported to activate a number of cellular 
signaling pathways such as mitogen-activated protein kinase (MAPK), Janus 
family tyrosine kinase (JAK)/signal transducer and activators of transcription 
(STAT) pathways [9, 10]. Hence, HBV contributes to HCC oncogenesis by 
impacting on multiple crucial cellular processes through a combination of 
highly complex mechanisms, resulting in the long term destabilization of 







Figure 1.1.3 Hepatitis B virus genome organization. The HBV genome is a 
partially double-stranded DNA with four overlapping open reading frames, 
Polymerase (P), Surface (S), Core (C) and X gene (X).                                  
(Source: http://en.wikipedia.org/wiki/File:HBV_genome.png, free license 




1.1.4 HCC prevention, detection and treatment  
 Since 1980s, safe and affordable HBV vaccine has been made 
available through recombinant technology. Mass vaccine programs have been 
shown to be effective at reducing the incidence rate of acute HBV infection 
and chronic HBV carriers, with a corresponding drop in HCC incidence in the 
vaccinated population [11]. As a result, World Health Organization (WHO) 
has recommended national HBV immunization programs for all countries in 
1992 and by 2002 more than 135 countries have included HBV vaccine in 
their national vaccination programs. Unfortunately, no equivalent vaccine is 
available for HCV. Reduction of risky behaviors and the improvement of 
hygiene standards are currently the main measures for prevention of HCV. 
Early detection of HCC has been difficult as the progression of HCC is 
largely asymptomatic. Currently, surveillance of HCC relies mainly on 
monitoring serial α-fetoprotein (AFP) levels and regular ultrasound or 
computed tomography (CT) examination [12]. A definitive diagnosis of HCC 
depends on histological analysis via fine needle biopsy. However, elevated 
AFP as a biomarker lacks specificity and the ultra-sound or CT scan is too 
costly for a general screening application. A simple plasma-based test will be 
an important contribution to HCC screening programs. 
 The only treatment modalities that consistently convey survival 
advantage to HCC patients are surgical resection and liver transplantation. 
Surgical resection is to remove a tumor together with surrounding liver tissue 
while preserving enough liver remnants for normal body function. This 
treatment offers the best prognosis for long-term survival, but unfortunately 
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only 10-15% of patients are suitable for surgical resection. This is often due to 
late stage presentation of HCC tumor at the time of diagnosis and associated 
poor liver function of the patients [13]. Resection in cirrhotic patients carries 
high morbidity and mortality. For better prognosis after resection, the expected 
liver remnant should be more than 25% of the total size for a non-cirrhotic 
liver and more than 40% of the total size for a cirrhotic liver. The overall 
recurrence rate after resection is 50-60% [14, 15]. On the other hand, liver 
transplantation is used as a curative therapeutic approach. However, this 
approach is very much limited by the low survival rate of patients post 
operation due to rejection and shortage of appropriate liver donors. Non-
surgical treatment of HCC such as chemotherapy, hormone therapy and 
radiotherapy has been largely disappointing. Regional therapies such as 
percutaneous alcohol injection (PEI) [16], radiofrequency ablation (RFA) [17] 
and transarterial chemoembolization (TACE) [18] are associated with too 
many side effects and doubtful long term benefits for HCC patients. They are 
mainly used as options for pre-resection treatment or prolonging survival time 
for liver transplantation. 
 The current limitation on the availability of easy detection and 
effective treatment measures highlights the urgent need to better understand 
HCC as a complex disease in the hope that novel targets for early detection 
and better treatment can be identified. Recent advances in microRNA (miRNA) 
research has presented this group of small non-coding RNAs as promising 
new targets where novel therapeutic and diagnostic strategies can be designed 




1.2 microRNA and cancer 
MiRNAs are a class of small non-coding RNAs of ~ 22 nucleotides in 
mature sequences and negatively regulate gene expression at the post-
transcriptional and/or translational level. They were first discovered by 
Ambros and colleagues in 1993 [19] when they studied  the larval 
development in C. elegans. Since then miRNAs have been shown to be 
abundantly expressed in viruses [20], plants [21] and animals [22]. According 
to the miRBase Release 15, there are a total of 14,197 miRNAs identified to 
date, out of which, 940 miRNAs are found in humans [23-25]. Many miRNAs 
show sequence and function conservation between distantly related organisms, 
suggesting that this class of small RNAs is an integral part of essential cellular 
processes [26]. For example, Lethal-7 (let-7) was discovered to be responsible 
for the developmental transition of L4 larvae to the adult cell fates [27] in C. 
elegans and later found to be evolutionarily conserved to regulate 
development in Drosophila, zebrafish, annelids, mollusks [26] and mouse [28]. 
The human let-7 family contains 12 homologue members. Despite their recent 
discovery, microRNAs represent a novel class of gene regulators that may 
have an ancient origin. Their discovery has opened up a new dimension in our 
understanding of gene regulation. 
1.2.1 miRNA biogenesis 
As illustrated by Figure 1.2.1, microRNAs are encoded in the genome and 
transcribed by RNA polymerase II as primary transcripts that are called pri-
miRNAs. Pri-miRNAs are typically 3 to 4 kilobase long single-stranded RNAs 
with 5’ cap, 3’ poly(A) tail and profound secondary structure [29, 30]. They 
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can contain one or more precursor miRNA (Pre-miR) sequences which are 
processed in the nucleus by microprocessor complex comprising of nuclear 
RNase III, Drosha, and the double-stranded RNA binding protein, 
Pasha/DGCR8, into ~70 nuceotide pre-miRNAs [29-31]. Pre-miRNAs are 
then actively exported to the cytoplasm through exportin-5 in association with 
RAN-GTPase [32, 33]. In the cytoplasm, another RNase III, Dicer, further 
processes the pre-miRNAs into ~ 22 nucleotide miR: miR* duplex [34, 35] of 
which one of the strands (miR strand) is incorporated into the multi-protein 
RNA induced silencing complex (miRISC) while the other strand (miR* 
strand) is degraded. This strand preference is probably due  to the difference in 
the thermodynamic stability of the strands [36]. In mammalian system, the 
functional miRISC carrying the mature miR can bind to the 3’untranslated 
region (3’UTR) of its target gene mRNA to result in either mRNA degradation 
(for nearly perfect complementary base-paring) or protein translation 
inhibition (for imperfect complementary base-paring). The mechanism of 
inhibition will depend on the miR sequence, the target mRNA sequence and 
the exact composition of the miRISC protein complex [37, 38]. 
1.2.2 miRNA and cancer 
The importance of microRNAs to cancer is highlighted by the 
observation that ~50% of miRNA genes are located in cancer associated 
genomic regions or fragile sites [39, 40], which are frequently amplified or 
deleted in tumorigenesis. Global repression of microRNA processing 
machinery (Drosha, Pasha/DGCR8 and Dicer1) promotes cellular 
transformation and miRNA processing-impaired cells formed tumors with 





Figure 1.2.1 micoRNA biogenesis.  miRNAs are transcribed from their 
genomic loci as long primary transcript miRNA, Pri-miRNAs, which are 
processed to hairpin-looped precursor miRNAs, Pre-miRNAs, in the nucleus. 
Pre-miRNAs are then actively transported into the cytoplasm where they will 
be processed by Dicer to generate mature miRNAs to be loaded into the multi-
protein miRNA induced silencing complex (miRISC). 
Source: http://en.wikipedia.org/wiki/File:MiRNA-biogenesis.jpg#filehistory, 
licensed under Creative Commons Attribution-ShareAlike 3.0 License. 
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in cancer-related processes [41]. Large-scale microRNA expression profiling 
of human cancers have revealed that miRNA deregulation is frequently 
associated with many cancer types originating from the blood [42-47], brain 
[48-50], thyroid [51-53], breast [54], lung [55-57], tongue [58], nose and 
pharynx [59], liver [60-63], the gastro-intestinal system (esophageal cancer 
[64], gastric cancer [65], pancreatic cancer [66, 67] and colorectal cancer [68, 
69]) and genitor-urinary system (cervical cancer[70], ovarian cancer [71, 72] 
and prostate cancer[73, 74]).  
Table 1.2.2 summarizes our current knowledge on miRNA expression 
profiles in various human cancers. In these studies miRNA expression in 
tumors is compared against the paired non-tumorous tissues from cancer 
patients and significantly up- and down-regulated miRNAs are indicated with 
red/up-arrows and green/down-arrows respectively. More than one quarter of 
known human miRNAs (175 out of 678 miRNAs) have been reported to be 
de-regulated in at least one cancer type. This is only a gross underestimation 
as the majority of the known miRNAs are only identified in recent years and 
not included in previous miRNA expression profiling studies. This places 
microRNAs as the largest class of gene regulators implicated in cancer-related 
processes and of which we still know very little about. Table 1.2.2 has also 
revealed some interesting patterns of miRNA expression in cancers. Of these 
cancer-implicated miRNAs, miR-21 is the most commonly up-regulated 
miRNA in both solid and hematological tumors, consistent with the report in 
2006 by Volinia et al [74]. In addition, miR-155, miR-181b, miR-221 and 
miR-222 are also frequently up-regulated in cancers of the blood, brain, 
thyroid and the gastro-intestinal (GI) systems, and to a lesser extent in liver  
14 
 
Table 1.2.2 miRNAs that are differentially expressed in human cancers 





Table 1.2.2 continued: miRNAs that are differentially expressed in human 




cancer, lung cancer and breast cancer. In contrast, the let-7/miR-98 cluster is 
commonly down-regulated in tumors of the thyroid, breast, lung, upper GI and 
the genitor-urinary system. Similarly miR-143 and miR-145 are frequently 
down-regulated in the hematological tumors and solid tumors of the breast, 
lung, prostate and the lower GI system. Such common deregulation of miR 
expressions across various tumor types suggests that these miRNAs may be 
involved in crucial cellular pathways that are commonly deregulated in cancer 
development. Indeed, functional studies have demonstrated that let-7/miR-98 
negatively regulates Rat sarcoma viral oncogene homolog (RAS) [75] and v-
myc myelocytomatosis viral oncogene homolog (avian) (MYC) [76] whilst 
miR-21 negatively regulates Phosphatase and tensin homolog (PTEN) [60] 
and Programmed cell death 4 (PDCD4) [77], which are important cellular 
proto-oncogenes or tumor suppressors that regulate cell growth, cell 
proliferation and apoptosis. The deregulation of these important cellular 
processes represents an important hallmark of cancer. Other than the common 
deregulation of miRNAs, we can also identify some tumor type specific 
pattern of miR expression in Table 1 as well. The miR-17-92 cluster and miR-
93 are frequently reported to be up-regulated mainly in cancers of the GI 
system. A higher proportion of miRNAs were reported to be up-regulated in 
thyroid tumors whilst a greater percentage of miRNAs were reported to be 
down-regulated in nasopharyngeal cancer and cancers of the genito-urinary 
system. This suggests that some tumor-specific mechanisms may be in place 
to favor a specific miR profiles depending on the tumor micro-environment.  It 
is also worth noting that miR-105, miR-144, miR-193 and miR-199b are 





































































































































































































discovery, suggesting that these miRNAs probably take part in cellular house-
keeping processes that have little role in oncogenesis. 
Although much is known about the aberrant miR expression pattern 
associated with various cancers, much less is known about the functional 
relevance of such miR deregulation or the in vivo miR targets. Table 1.2.2 also 
summarizes a total of 65 non-overlapping experimentally validated miR direct 
cellular targets reported to date [49, 59-61, 63, 71, 75-124]. Functional 
annotation with Gene Ontology (GO) and KEGG pathways reveals that these 
65 validated miRNA target genes show a significant enrichment in the 
classical cancer-associated pathways such as transcription, cell-cell adhesion 
and signaling, cell cycle regulation, cell proliferation and apoptosis, strongly 
implying that the deregulation of these miRNA target genes may play 
significant roles in carcinogenesis. However, as predicted by miR target 
prediction algorithms (miRanada[24], PicTar[125] and TargetScan[126]), each 
individual miRNA can potentially regulate hundreds of cellular gene targets 
and the identification of these in vivo miRNA targets still represent a real 
challenge to the comprehensive understanding the miRNA regulated networks 
that impact significantly in cell differentiation, cell proliferation and 
apoptosis[127].  
1.2.3 microRNA implication in HCC 
 1.2.3.(1) microRNA deregulation is frequently observed in HCC 
Like other cancers, aberrant microRNA expression features significantly in 
HCC. Since Murakami et al. first reported miRNA deregulation in human 
HCC in 2006, a total of 14 publications on comprehensive profiling of miRNA 
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expression in HCC have been reported in reputable journals (Table 1.2.3.(1)) 
[60-63, 128-137]. HCC patient samples included in these 14 studies are from 
diverse geographic origins with very different etiologies of HCC, such as 
China (5 studies), France (2 studies), Germany (1 study), Italy (1 study), Japan 
(2 studies), Singapore (1 study) and United States (2 studies). Expression of 
hundreds of miRNAs has been examined between HCC tumor samples and 
either paired adjacent non-tumor samples, unpaired non-tumor or cirrhotic 
liver samples or normal liver samples, utilizing different profiling technologies 
such as bead-based flow, reverse transcription quantitative PCR, miRNA 
cloning or microRNA microarrays.  
Table 1.2.3.(2) summarizes the list of aberrantly expressed miRNAs in 
HCC as reported by these 14 studies. A total of 147 miRNAs have been shown 
to be deregulated in HCC by at least one of the 14 studies. 80 of these 147 
miRNAs (~55 %) are reported by a single study where 67 of them (~45 %) 
have been reported to be deregulated in HCC by at least two studies. The 
pattern of deregulation for 41 of these 67 miRNAs (~61 %) has been 
consistent while discrepancies in reported deregulation exist for the remaining 
26 miRNAs (~39 %). These diverse miRNA signatures may be a result of the 
highly heterogeneous makeup of HCC patients included in the different 
studies, differing greatly by their etiologic factors based on the geographical 
origins and ethnicity, compounded by the difference in number of miRNAs 
included in each study and the profiling methods used.  This re-emphasizes the 
complexity of HCC as a disease and much effort is needed to elucidate the role 




Table 1.2.3.(2) List of microRNAs deregulated in HCC. 
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1.2.3.(2) Deregulated miRNAs in HCC impacts cellular functions  
MiRNAs which have been consistently reported to be aberrantly 
expressed by multiple studies, irrespective of the nature of the patient samples 
or the profiling technologies, are most likely to be involved in hepatocellular 
carcinogenesis. Table 1.2.3.(3) summarizes the 26 miRNAs which have been 
consistently reported by three or more studies.  Virtually all of the 26 miRNAs 
have been reported to be deregulated in at least one other type of cancer 
(Review [138]), suggesting a panel of miRNAs may be needed to achieve 
specificity for characterizing HCC. Table 1.2.3.(3) also summarizes a total of 
175 experimentally validated cellular miRNA targets for these 26 miRNAs, 
out of which 161 are non-overlapping targets [59-61, 63, 71, 88, 89, 109-111, 
116, 118-120, 136, 137, 139-240]. Many of these miRNA targets are very 
crucial cellular genes such as RAS (miR-214), MYC (miR-145) and PTEN 
(miR-21, miR-214 and miR-221/222) whose deregulation will have 
detrimental effect on the cell.  Functional annotation of these miRNA targets 
with Gene Ontology (GO) has revealed significant enrichment in cancer-
implicated cellular processes such as cell proliferation, cell death and cell 
differentiation, in favor of tumorigenesis [241]. Hence, miRNA deregulation 
can play an important role in hepatocellular carcinogenesis by interfering with 
biological and molecular functions of the cell. 
1.2.3.(3) microRNAs as prognostic and diagnostic markers for HCC 
Current classification of HCC replies exclusively to clinical parameters 
and miRNA profile may have the potential to improve our ability to classify 





























































to be able to differentiate liver samples based on histology (hepatocellular 
adenoma from HCC), etiology (alcohol induced HCC from HBV associated 
HCC) and cancer gene mutation (β-catenin and hepatocyte nuclear factor 1α) 
[131].  Recently, a signature of 20 miRNAs has been shown to associate with 
HCC metastasis and correlates with overall survival [242]. Furthermore, high 
miR-221 levels in HCC were associated with tumor multifocality and reduced 
time to recurrence after surgery [226] and high miR-222 level negatively 
correlates with disease free survival [137]. These promising early studies 
suggest that miRNA profiling, in combination with existing clinical 
parameters, may provide additional information on HCC classification and 
prognostic risk stratification and help oncologists make better informed 
decisions.  
The easily detectable, serum bound miRNAs are good candidates to 
screen for specific biomarkers to improve existing screening strategies for 
early HCC detection. Significant differences in blood miRNA expression can 
be detected and associated with well-controlled liver tumorigenesis in a mouse 
model [243]. In human HCC, miR-500 is reported to be elevated in the sera of 
HCC patients and returned to normal after surgical resection [244]. MiR-500 
and others represents potential diagnostic markers for HCC detection.  
As miRNAs play an important role in HCC, they represent promising 
therapeutic targets for novel treatment strategies for HCC patients. Exciting 
data have emerged in the use of antagomirs which are chemically modified 
oligonucleotides to specifically and effectively knock down miRNA 
expression. Systemic delivery of antagomirs against miR-122 has resulted 
remarkably specific and stable down-regulation of miR-122 in the liver up to 
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20 days [245]. As miR-122 promotes HCV replication, knock-down of miR-
122 may provide a novel approach to manage HCV load in HCV-associated 
HCC. Recently Kota et al demonstrated the efficacy of the systemic delivery 
of miR-26a in an adeno-associated virus vector to protect disease progression 
without toxicity in a mouse liver cancer model [246-248], opening new doors 
to miRNA replacement therapy. 
 
1.3 Aims and significance of this study 
At the time when this project started, microRNAs were only starting to 
gain recognition as functional molecules with meaningful biological functions. 
MicroRNA deregulation was first reported in acute myeloid leukemia [43, 44] 
but very little was known about its status in human HCC. Therefore, in this 
thesis, we aim to: 
1. Profile miRNA expression of tumor versus adjacent non-tumor 
samples from local HCC patients to identify significantly 
differentially expressed miRNAs in HCC. 
2. To functionally characterize these significantly differentially 
expressed miRNAs to understand their roles in HCC. 
3. To identify the cellular targets through which these deregulated 
miRNAs impact cellular processes. 
We hope our work will contribute to improve the understanding of 
HCC from a fresh perspective of miRNA deregulation and offer novel 
approaches to treat this complex disease.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Cell lines  
The immortalized untransformed human liver cells, THLE3, was 
purchased from American Type Culture Collection (ATCC) and cultured in 
ATCC complete growth medium consisting of BEGM® Bronchial Epithelial 
Cell Growth Medium (CC-3170, Lonza) without gentamycin/amphotericin 
(GA) and epinephrine, supplemented with additional 10 ng/ml epithelial 
growth factor (EGF), 200 ng/ml O-phosphoethanolamine and 10% fetal 
bovine serum (FCS, Bio-industries). THLE3 cells were grown on surfaces 
precoated with rat tail collagen type I (BD). 
The human hepatocellular carcinoma cells, HepG2 and SNU-182, and 
the human embryonic kidney cells, HEK293, were purchased from ATCC and 
cultured in Dulbecco’s modified Eagle’s media (DMEM) supplemented with 
25 mM HEPES (Invitrogen) and 10 % FCS. The human colorectal carcinoma 
cells, HCT116, was purchased from ATCC and cultured in Modified McCoy’s 
5A Medium (Sigma) supplemented with 2.2 g/L sodium bicarbonate and 10 % 
FCS. All cells were incubated at 37 °C in a humidified atmosphere with 5 % 
CO2. 
 
2.2 Patient samples 
Paired tumorous and adjacent nontumorous liver tissues from 100 
hepatocellular carcinoma patients were obtained from the National Cancer 
Centre of Singapore Tissue Repository with prior approval from the National 
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Cancer Centre (NCC) Institutional Review Board (IRB) (NCC IRB No: 
NC08-12).  As it is ethically not possible to obtain normal livers from healthy 
individuals, the ‘normal’ non-tumorous portion of the livers from 40 colorectal 
cancer patients with metastasis to the liver was obtained when these patients 
undergo surgery to remove the colorectal metastatic tumor in the liver.  These 
tissues were also obtained from the National Cancer Centre of Singapore 
Tissue Repository with prior approval from the National Cancer Centre (NCC) 
Institutional Review Board (IRB) (NCC IRB No: NC05-022).  These non-
tumorous livers from colorectal cancer patients represent ‘normal’ liver in our 
study. 
 
2.3 Total RNA extraction  
Total RNA including low molecular weight (LMW) RNAs were extracted 
with mirVanaTM microRNA Isolation Kit (Ambion) following manufacturer’s 
instructions. Briefly, 1x106 cells or 0.3 g of homogenized patient tissues were 
lysed in 500 µl of lysis buffer and 50 µl of miRNA homogenate additive and 
incubated on ice for 10 minutes. The lysate were then passed through a 
collection column. The columns were washed once with 600 µl of Wash 
Buffer 1, twice with 500 µl Wash Buffer 2/3 and once with 700 µl of 80 % 
ethanol in nuclease free water, by centrifuging briefly at 10,000 rpm.  The 
columns were then dried by centrifuging at 13,000 rpm for an additional 
minute and the total RNA including LMW RNAs were then eluted with 50 µl 




2.4 microRNA expression profiling in HCC patients 
Total RNA extracted from tumor and paired adjacent non-tumor 
tissues from 117 HCC patients were first checked for quality using the Agilent 
2100 Bioanalyzer. RNA Integrity Number (RIN) was calculated for each 
sample. A RIN number of 10 indicates high RNA quality, and a RIN number 
of 1 indicates low RNA quality. According to published data, RNA with a 
RIN number > 6 is of sufficient quality and 100 out of 117 pairs of HCC 
samples were processed for miRNA microarray experiments[249]. The HCC 
tumor samples were labeled with Hy5 (red) and the paired adjacent non-tumor 
samples were labeled with Hy3 (green) according to the undisclosed 
miRXploreTM user manual. Subsequently, the fluorescently labeled samples 
were hybridized overnight to miRXploreTM Microarrays using the a-HybTM 
Hybridization Station. Fluorescence signals of the hybridized miRXploreTM 
Microarrays were detected using an Agilent laser scanner. Mean signal and 
mean local background intensities were obtained for each spot of the 
microarray images using the ImaGeneâ software (Biodiscovery). Low-quality 
spots were flagged and excluded from data analysis. Unflagged spots were 
analysed with the PIQORTM Analyzer software. The PIQOR Analyzer allowed 
automated data processing of the raw data text files derived from the ImaGene 
software. This included background subtraction to obtain the net signal 
intensity, data normalization, and calculation of the Hy5/Hy3 ratios for the 
species of interest. As an additional quality filtering step, only spots/genes 
were taken into account for the calculation of the Hy5/Hy3 ratio that have a 
signal that was equal or higher than the 50 % percentile of the background 
signal intensities. The above steps were performed by Miltenyi Biotec 
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microarray servicing facility in Germany and normalized ratios of tumor vs 
paired adjacent non-tumor samples were returned to us for further analysis. 
Significance Analysis of Microarrays (SAM) [250] was then utilized to 
identify miRNAs that displayed significantly differential expression between 
the tumor and adjacent non-tumorous liver tissues of HCC patients, at a false 
discovery rate (FDR) of less than 0.05 and an absolute SAM score of more 
than 2.5. 
 
2.5 Validation of let-7 down-regulation and miR-224 up-regulation 
in HCC patients 
2.5.1 Reverse transcription quantitative polymerase chain reaction (RT-qPCR) 
The expression of specific miRNAs identified to be significantly 
differentially expressed in HCC was validated with Taqman-based RT-qPCR 
using Taqman MicroRNA Individual Assays (hsa-let-7a, hsa-let-7b, hsa-let-7c, 
hsa-miR-224, RNU48, Applied Biosystems). Reverse transcription reaction 
was carried out on 75 ng of template total RNA with the High Capacity cDNA 
Archive Kit (Applied Biosystems) and miRNA specific reverse transcription 
primers. The reaction mixture was incubated at 16 °C for 20 minutes for 
primer annealing and this was followed by reverse transcription at 42 °C for 
one hour, deactivation at 85 °C for 5 minutes and pause at 25 °C. Real-time 
PCR was performed in a 10 µl reaction mix comprising 2 µl of 2X diluted 
reverse transcription product, 5 µl of Taqman 2X Universal PCR Master Mix 
without UNG Amperase, 2 µl of miRNA specific probes and primers and 1 µl 
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of nuclease free water, on an Applied Biosystems 7500 Real Time PCR 
system, with an initial denaturation step at 95 °C for 10 minutes, followed by 
40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. Fluorescence signal 
was measured at each extension step. 
2.5.2 Northern blot analysis  
Northern blot analysis was performed to further validate miR-224 
over-expression in the tumors of HCC patients.  Briefly, 1 g of total RNA 
(HCT116 cells transfected with Pre-miRTM miR-224 precursor as positive 
controls) or 2 g of low molecular weight RNA from both the tumor and 
adjacent non-tumorous tissues of selected HCC patients that were previously 
profiled was separated on a 15 % denaturing polyacrylamide gel and electro-
blotted onto a nylon membrane (Schleicher & Schuell GmbH, Dassel 
Germany) at 300 mA for 30 minutes. The miRNA-224 probe (5’-
TAAACGGAACCACTAGTGACT TG-3’ [62]) and U6 probe (5’-
ATGTGCTGCCGAAGCGAGCAC -3’) were end-labeled with Redivue γ-32P 
ATP (Amersham Biosciences, UK) using T4 Polynucleotide Kinase (NEB, 
Ipswich, MA) and purified using the Nucleotide Removal Kit according to the 
manufacturer’s instructions (Qiagen GmbH, Germany). Hybridization was 
performed using Express Hybridization solution (Clontech, Mountain View, 
CA) at 42 °C for 16 hours, and the blots were exposed to Hyperfilm MP 





2.6 Western blot quantitation of hepatitis B virus protein X (HBx) 
status in HCC patients 
HBx protein level in tumor and non-tumor samples from HCC patients 
was measured through Western blot analysis with a specific rabbit anti-HBx 
polyclonal antibody generated against full-length HBx by our lab. Briefly, 
tissue samples from HCC patients were first homogenized and lysed with 
RIPA (150 mM NaCl, 50 mM Tris-HCl pH 7.0, 1 % Deoxycholate, 1 % NP40, 
0.1 % SDS) buffer supplemented with protease inhibitor cocktail (Roche, 
Germany), sonicated at 30 seconds on and 30 seconds off for a total time of 10 
minutes in a Bioruptor (Diagenode, Belgium) with high settings and 
centrifuged at 13,000 rpm for 5 minutes to collect total cell lysate. 20 μg of 
total protein lysates were resolved on a 12 % SDS-PAGE gel and transferred 
onto a polyvinylidene difluoride (PVDF) membrane. The blots were blocked 
with 2 % ECLTM advanced blocking agent (GE health) in 1X phosphate 
buffered saline with 0.1 % Tween-20 (PBST) for one hour and probed with 
rabbit-anti-HBx at a dilute of 1:10,000 and goat-anti-β-actin 1:40,000 (Santa 
Cruz, USA) and horseradish peroxidase (HRP) conjugated goat-anti-rabbit or 
rabbit-anti-goat secondary antibody, respectively, at a dilute of 1:100,000 
(Pierce). The blots were then washed and visualized with Enhanced 
Chemiluminescence Reagent Kit (ECL, Amersham Bioscience) in a Biomax 
machine (Kodak, USA). The intensity of the HBx protein Western blot signal 
was quantified with AlphaImager 2000 software and normalized against that 
of beta-actin of the same sample. Relative fold change of HBx was calculated 
as the ratio between the normalized HBx expression in tumor and non-tumor 
samples in Log2 scale. 
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2.7 Recombinant adenovirus propagation, titration, optimization 
and transduction 
 Recombinant adenovirus carrying the full length HBx gene (AdHBx) 
and the control adenovirus (AdControl) was previously constructed in our lab 
and reported to achieve > 90 % transduction efficiency with minimal 
cytotoxicity [251] (Figure 2.7A). 
2.7.1 Virus propagation 
AdHBx and AdControl recombinant adenovirus were propagated in the 
packaging HEK293 cells. Briefly, HEK293 cells were seeded into 175 cm2 
tissue culture flasks and grown to ~70 % confluency. Stock AdHBx or 
AdControl viruses were used to infect these HEK293 cells at a multiplicity of 
infection (MOI) ratio of 1:1. 72 hours post transduction, infected cells were 
harvested and suspended in 1 ml PBS per 175 cm2 flask. Total cell content 
containing the propagated viruses was extracted by three repeated cycle of 
freezing in liquid nitrogen and thawing at 37 °C and centrifuged at 10,000 g to 
remover cell debris. The supernatant was the freshly prepared virus stock and 
stored at -80 °C in 100 µl aliquots.  
2.7.2 Virus titration 
 HEK293 cells were seeded into 24 well plates and grown to 60 % 
confluency. Freshly prepared AdHBx or AdControl virus stock were serially 
diluted to 10-5 to 10-9 per ml and used to transduced the HEK293 cells in 4 
wells for each dilution and 4 wells were left untransduced. The titer of the 
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virus (expression-forming units/ml) was evaluated by counting the number of 
fluorescent cells 48 hours after transduction with serially diluted viruses. 
2.7.3 Virus transduction optimization 
 HepG2 cells were seeded into 6 well plates and grown to 60 % 
confluency. Appropriately titrated AdHBx or AdControl viruses were used to 
transduce HepG2 cells at MOI of 0, 1, 2, 5, 10 and 25 virues to each cell. 
Transduction efficiency was assessed as the percentage of green fluorescent 
cells with respect to the total number of cells, as seen from a fluorescence 
microscope, 48 hours post transduction (Figure 2.7B). Cytotoxicity was 
assessed by comparing the cell death and cell growth of infected cells at 
various MOI to the uninfected cells. Western blot analysis with specific rabbit-
anti-HBx (1:10,000), goat-anti-beta-actin (1:40,000) and mouse-anti-enhanced 
green fluorescent protein (EGFP) (1:40,000) were used to assessed the 
expression of HBx and EGFP in the infected cells. Best MOI of 10:1 for 
AdHBx virus was determined as one at which there is significant HBx 
expression with > 90 % transduction efficiency and minimal cytotoxicity. Best 
MOI of 5:1 for AdControl virus was determined as one at which similar level 
of EGFP is observed in AdControl cells with similar transduction efficiency, 
compared to the AdHBx cells with the optimized MOI. 
2.7.4 Virus transduction for miRNA microarray 
HepG2 cells were transduced with AdHBx or AdControl recombinant 
adenovirus at a MOI of 10:1 and 5:1, respectively. Cells were harvested 72 
hours post transduction. Total RNA was extracted as previously described 



















Figure 2.7 Optimization of recombinant adenovirus transduction. (A) 
Recombinant adenovirus can achieve high transduction efficiency with 
minimal cytotoxicity. (B) Composite image of HepG2 cells transduced with 
recombinant adenovirus (AdControl or AdHBx) at various MOI as indicated. 
“C” denotes AdControl and “X” denotes AdHBx. The number denotes the 
MOI used. (C) Western blot analysis of EGFP, HBx and β-actin in HepG2 






2.8 microRNA expression profiling in HBx expressing HepG2 cells 
A total of 286 human microRNAs were examined between AdControl 
and AdHBx transduced HepG2 cells, using Ambion mirVanaTM Bioarray V2 
version 7.1 following manufacturer’s instructions (Ambion, USA). Briefly, 
low molecular RNA were enriched from 20 µg of total RNA samples in a 
FlashPAGETM fractionator (Ambion, USA) and the <40 nucleotide-long RNA 
were recovered with sodium acetate/ethanol and precipitated at -20 °C 
overnight.  The enriched low molecular RNA from HBx-expressing samples 
were labeled with Cyanine-5 (Cy-5) while that from the control samples were 
labeled with Cyanine-3 (Cy-3) with ULS™ Small RNA Labeling Kit 
according to manufacturer’s instructions (Kreatech, Netherlands).  The Cy-5 
and Cy-3 labeled samples were then mixed in equal amount and hybridized 
onto the mirVanaTM bioarrays at 42 °C overnight. The hybridization signals 
were detected in dual colours with a GenePix 4000B scanner and quantitated 
with GenePix Pro 6.0 (Molecular Devices, Canada). The miRNA expression 
in HBx- versus control cells were profiled in three independent experiments 
using three separate bioarrays. Raw data from the two-colour miRNA 
microarrays  were normalized with locally weighted scatterplot smoothing 
(LOWESS) algorithms with GeneSpring GX Software version 7.3 (Agilent 
Technologies).  Significantly expressed miRNAs were identified as those with 
foreground signal intensity greater than the background intensity plus 3 
standard deviations. Significantly differentially expressed miRNAs between 
HBx-expressing cells and control cells were determined using a Volcano Plot 
with threshold set at absolute mean fold change of greater than 1.5 and p-value 
of less than 0.01. 
35 
 
2.9 Transfection of small oligos into cell lines  
2.9.1 Chemical transfection 
HCT116 or THLE3 cells were seeded into 6 well plates and grown to 
50% confluency. siPORTTM Amine Transfection Reagent (Ambion) was used 
to transfect small oligos such as Control Oligos, miRNA precursors and 
miRNA inhibitors in a final concentration of 30 nM according to 
manufacturer’s recommendations. Table 2.9 listed the small oligos used in this 
study. Briefly, 9 µl of siPORT Amine were mixed with 1ul of 50 uM stock 
oligos in 200 µl of OptiMEM I (Invitrogen) medium and incubated at room 
temperature for 30 mins. These 210 µl reaction mixture was then added into 
individual wells containing 1.5 ml of normal growth medium each and 
incubated overnight.  
2.9.2 Electroporation 
2x106 HepG2 cells were electroporated with 50 nM of Control oligos, 
let-7a precursor, let-7a inhibitor or siRNA against STAT3 in 200 µl of 
OptiMEM I (Invitrogen, USA) at 175 V for 100 ms in a BTX Electro Square 
Porator 830 (BTX, USA). Cells were harvested 24 hours post electroporation 









2.10 Generation of 3’UTR reporter constructs 
The 1080 base pairs of wild type STAT3 3’UTR was amplified from 
human genomic DNA and cloned downstream a β-galactosidase reporter gene 
driven by multidrug resistance associated gene (MRP1) promoter at the SacII 
restriction site (Figure 3.2.5.(1)A). The human MRP1 promoter was chosen 
over the constitutive human cytomegalovirus (CMV) promoter, because the 
MRP1 promoter is ~30 times weaker than the CMV promoter which will 
facilitate the measurement of subtler changes in reporter gene activity. The 
reporter construct also carried a CMV promoter driven enhanced green 
fluorescence protein (EGFP) to normalize for differences in transfection 
efficiencies. The recombinant reporter vector carrying the wildtype STAT3 
3’UTR was termed pSTAT3-3UTR-WT. A mutant pSTAT3-3UTR-MUT, 
where the putative let-7 binding site was mutated, was also generated by PCR 
mutagenesis. The cloning strategies and primers used were listed in Figure 
2.10.1A&B. The mutant site was verified in silico not to bind to known human 
miRNAs using miRBase (Release 12.0). Both constructs were verified by 
sequencing (Figure 2.10.1C). 
As outlined in Figure 2.10.2, using a similar strategy, the 2015 bp 
wildtype API5 3’UTR was amplified from human genomic DNA and cloned 
into the same backbone β-galactosidase reporter construct (pAPI5-3UTR-WT) 
as described above (Figure 3.3.5.(1)A). A mutant pAPI5-3UTR-MUT was 
also generated by PCR mutagenesis where three point mutations were 
generated on each of the three miR-224 target recognition sites.  The 1310 bp 
wildtype SMAD4 3’UTR was amplified from non-tumorous human liver 
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tissue and cloned into the reporter construct (pSMAD4-3UTR-WT) (Figure 
3.3.8.(1)A). A mutant pSMAD4-3UTR-MUT, where the two putative miR-
224 binding sites were abolished through point mutations, was also generated 
by PCR mutagenesis. All mutant recognition sites were verified in silico not to 
bind to any of the known human miRNAs using miRBase.  All reporter 
constructs generated were confirmed by sequencing. 
 
2.11 Characterization of miRNA interaction with putative binding 
sites on target gene 3’UTR through 3’UTR β-galactosidase assay 
HCT116 cells were transfected in 6-well plates by using siPORT™ 
Amine Transfection Agent (Ambion, Austin, TX) according to the 
manufacturer’s instructions with either 1.0 μg of the β-gal reporter construct 
containing the wild type target gene 3’UTR sequences (pSTAT3-3UTR-WT, 
pAPI5-3UTR-WT or pSMAD4-3UTR-WT), or the corresponding β-gal 
reporter construct containing the mutant target gene 3’UTR sequences 
(pSTAT3-3UTR-MUT, pAPI5-3UTR-MUT or pSMAD4-3UTR-MUT); and 
co-transfected with either 30 nM of Control Oligos or miRNA precursors 
(Ambion Pre-miRTM hsa-let-7a or hsa-miR-224 precursor molecules). β-gal 
reporter gene activity was assayed kinetically using chlorophenol red-β-D-
galactopyranoside (CPRG) as a substrate and measured at 1 minute intervals 
over 60 minutes at 570 nm in a SpectraMAX PLUS microplate reader 
(Molecular Devices, Sunnyvale, California, USA) with crude lysate from the 


















Figure 2.10.1 Generation of STAT3 3’UTR reporter constructs. (A)  
Strategy for the generation of mutations at the let-7 binding site of STAT3 
3’UTR. (B) Primers used for the generation of mutations at the let-7 binding 
site of STAT3 3’UTR.  (C)  Product of the mutagenesis that was used to clone 



































Figure 2.10.2 Generation of API5 and SMAD4 3’UTR reporter constructs. 
(A)  Strategy for the generation of mutations at the miR-224 binding site of 
API5 3’UTR. (B) Primers used for the generation of mutations at the miR-224 
binding site of API5 3’UTR.  (C)  Strategy for the generation of mutations at 
the miR-224 binding site of SMAD4 3’UTR. (D) Primers used for the 
generation of mutations at the miR-224 binding site of SMAD4 3’UTR.   
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To normalize for differences in transfection efficiencies, Western blot analyses 
were performed using mouse anti-EGFP (Roche Diagnostics) at 1:40,000 
dilution and HRP-conjugated goat anti-mouse (Pierce Biotechnology) 
secondary antibody at 1:100,000. β-gal activity was then normalized against 
EGFP expression levels.  The data was also normalized against differences in 
basal β-gal activity of each construct in the absence of any miRNA oligos. 
 
2.12 Functional assays 
2.12.1 Apoptosis assay 
HepG2 cells were transduced with recombinant HBx or control 
adenovirus as mentioned above. 48 hours post transduction, the Control cells 
or HBx cells were treated with either 20µM of control inhibitor (z-FA-FMK, 
550377,BD Pharmingen) or 20µM of general caspase inhibitor (z-VAD-FMK, 
550377, BD Pharmingen) for an additional 24 hours. The apoptotic profile of 
these treated cells were then assayed with PE-Annexin V Apoptosis Kit I (BD 
Bioscience) according to manufacturer’s protocol and analyzed with FACS-
Calibur flow cytometer (BD Biosciences).  Apoptotic cells were represented 
by high PE-Annexin V and low 7-AAD fluorescence signals.   
HCT116 cells were transfected using siPORTTM Amine Transfection 
Agent with either 60 nM Control or 30 nM miR-224 precursor and 30 nM 
Control or 30 nM miR-224 precursor and 30 nM Anti-miRTM miR-224 
inhibitor (miR-224 inhibitor (AM17000, Ambion). Apoptosis assay was 
performed 48 hours post transfection as described above. 
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2.12.2 Cell proliferation assay 
Cell proliferation of HepG2 cells transfected let-7a precursors or 
transduced with recombinant adenoviral vectors was measured with Cell 
Proliferation Reagent (WST-1) (Roche, Germany) according to supplier’s 
protocol. Briefly, 10,000 treated cells were seeded in a 96-well flat bottom 
tissue culture plate and incubated with WST-1 for 2 hours. Cell proliferation 
was measured as the absorbance at OD440 in a VersaMaxTM Microplate Reader 
(Molecular Devices, USA). 
Cell proliferation of HCT116 cells transfected with miR-224 
precursors was assayed using the BrdU cell Proliferation Assay kit 
(Calbiochem, San Diego, USA) following the manufacturer’s protocol.  BrdU 
incorporation measured as absorbance at OD450 in a SpectroMAX PLUS 
microplate reader (Molecular Devices, Sunnyvale, California, USA) 48 hours 
after BrdU incubation. 
 
2.13 Reverse transcription quantitative real-time PCR analysis 
 The differential expression of mature miRNAs was validated using 
Taqman MicroRNA Individual Assays (Applied Biosystems). Each sample 
was analyzed in triplicates. Reverse transcription reaction was carried out on 
75 ng of template total RNA using the High Capacity cDNA Archive Kit 
(Applied Biosystems) and miRNA specific reverse transcription primers . 
Real-time PCR was performed in a 10 µl reaction mix comprising 2 µl of 2X 
diluted reverse transcription product, 5 µl of Taqman 2X Universal PCR 
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Master Mix without UNG Amperase, 2 µl of miRNA specific probes and 
primers and 1 µl of nuclease free water, on an Applied Biosystems 7500 Real 
Time PCR system, with an initial denaturation step at 95 °C for 10 minutes, 
followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. 
Fluorescence signal was measured at each extension step. The Taqman 
microRNA individual assays used in this study are listed in Table 2.13 (Top) 
Target gene transcript expression was analyzed with QuantiTectTM 
SYBR Green PCR Kit (Qiagen). cDNA was synthesized from 2 µg of total 
RNA with the High Capacity cDNA Archive Kit (Applied Biosystems) and a 
poly-T containing primer (RT reverse, 5’- GGCCACGCGTCGACTAGTAC 
TTTTTTTTTTTTTTTTT-3’).  Real-time PCR was performed on an Applied 
Biosystems 7500 Real-time PCR Machine. Amplification reaction mix 
included cDNA template (25 ng), target gene primers (0.25 µM), and 2X PCR 
Mater Mix (5 µl, Qiagen) in a total volume of 10 µl. Amplification conditions 
included an initial denaturation step at 95°C for 15 minutes, followed by 40 
cycles of denaturation at 95°C for 30 seconds, annealing at 56°C for 30 
seconds and extension at 72°C for 33 seconds. SYBR Green fluorescence was 
measured at each extension step. The specific primer sequences for each target 
gene examined are listed in Table 2.13(Bottom). 
The level of transcript expression was measured by threshold cycle 
(CT), which was determined as the fractional cycle number at which the 
fluorescence intensity exceeded a fixed threshold, and the ΔΔCT method was 
employed for relative quantitation of gene expression [252]. The normalized 
CT (ΔCT) was calculated by subtracting the CT of an endogenous control 
from the CT of gene of interest. The ΔΔCT was calculated by subtracting the 
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Table 2.13 List of Taqman microRNA individual assays (Top) and primer 






































ΔCT of the control sample from that of the treated samples. The fold change 
was calculated with the equation 2-ΔΔCT. 
 
2.14 Western blot analysis 
Cells were lysed with RIPA (150 mM NaCl, 50 mM Tris-HCl pH 7.0, 
1% Deoxycholate, 1% NP40, 0.1% SDS) lysis buffer supplemented with 
protease inhibitor cocktail (Roche, Germany), sonicated for 10 minutes in a 
Bioruptor (Diagenode, Belgium) and centrifuged at 13,000 rpm for 5 minutes 
to collect total cell lysate. Protein lysates were resolved on a 12 % SDS-PAGE 
gel and transferred onto a polyvinylidene difluoride membrane. The blots were 
blocked with 2 % ECLTM advanced blocking agent (GE health) in 1X PBST 
for one hour and probed with respective primary antibody and horseradish 
peroxidase conjugated secondary antibody. The primary and secondary 
antibodies were diluted as indicated in Table 2.14. The blots were then washed 
and visualized with Enhanced Chemiluminescence Reagent Kit (ECL, 





Table 2.14 List of antibodies used in Western blot analysis 
  
Primary antibody Source Type Company Catalogue number Dilution Factor
HBx Rabbit Polyclonal Custom made - 1:10000
STAT3 Mouse monoclonal Santa Cruz SC-8019 1:1000
MYC Mouse monoclonal Santa Cruz SC-142 1:2000
EGFP Mouse monoclonal Roche 11814460001 1:40000
Smad4 Mouse monoclonal Santa Cruz SC-56479 1:2000
Beta-actin Goat Polyclonal Santa Cruz SC-1646 1:40000
Secondary antibody Conjugation Type Company Catalogue number Dilution Factor
Goat-anti-Mouse HRP Polyclonal Pierce 31430 1:100000
Goat-anti-Rabbit HRP Polyclonal Pierce 31460 1:100000
Rabbit-anti-Goat HRP Polyclonal Pierce 31402 1:100000
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2.15 Statistical analyses of experimental data 
Unpaired two-tailed t test was performed to analyze the significance of 
differences between sample means obtained from at least three experiments.  
Pearson correlation was used to analyze the relationship between the HBx 
protein expression and the let-7 miRNA expression, between miR-224 
expression and API5 transcript expression, between miR-224 expression and 




CHAPTER 3: RESULTS 
3.1 miRNA expression profiling identifies dysregulation of miRNAs 
that are associated with HCC. 
 To identify deregulated miRNAs in HCC, we examined the expression 
profile of 859 human mature miRNAs/miRNA* in 100 HCC tumor versus the 
paired adjacent non-tumor tissues using miRXplore microRNA microarrays 
(miRBase release 12). Of these 859 miRNAs, 267 miRNAs were not 
expressed in samples from HCC patients and 411 miRNAs were expressed in 
less than 10 % of HCC samples. Only a total of 181 miRNAs were found to be 
significantly expressed in more than 10 patient samples. Only these miRNAs 
were included in subsequent analysis. Significance Analysis of Microarrays 
(SAM) was used to identify statistically significantly deregulated miRNAs in 
HCC.  A total of 66 miRNAs were identified to be significantly differentially 
expressed between tumor versus adjacent non-tumor samples in HCC patients 
with a threshold of false discovery rate (FDR) < 0.000 and absolute d score 
(|d| > 3).  
 Figure 3.1 is a Heat Map showing these 66 significantly differentially 
expressed miRNAs, 50 of which were up-regulated (red) and 16 were down-
regulated (green). Using unsupervised hierarchical clustering analysis with 
Pearson correlation and average linkage, distinct clusters of miRNAs were 
observed to be associated with either functional families: let-7 family (let-7a, 
let-7b and let-7c, in yellow box), miR-15 family (miR-15a and miR-15b, in 
orange box), miR-221 family (miR-221 and miR-222, in light blue box), miR-



























































































































































































































































































































family (miR-199A-5P and miR-199A-3P, in brown box), or associated with 
genomic loci: miR-221/222 genomic cluster on ChrXp11.3 (in light blue box) 
and miR-143/145 genomic cluster on Chr5q32 (in dark blue box). These data 
suggests that these miRNA clusters may be coordinately regulated base on 
either the family-defining seed sequences or the genomic loci. 
 As shown from Table 3.1 which annotated these significantly 
deregulated miRNAs based on genomic loci,  these 66 differentially expressed 
miRNAs were distributed across all human chromosomes except 
Chromosomes 4, 6, 10 and 20, with a slight enrichment in Chromosome 1 ( 6 
miRNAs),  Chromosome 3 & X ( 6 miRNAs each) and Chromosome 7, 11, 17 
& 19 (5 miRNAs each). 32 miRNAs (~50 %, top half of Table 3.1) were 
found in miRNA clusters on the human genome and many of these miRNA 
clusters showed evidence of co-regulation at these genomic loci. For example, 
let-7a-3/7b cluster on Chr22q13.31 may account for the coordinated down-
regulation of let-7a and let-7b in HCC tumors. Similarly, miR-25/93/10b 
cluster on Chr7q22.1 may be responsible for the coordinated up-regulation of 
miR-25, miR-93 and miR-106b. A total of 7 such miRNA clusters (shaded in 
light green and pink) can be identified to potentially account for coordinated 
regulation of 16 miRNAs out of a total of 32 miRNAs found in genomic 
clusters, suggesting the regulation of genomic loci as a common mechanism of 
regulationg miRNA expression. Besides the two miRNA clusters mentioned, 
the other miRNA clusters include miR-99a/let-7c on Chr21q21.1 (miR-99a 
and let-7c down-regulation), miR-17-92 cluster on Chr13q31.3 (miR-18a and 
miR-92a up-regulation), miR-143/145 cluster on Chr5q32 (miR-143 and miR-
145 down-regulation), miR-191/425 cluster on Chr3p21.31 (miR-191 and  
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 Table 3.1 List of differentially expressed miRNAs in HCC with genomic 












































































































let‐7b ↓ ↑ ↓ 22q13.31 let‐7a‐3/7b
let‐7c ↓ ↑ ↓ ↓ 21q21.1 miR‐99a/let‐7c
miR‐99a ↓ ↓ ↓ ↓ 21q21.1 miR‐99a/let‐7c miR‐99
let‐7i ↑ ↑ 12q14.1 ‐ let‐7
miR‐25 ↑ ↑ ↑ ↑ ↑ 7q22.1 miR‐25/93/106b miR‐25
miR‐93 ↑ ↑ ↑ ↑ ↑ 7q22.1 miR‐25/93/106b
miR‐106b ↑ ↑ ↑ 7q22.1 miR‐25/93/106b
miR‐18a ↑ ↑ ↑ ↑ ↑ 13q31.3 miR‐17/18a/19a/20a/19b‐1/92a‐1
13q31.3 miR‐17/18a/19a/20a/19b‐1/92a‐1
 Xq26.2 miR‐106a/18b/20b/19b‐2/92a‐2/363
miR‐143 ↓ ↓ ↓ 5q32 miR‐143/145 miR‐143
miR‐145 ↓ ↓ ↓ ↓ ↓ ↓ 5q32 miR‐143/145 miR‐145
miR‐15a ↑ ↑ ↑ ↓ ↑ 13q14.2 miR‐15a/16‐1
miR‐15b ↑ 3q25.33 miR‐15b/16‐2
miR‐191 ↑ ↑ 3p21.31 miR‐191/425 miR‐191
miR‐425 ↑ ↑ 3p21.31 miR‐191/425 miR‐425
miR‐221 ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ Xp11.3 miR‐221/222
miR‐222 ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ Xp11.3 miR‐221/222
7q32.3 miR‐29b‐1/29a 
 1q32.2 miR‐29b‐2/29c
miR‐140‐3P ↑ 16q22.1 miR‐17/18a/19a/20a/19b‐1/92a‐1 miR‐140
9q33.3 miR‐181a‐2/181b‐2
1q32.1 miR‐181a‐1/181b‐1
miR‐193b ↑ 16p13.12 miR‐193/365‐1 miR‐193
19p13.2 ‐
1q24.3  miR‐199a‐2/214/3120
miR‐212 ↑ 17p13.3 miR‐212/132 miR‐132
miR‐215 ↑ ↓ ↑ 1q41 miR‐194‐1/215 miR‐192
miR‐224 ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ Xq28 miR‐224‐452 miR‐224
miR‐331 ↑ ↑ 12q22 miR‐331/3685 miR‐331
miR‐371‐5P ↑ 19q13.42 miR‐371/372/373 miR‐290
miR‐423‐5P ↑ 17q11.2 miR‐423/3184 miR‐423
miR‐423‐3P ↑ 17q11.2 miR‐423/3184 miR‐423
miR‐451 ↓ 17q11.2 miR‐144/451 miR‐451
miR‐487b ↑ 14q32.31 miR‐376c/376a‐2/654/376b/376a‐1/300/1185‐1/1185‐2 
/381/487b/539/889/544/655/487a/382/134/668/485/323b
miR‐494 ↑ 14q32.31 miR‐379/411/299/380/1197/323/758/329‐1/329‐2 
/494/1193/543/495
miR‐130b ↑ ↑ 22q11.21 miR‐130b/301b







miR‐1274A ↑ 5p13.1 ‐
miR‐1274B ↑ 19q13.43 ‐
miR‐21 ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 17q23.2 ‐ miR‐21
3p22.2 ‐
12q14.1 ‐
miR‐34a ↑ ↑ ↑ ↑ 1p36.22 ‐ miR‐34
miR‐122 ↓ ↓ ↓ ↓ ↓ ↓ ↓ 18q21.3 ‐ miR‐122
11q24.1 ‐
 21q21.1 ‐
miR‐148a ↑ ↑ ↑ 7p15.2 ‐ miR‐148
miR‐151 ↑ ↑ 8q24.3 ‐ miR‐28
miR‐185 ↓ ↓ ↑ ↑ 22q11.21 ‐ miR‐185
miR‐210 ↑ ↑ ↑ ↑ 11p15.5 ‐ miR‐210
miR‐223 ↓ ↓ ↓ ↓ ↓ Xq12 ‐ miR‐223
miR‐378 ↓ ↓ 5q32 ‐ miR‐378
miR‐638 ↑ 19p13.2 ‐ miR‐638
miR‐663 ↑ 20Centromere ‐ miR‐663
miR‐720 ↑ 3q26.1 ‐ miR‐720
miR‐885‐5P ↑ 3p25.3 ‐ miR‐885
miR‐1246 ↑ 2q31.1 ‐ miR‐1246
miR‐1260 ↑ 14q24.3 ‐ miR‐1260
miR‐1469 ↑ 15q26.2 ‐ miR‐1469
miR‐1908 ↑ 11q12.2 ‐ miR‐1908














↓ ↓ ↓ miR‐199
miR‐320b
↓ ↓ ↓miR‐199a ↓ ↓ ↓
↑ miR‐181
↓ ↓ ↓ miR‐125
miR‐181a ↓








↓ ↓let‐7a ↓ ↑
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 miR-425 up-regulation) and miR-221/222 cluster on ChrXp11.3 (miR-221 
and miR-222 up-regulation). 
 Table 3.1 also summarized the functional miRNA family classification 
of these 66 significantly differentially expressed miRNAs in HCC. These 66 
miRNAs belonged to a total of 46 miRNA families with slight enrichment in 
let-7 family (let-7a, let-7b, let-7c and let-7i), miR-17 family (miR-18a, miR-93 
and miR-106b), miR-320 family (miR-320b, miR-320c and miR-320d), miR-
15 family (miR-15a and miR-15b), miR-25 family (miR-25 and miR-92a), 
miR-130 family (miR-130a and miR-130b), miR-221 family (miR-221 and 
miR-222), miR-154 family (miR-487b and miR-494) and miR-1274 family 
(miR-1274a and miR-1274b). These data suggest that in addition of regulation 
at the genomic loci, the family-defining seed sequence may play a role in 
miRNA regulation at the processing and maturation level.  
 In Table 3.1, we compared our data (Thesis column or Column 15) 
with the 14 previous miRNA profiling studies reported in the literature 
(Column 2-14) and found high degree of consistency in the observed miRNA 
deregulation. We identified 30 novel miRNAs deregulated in HCC. Majority 
of these 30 miRNAs were recently discovered and not profiled in the previous 
studies reported in the literature. The other 36 miRNAs were all consistently 
reported by at least one other study except miR-181a. This gave us confidence 
that our method of profiling for miRNA deregulation in HCC is reliable and 
accurate, independent of the patient samples selected.  To understand the 
functional relevance of these miRNA deregulations in HCC, we subsequently 
validated and functionally characterized for let-7a down-regulation and miR-
224 up-regulation in HCC.  
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3.2 Characterization of let-7a down-regulation in HCC tumors 
        * This section is adapted from original research article, Wang, Y., Lu, Y., Toh, S. 
T., Sung, W. K., Tan, P., Chow, P., Chung, A. Y., Jooi, L. L. and Lee, C. G. (2010). 
Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal 
transducer and activator of transcription 3. J Hepatol 53, 57-66. 
3.2.1 Let-7a is down-regulated in tumors of HCC 
As shown by the miRNA microarray profiling data in Figure 3.1 
(yellow box), members of let-7 family of miRNAs, namely let-7a, let-7b and 
let-7c, were significantly down-regulated in tumors of HCC. Let-7 is the first 
miRNA identified in humans and evolutionarily conserved from C. elegans to 
humans. Let-7 was demonstrated to play crucial roles in developmental 
processes. Its reduced expression has been reported in a number of human 
cancers[138]. Hence, we would like to further characterize the functional 
relevance of let-7 down-regulation in human HCC. 
We proceeded to validate the miRNA microarray findings with 
Taqman reverse transcription quantitative PCR (RT-qPCR) using specific 
human let-7a Taqman miRNA assays in 20 normal liver samples as well as 
paired tumor and adjacent non-tumor samples from 20 HBV-associated HCC 
patients. As shown in Figure 3.2.1, let-7a expression is significantly lower in 
tumors compared to the adjacent non-tumorous liver tissues of HCC patients 
(p<0.001). This is consistent with our observation of let-7 down-regulation in 
HCC tumors from the miRNA microarray data. Additionally, both HCC tumor 
and adjacent non-tumorous liver tissues showed significantly lower let-7a 













Figure 3.2.1 Let-7a expression is significantly lower in HCC tumor than 
non-tumor samples. Box plot of let-7a expression in the normal liver samples 
from 20 metastatic colorectal cancer patients (Normal Liver), the adjacent 
non-tumorous liver (HCC Non-tumor) and tumor tissues (HCC Tumor) from 







As the 20 HCC patients examined in let-7a validation are all HBV positive 
and HBV X protein (HBx) is known to be selectively over-expressed in 
tumors of HCC, we proceeded to evaluate whether reduced let-7a expression 
in these HCC patients were related to HBx expression.  
3.2.2 HBx expression is inversely correlated with let-7a expression in 
hepatocellular carcinoma patients 
We proceeded to examine the HBx protein expression in HCC patient 
samples through Western blot analysis with a custom-made polyclonal rabbit-
anti-HBx antibody against full length HBx as antigen. As shown by Figure 
3.2.2 (1), HBx protein is detectable in all 20 HBV-associated HCC cases. In 
16 of these 20 HBV+ HCC patients, HBx is selectively over-expressed in the 
tumor tissues compared to the paired adjacent non-tumor tissues while 4 HCC 
patients showed higher HBx expression in non-tumor than tumor tissues. We 
subsequently examined the correlation between HBx and all members of let-7 
miRNAs using Pearson correlation and observed statistically significant 
inverse correlation between HBx and let-7a (p<0.01), let-7b (p<0.05) & let-7c 
(p<0.01) (Figure 3.2.2 (2)).  Furthermore, when the HBV+ HCC patients were 
sub-grouped based on the relative HBx status between tumor and non-tumor 
tissues as shown in Figure 3.2.2.(3), let-7a expression is significantly lower 
while HBx expression is significantly higher in the tumor compared to the 
non-tumorous liver tissues in 16 HCC patients (p<0.001).  In contrast, 
although not statistically significant, let-7a expression is higher while HBx 
expression is lower in the tumor compared to the non-tumorous tissues in the 
remaining four HCC patients. Taken together, our data strongly suggests that 




Figure 3.2.2. (1) HBx is selectively over-expressed in tumors of HCC 
Western blot detection of HBx protein in tumor (T) and paired adjacent non-
tumor (N) samples from 20 HBV-associated HCC patients, normalized against 
β-actin as endogeneous control. 




Figure 3.2.2.(2) HBx expression is inversely correlated with let-7a, let-7b 
and let-7c expression in HCC patients. Scatter plots showing the statistically 
significant correlation in the relative expression of HBx and the relative 
expression of let-7a (p<0.01), let 7b (p<0.05) and let-7c (p<0.01) in the tumor 
versus paired adjacent non-tumorous tissues of 20 HCC patients.  Each spot 
represents data from one HCC patient presented in the Log2 scale and the 






Figure 3.2.2. (3) Let-7a expression is only significantly reduced in HCC 
tumors where HBx is selectively over-expressed, compared to the paired 
adjacent non-tumor tissues. Box plot of let-7a expression in 20 normal liver 
samples (Normal Liver), 16 HCC patients with higher HBx protein expression 
in tumor than paired non-tumorous tissues and 4 HCC patients with lower 
HBx protein expression in tumor than paired non-tumorous tissues, measured 
with Western Blot analysis. Representative western blot of HBx versus β-actin 
as loading control are shown below the box plot to illustrate the HBx status 
between the two groups of HCC patients. * denotes p<0.05 and *** denotes 
P<0.001.  
(Published data)  
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3.2.3 Let-7 family of miRNAs are significantly down-regulated in HBx-
expressing HepG2 cells 
To ascertain whether HBx directly deregulates the expression of 
cellular miRNAs such as let-7, we transiently expressed HBx in HepG2 cells 
through a recombinant adenovirus carrying full length HBx.  The expression 
profile of 286 human miRNAs was examined in HBx-expressing versus 
control HepG2 cells from three independent experiments. The miRNA 
microarray data can be obtained from http://www.ncbi.nlm.nih.gov/geo/query 
/acc.cgi?token=tlmdlkmyimcewhm&acc=GSE17474, Accession number: 
GSE17474. 
Ninety miRNAs were found to exhibit significant expression in all 
three paired biological samples and these miRNAs were presented in Figure 
3.2.3.(1)A as a Volcano plot. In the volcano plot, the X-axis is the logarithmic 
transformation to the base 2 of the mean fold change of miRNA expression in 
HBx versus Control HepG2 cells and the Y-axis is the negative logarithm to 
the base 10 of the p-value of Student’s t test.  Significantly differentially 
expressed miRNAs were identified as absolute mean fold change of greater 
than 1.5 and p-value of less than 0.01 and located in the two upper lateral 
quandrants.  Seven miRNAs ( miR-30c, miR-193b, miR-342, miR-199a, miR-
125a, miR-99b and miR-191) were found to be significantly up-regulated 
while 11 miRNAs ( miR-196a, miR-106a, miR-20a and let-7 family of 
miRNAs) were found to be significantly down-regulated in HBx-expressing 
HepG2 cells compared to the control cells (Figure 3.2.3.(1)B).  Notably, all 
members of the let-7 family were down-regulated, eight of which showed 



















Figure 3.2.3. (1) Profile of miRNAs deregulated by HBx in HepG2 cells. 
(A) Volcano plot showing 90 miRNAs that were significantly expressed in 
HBx cells. miRNA microarray data were collected by comparing the miRNA 
expression in HBx-expressing HepG2 cells (HBx cells) versus the Control 
cells from three biological replicates. Y-axis: -log10 (p-value); X-axis: 
log2(Ratio(HBx/Control)). Differential expression of miRNAs in HBx cells 
versus Control cells that were both biologically and statistically significant 
were indicated in the two upper-lateral quadrant with absolute fold change > 
1.5 and p-value < 0.01. Green spots indicated miRNAs that were significantly 
down-regulated while red spots indicated miRNAs that were significantly 
over-expressed in HBx cells. (B) Hierarchical clustering of miRNAs that were 
differentially expressed in HBx-expressing cells using Euclidean correlation 
with average linkage.  Up-regulated miRNAs are represented by Red blocks 



























Figure 3.2.3.(1)B presented the 18 significantly differentially 
expressed miRNAs in a Heat Map using unsupervised hierarchical clustering 
with Euclidean distance and average linkage analysis. We chose to validate the 
expression of two up-regulated miRNAs (miR-30c and miR-199a) and all the 
members of the let-7 family using reverse transcription Taqman real-time PCR 
to confirm the miRNA microarray findings. The data was normalized against 
endogenous control RNU48. The let-7 family of miRNAs showed greatly 
variable endogenous level of expression.  Expression of let-7a, let-7b and let-
7c were high whereas the expression of let-7e and let-7i were very low (Figure 
3.2.3.(2)A). Nonetheless, all 9 mature miRNAs were validated to be 
significantly down-regulated in HBx-expressing HepG2 cells, compared to 
those of the Control HepG2 cells. (Figure 3.2.3.(2)A and Table 3.2.3).  To 
ensure that the observed effect of HBx on let-7 is not cell line specific, we 
repeated the experiment in a second liver cell line SNU-182 [253]. As evident 
in Figure 3.2.3.(2)B, expression of let-7a, let-7b, let-7c, let-7e and let-7i were 
significantly reduced in HBx-expressing SNU-182 cells. Taken together, we 
have demonstrated a distinct miRNA expression profile, including the down-
regulation of the entire let-7 family of miRNAs, which was associated with 
HBx in HepG2 cells. The down-regulation of selected members of the let-7 
miRNAs by HBx is reproducible in SNU-182 cells.  
Hence, we have demonstrated that HBx plays a role in down-
regulating the expression of let-7a, let-7b and let-7c in liver cancer cell lines 
and is inversely correlated with these let-7 miRNAs in HCC patient samples. 
This suggests that the down-regulation of let-7 miRNAs may happen as an 
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early event in HCC development upon HBV infection. The down-regulation of 
let-7 may thus play an important role in hepatocellular carcinogenesis. 
3.2.4 Let-7 negatively regulates cell proliferation 
Let-7 miRNAs have been reported to play important roles in cell 
differentiation and cell proliferation (See review [254]). To evaluate the 
functional significance of HBx-mediated let-7 down-regulation, levels of 
cellular let-7 expression was altered by exogenously introducing the let-7 
precursor or let-7 inhibitor into either HepG2 or SNU-182 cells.  As the 
members of the let-7 family of miRNAs have previously been shown to have 
similar functions [255], let-7a was selected as a representative member of the 
let-7 family of miRNAs since it is one of the most highly expressed let-7 
miRNA in liver cells and consistently down-regulated by HBx in both HepG2 
and SNU-182 cells (Figure 3.2.3.(2)).  A significant 30% decrease (p<0.001) 
in cell proliferation (Figure 3.2.4B, left panel) was observed when let-7a 
precursor was introduced into HepG2 cells (Figure 3.2.4A, left panel).  
Inversely, when let-7a expression was inhibited by ~50% through the 
introduction of let-7a inhibitor (Figure 3.2.4A, left panel), there was a 
corresponding significant increase (P<0.01) in cell proliferation (Figure 3.2.4B, 
left panel) in HepG2 cells. The expression of unrelated miR-100 which was 
used as a control remained undisturbed, demonstrating the specificity of the 
small oligos in perturbing endogeneous let-7a level. Similar results were 
observed in the SNU-182 cells (Figure 3.2.4 A&B, right panel).  Our data 
confirms the observation made by Johnson et al previously [255] highlighting 




Figure 3.2.3.(2) Validation of let-7 down-regulation in HepG2 and SNU-
182 cells. Let-7 expression normalized against RNU48 measured using reverse 
transcription Taqman real-time PCR in HBx expression HepG2 cells versus 
Control cells (A) and HBx-expressing SNU-182 cells versus Control cells (B). 
Data is presented as Mean ± S.E. from three independent experiments. * 
denotes p<0.05, ** denotes P<0.01 and *** denotes P<0.001. 
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Table 3.2.3 Significantly differentially expressed miRNAs in HBx-expressing 
HepG2 cells versus Control cells as measured with miRNA microarray and 
validated with Taqman RT-qPCR 











 miR-30c +2.24 1.90E-03 ** +2.32 3.54E-02 *
miR-193b +1.63 4.59E-03 ** +1.78 1.31E-01
 miR-199a +1.55 5.00E-03 ** +3.41 4.33E-02 *
 miR-191 +1.50 6.85E-04 *** +4.61 9.99E-02
let-7a -2.18 7.33E-04 *** -1.98 2.54E-02 *
let-7b -1.65 7.08E-02 -2.07 3.38E-02 *
let-7c -2.70 1.53E-03 ** -1.95 3.48E-02 *
let-7d -2.03 7.61E-03 ** -2.33 7.33E-03 **
let-7e -1.98 3.03E-04 *** -2.25 2.33E-02 *
let-7f -2.18 1.63E-03 ** -2.27 1.62E-02 *
let-7g -1.80 6.53E-05 *** -2.04 3.05E-02 *
let-7i -1.77 7.67E-04 *** -2.28 8.90E-03 **



















Figure 3.2.4 Let-7 negatively regulates cell proliferation.  A. Relative let-7a 
(left two panels) and miR-100 (right two panels) expression normalized 
against RNU48, measured using reverse transcription Taqman real-time PCR, 
in HepG2 and SNU-182 cells transfected with Control oligos, let-7a precursor 
or let-7a inhibitor. B. Relative cell proliferation measured using the WST1 
assay in the same experimental setup. Data presented as Mean ± SE from three 








































3.2.5 STAT3 is a direct cellular target of let-7 
3.2.5.(1) Let-7a specifically interacts with the putative let-7a binding 
site along STAT3 3’UTR to negatively regulate reporter gene expression. 
To elucidate the cellular targets through which let-7 affects cell 
proliferation, we performed in silico analysis with miRecords which is an 
online resource that compiles predicted miRNA targets produced by 11 
established miRNA target prediction programs [256]. Six of these 11 
prediction programs, namely miRanda, NBmiRTar, PicTar, PITA, 
RNAHybrid and RNA22, predicted Signal Transducer and Activator of 
Transcription 3 (STAT3) as a putative let-7 target. STAT3 is the central 
mediator of JAK/STAT pathway that plays an important role in cell 
proliferation. Several studies have previously demonstrated the role of HBx in 
activating STAT3 [257, 258]. Hence we proceeded to investigate whether 
HBx can also regulate STAT3 expression through down-regulating let-7 
miRNAs. One strong putative let-7 binding site was identified along STAT3 
3’UTR by miRanda (Release 2008). To validate whether let-7 directly targets 
STAT3, we cloned the wild-type 3’UTR of STAT3 as well as a mutant 3’UTR 
which is mutated at the putative let-7 binding site downstream the β-
galactosidase (β-gal) reporter gene (Figure 3.2.5.(1)A).  As evident in Figure 
3.2.5.(1)B, introduction of let-7a precursors into cells containing wild-type 
STAT3 3’UTR reporter construct resulted in significantly lower (P<0.001) β-
gal activity compared to cells carrying the mutant STAT3 3’UTR reporter 
construct in which the let-7 binding site is mutated. Conversely, when let-7a 
inhibitor was introduced, cell containing the wildtype STAT3 3’UTR reporter 




Figure 3.2.5.(1) Let-7a interacts with the putative binding sites on STAT3 
3’UTR. (A) Schematic diagram of the constructs utilized to validate that the 
let-7 targets the 3’UTR region of STAT3.  The wildtype STAT3 3’UTR 
carrying the predicted let-7 binding site (left box) or the mutant STAT3 
3’UTR carrying the mutated let-7 binding site (right box with the mutation 
residues in BOLD) were cloned downstream β-galactosidase reporter gene 
driven by MRP1 promoter. (B) Effect of let-7a on STAT3 3’UTR examined 
through normalized β-galactosidase activity in cells co-transfected with 
Control oligos, let-7a precursor or let-7a inhibitor and wildtype STAT3 
3’UTR (Black bar) or mutant STAT3 3’UTR reporter construct (White bar). 
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carrying the mutant STAT3 3’UTR reporter construct. No significant 
difference was observed between cells carrying wild-type or mutant STAT3 
3’UTR reporter construct when Control Oligos were introduced.  Hence, our 
data demonstrate that let-7a specifically interacted with the putative let-7a 
binding site on STAT3 3’UTR to negatively regulate the β-gal reporter gene 
activity.  
3.2.5.(2) Let-7a negatively regulates endogeneous STAT3 expression. 
To evaluate whether let-7a affects endogenous STAT3 expression, we 
manipulated the endogenous let-7a expression with specific let-7a precursors 
or inhibitors. The endogenous STAT3 transcript and protein expression was 
found to be significantly decreased (P<0.001) when let-7a precursor was 
introduced (Figure 3.2.5.(2)).  Conversely, when the let-7a inhibitor was 
introduced, the endogenous STAT3 transcript and protein expression was also 
significantly increased (P<0.01) (Figure 3.2.5.(2)). As a positive control, we 
concurrently examined if the addition of let-7a precursor or inhibitor into cells 
affected a previously reported validated cellular target of let-7a, c-Myc [76].  
As evident in Figure 3.2.5.(2) (right panel), similar decrease and increase in c-
myc protein expression was observed when let-7a precursor and inhibitor, 
respectively, was introduced into the cells.  Taken together, our data 
demonstrated that let-7a physically interacted with the 3’UTR of STAT3 to 
negatively regulate STAT3 cellular expression.  
 3.2.5.(3) STAT3 inhibition  phenocopies let-7a over-expression. 
To ascertain that STAT3 is indeed a target through which let-7a affects 
cell proliferation, we inhibited STAT3 expression with siRNA that specifically 
69 
 
targets STAT3 (si-STAT3) and examined its effect on cell proliferation. As 
shown in Figure 3.2.5.(3)B, STAT3 inhibition reduced cell proliferation 
(rightmost lane), phenocopying the effect of overexpression of let-7a (middle 
lane).  Figure 3.2.5.(3)A shows the expression of let-7a and STAT3 when let-
7a precursor and si-STAT3 were introduced into the cells. Moreover, STAT3 
expression was also found to positively correlate with HBx expression in HCC 
patients (Figure 3.2.5.(4)).  Taken together, our data demonstrated that let-7a 
regulates cell proliferation at least partially through its direct target, STAT3. 
3.2.6 Down-regulation of Let-7 by HBx supports cell proliferation in HBx-
expressing cells 
To reaffirm the relationship between let-7a and STAT3 in HBx-
expressing cells, we examined the expression of let-7a and STAT3 in HepG2 
cells transduced with Control or HBx recombinant adenoviruses. As evident in 
Figure 3.2.6.(1), let-7a showed significantly reduced expression (p<0.05) 
while STAT3 expression was significantly increased at both the transcript 
(p<0.01) and protein (p<0.05) levels in HBx-expressing cells versus Control 
cells. As HBx down-regulated let-7 and let-7 negatively regulates cell 
proliferation, we hypothesized that HBx would upregulate cell proliferation 
through down-regulating let-7a. Interestingly, cell proliferation is not 
significantly different in control- versus HBx-infected cells (Figure 3.2.6.(2), 
leftmost panel, 1st two bars).  Nonetheless, when let-7a precursors were 
introduced, both let-7a as well as STAT3 expression in the HBx cells was 
restored to a similar level as those in the control cells (Figure 3.2.6.(2), middle 
and rightmost panels).  Introduction of let-7a also results in the significant 








































































































































































































































































































































































Figure 3.2.5.(3) Cells whose STAT3 expression is inhibited shows similar 
proliferation phenotype as cells over-expressing let-7a. (A) Expression of 
let-7a and STAT3 after the introduction of either let-7a or siRNA against 
STAT3, measured with RT-qPCR (left panel) and Western blot analysis (right 
panel). (B) Relative cell proliferation of HepG2 cells transfected with Control 
oligos, let-7a precursor or siRNA against STAT3 measured using the WST1 
assay. * denotes P<0.05, ** denotes P<0.01 and *** denotes P<0.001. 



































Figure 3.2.5.(4) HBx expression is postively correlated STAT3 expression 
in HCC patients. Scatter plots showing the positive correlation in the relative 
expression of HBx and the relative expression of STAT3 (p=0.058) in the 
tumor versus paired adjacent non-tumorous tissues of 20 HCC patients.  Each 
spot represents data from one HCC patient presented in the Log2 scale and the 
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(Figure 3.2.6.(2), leftmost panel) with the reduction of cell proliferation in 
HBx-expressing cells being twice as much as that observed in the control cells 
(p<0.05). As HBx has long been known as a pleiotropic protein implicated in 
both cell death [251] and cell proliferation [259], our data indirectly suggests 
that HBx’s effect on cell apoptosis may negate its effect on cell proliferation.   
To reaffirm that HBx’s role in cell proliferation is through its down-
regulation of let-7a, we limited the effect of HBx on apoptosis by treating the 
cells with a general apoptosis inhibitor, zVAD, before assaying for cell 
proliferation. As shown by Figure 3.2.6.(3), when apoptosis was not inhibited, 
HBx-expressing cells showed similar cell proliferation despite ~50% more cell 
death, compared to the control cells.  HBx-expressing cells only showed 
significantly higher cell proliferation (~30%, p<0.01) than the control cells 
upon treatment with apoptosis inhibitor. The treatment with control or 
apoptosis inhibitor did not affect HBx’s ability to down-regulate let-7a and up-
regulate STAT3 (Figure 3.2.6.(3)). The above observations thus provided 
direct evidence that the pleiotropic HBx can influence both cell death and cell 
proliferation and HBx-mediated down-regulation of let-7 may function to 
support cell proliferation in HBx cells. Taken together, these data further 
confirms the pleiotropic nature of HBx protein and demonstrates that HBx-
mediated down-regulation of let-7 and up-regulation of STAT3 plays a role in 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.3 Characterization of miR-224 over-expression in HCC tumors 
     *This section is adapted from original research article, Wang, Y., Lee, A. T., Ma, 
J. Z., Wang, J., Ren, J., Yang, Y., Tantoso, E., Li, K. B., Ooi, L. L., Tan, P. et al. 
(2008). Profiling microRNA expression in hepatocellular carcinoma reveals 
microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific 
target. J Biol Chem, with additional unpublished data presented. 
3.3.1 miR-224 is over-expressed in tumors of HCC 
 We chose to further characterize miR-224 which is the most up-
regulated miRNA in the tumors of HCC patients [61]. As shown in Figure 
3.3.1A, miR-224 expression is significantly higher (p<0.001) in tumor 
samples compared to the adjacent non-tumor samples from HCC patients. This 
is further confirmed by Northern blot analysis with specific miR-224 probes 
on selected HCC patient samples (Figure 3.3.1B). Notably, miR-224 
expression is lowest in the normal liver sample. Its expression significantly 
increased (p<0.001) in the non-tumor samples and further increased (p<0.001) 
in the tumor samples (Figure 3.3.1A). This suggests that miR-224 expression 
may increase as liver disease progresses, making it a possible biomarker for 
liver. Therefore, we proceeded to functionally characterize this miRNA to 
understand its role in HCC. 
3.3.2 miR-224 over-expression decreases cell viability without affecting cell 
growth. 
 The functional significance of increased miR-224 expression in the 
cells was evaluated by transfecting miR-224 precursor into HCT116 cells, 




















Figure 3.3.1 miR-224 is significantly up-regulated in tumors of HCC. (A) 
Box plot of miR-224 expression in the normal liver samples from 40 
metastatic colorectal cancer patients (Normal Liver), the adjacent non-
tumorous liver (HCC Non-tumor) and tumor tissues (HCC Tumor) from 100 
HBV-associated HCC patients. *** denotes P<0.001. (B) Northern Blot 
analyses to validate the increased miR-224 expression in tumor tissues of 
representative HCC patients.  ‘P (number)’ represents the identity of the 
patients examined through miRNA microarrays.  ‘T’ denotes tumor tissue 
from indicated HCC patients while ‘N’ denotes the paired adjacent non-
tumorous liver tissues.  ‘Control’ represent total RNA isolated from HCT116 
cells 72 hours after transfection with miR-224 precursor and hybridized with 
miR-224 probe.   





224 expression peaked 24 hours post transfection but its expression remained 
high (>100 fold higher than that of Control transfected cells) even at 168 hours 
post transfection (Figure 3.3.2.(1)).  Some of the primary hallmarks of cancer  
including cell growth, viability and apoptotic profiles (37), were examined on 
miR-224 expressing cells. Cell growth remained generally unaffected in cells 
transfected with either miR-224 precursor or Control (Figure 3.3.2.(2)A) but 
cell viability was significantly reduced (up to 20% reduced cell viability; 
P<0.05) in cells transfected with miR-224 precursor compared to cells 
transfected with Control Oligo 2 (Figure 3.3.2.(2)B).  These data suggest that 
miR-224 seems to affect the viability rather than the growth of these cells. 
3.3.3 miR-224 over-expression sensitizes cells to apoptotic cell death 
Annexin V labeling was performed to delineate if the reduced viability 
of cells over-expressing miR-224 is due to increased cell-death through 
apoptosis.  miR-224 precursor- or Control-transfected HCT116 cells were 
harvested 48 hours post transfection, stained with PE-conjugated Annexin V 
and 7-AAD and analyzed on the flow cytometer. Apoptotic cells are 
represented as cells with high PE-conjugated Annexin V fluorescence signals 
and low 7-AAD fluorescence signals.  As shown in Figure 3.3.3B, ~2 fold 
greater apoptosis was observed in cells expressing miR-224 than in cells 
expressing the control precursors (P<0.001).  Significantly, when miR-224 
inhibitor was introduced into cells over-expressing miR-224, the miR-224 
expression was significantly reduced (P<0.001) (Figure 3.3.3A) and 
significantly less apoptosis (P<0.001) (Figure 3.3.3B) was observed, 
consistent with cells not over-expressing miR-224. Hence, the reduced cell-























Figure 3.3.2.(1) miR-224 expression in HCT116 cells. Upper panel shows 
results from Taqman MicroRNA individual Assay (left) for hsa-miR-224 
(Applied Biosystems) in HCT-116 cells after transfection with miR-224 and 
normalization against hsa-Let-7a for the various time-points.  Results are 
expressed as fold difference between miR-224 expression in miR-224 
precursor transfected cells versus Control transfected cells.  Lower panel 
shows Northern Blot Analyses of untransfected HCT116 cells or HCT116 
























Figure 3.3.2.(2)  Cell growth properties of miR-224 expressing cells. (A)  
Cell growth expressed as percentage of viable cells at the respective time 
points relative to the transfection start time, Time Zero. miR-224 precursor 
transfected cells are represented by squares and Control transfected cells are 
represented by triangles.  (B)  Viability of cells expressed as the percentage of 
viable cells relative to the total number of cells at a particular time point.  
Results were obtained by counting cells from the same experiment twice in 
three independent experiments. Data are as mean ± S.E. from at least 3 














































































































































Figure 3.3.3 miR-224 increases apoptotic cell death. (A) miR-224 
expression of cells transfected with Control, miR-224 precursors or miR-224 
precursors and miR-224 inhibitors.  (B) Upper panel: Relative Apoptosis of 
similarly treated cells, as assayed using PE-conjugated Annexin V staining. 
Lower panel: Apoptotic cells were detected as high in PE-annexin V staining 
and low in 7-AAD staining. Profiles shown are a representative from 3 
independent experiments. Data are as mean ± S.E. from at least 3 independent 
experiments. *** denotes P<0.001. 





apoptosis of these cells in the presence of miR-224 as evident from the 
increased apoptosis observed in miR-224 over-expressing cells and the 
restoration of its normal phenotype when miR-224 inhibitor was co- 
introduced. 
3.3.4 miR-224 over-expression increases cell proliferation 
 Curiously, although miR-224 over-expression reduced cell-viability 
(Figure 3.3.2B) and increased apoptosis (Figure 3.3.3B), it did not seem to 
affect cell growth (Figure 3.3.2A), as measured by the percentage of viable 
cells at each time point relative to time zero.  We thus hypothesized that this 
observation could be due to miR-224 also increasing cell proliferation in 
addition to increasing cell apoptosis, consequently resulting a similar number 
of viable cells in miR-224-expressing cells compared to control cells at any 
time point.  The proliferation potential of these cells was then examined using 
the BrdU incorporation assay.  As shown in Figure 3.3.4, transfection of miR-
224 precursor into these cells significantly increased the proliferation potential 
of these cells (P<0.001) while the co-transfection of the miR-224 inhibitor 
with the miR-224 precursors restored the cell-proliferation potential to normal. 
Hence, the over-expression of miR-224 increases both apoptotic cell death as 























Figure 3.3.4 miR-224 increases cell proliferation. (A) miR-224 expression 
of cells transfected with Control, miR-224 precursors or miR-224 precursors 
and miR-224 inhibitors.  (B)  Relative Cell Proliferation of similarly treated 
cells assayed using the BrdU Proliferation Assay Kit. Data are as mean ± S.E. 
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3.3.5 miR-224 targets API-5 
 To elucidate the gene target that miR-224 acts through to sensitize 
cells to apoptosis, we examined the putative miR-224 targets as predicted by 
in silico miRNA target prediction algorithms. We used miRecords which is an 
online resource that compiles predicted miRNA targets produced by 11 
established miRNA target prediction programs [256]. Six of these 11 
prediction programs predict for human miR-224 targets and these are miRanda, 
mirTarget2, miTarget, PITA, RNAhybrid and TargetScan. Table 3.3.5 
summarized the 52 putative miR-224 targets as predicted by at least 5 
prediction programs and functionally annotated with Gene Ontology (GO) 
terms. Using Generic GO Term Mapper developed by the Lewis-Sigler 
Institute for Integrative Genomics, these 52 putative miR-224 targets were 
mapped into a total of 39 functional GO terms in biological processes with 
human generic GO slim as background. Many of these biological processes 
were associated with cancer, namely transcription, cell differentiation, cell 
death, growth and cell proliferation. As miR-224 increases apoptotic cell death, 
we focused on putative miR-224 targets that are negative regulators of cell 
death. Five gene targets were identified to be involved in cell death as boxed 
in red in Table 3.3.5. Of these five putative miR-224 gene targets, apoptosis 
inhibitor 5 (API-5) seems to be the most appropriate candidate through which 
miR-224 may act to increase apoptosis in cells since API-5 has previously 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.3.5.(1) miR-224 specifically interacts with the putative miR-224 
binding site along API5 3’UTR to negatively regulate reporter gene 
expression. 
We proceeded to validate whether API-5 was in fact a true gene target 
of miR-224.  As illustrated in Figure 3.3.5.(1)A, three miR-224 binding sites 
were identified along the 2035-bp long 3’UTR of API-5. The entire wild-type 
3’UTR of API-5 as well as a mutant 3’UTR where all three putative miR-224 
binding sites were mutated was then cloned downstream the β-galactosidase 
(β-gal) reporter gene to generate pAPI5-3UTR-WT and pAPI5-3UTR-MUT, 
respectively. The specific interaction between miR-224 and API-5 3’UTR to 
inhibit reporter gene activity was evident in Figure 3.3.5.(1)B.  When miR-224 
precursor was co-transfected with wild-type API-5 3’UTR reporter construct, 
significantly reduced β-gal activity was observed compared to cells co-
transfected with miR-224 precursor and mutant API-5 3’UTR reporter 
construct (P<0.01). No significant difference in β-gal activity was observed 
between HCT116 cells carrying either the wild-type or mutant API-5 3’UTR 
reporter construct when co-transfected with Control Oligos. 
3.3.5.(2) miR-224 negatively regulates endogenous API5 expression. 
To evaluate if miR-224 can affect the endogenous expression of API-5, 
HCT116 cells were initially transfected with either miR-224 precursor or 
Control. miR-224 inhibitor or Control were then introduced into these 
transfected cells 24 hours later and reverse transcription real-time PCR was 
performed at various time points after this 2nd transfection.  As shown in 





















Figure 3.3.5.(1) miR-224 interacts with the putative binding sites on API5 
3’ UTR. (A)  Upper panel: Schematic diagram of the construct utilized to 
validate that the API-5 3’UTR is target of miR-224. The API-5 3’UTR (wild-
type or mutant) is cloned downstream the -gal reporter driven by MRP1 
promoter. Lower panel:  Schematic representation of the 3’ UTR of API-5 in 
which the predicted sequences of the three miR-224 binding sites are mutated 
to abolish miR-224 binding to the API-5 3’UTR. (B) Action of miR-224 on 
the 3’UTR of API-5 examined through normalized β-gal reporter activities in 
cells cotransfected with miR-224 precursors or Control and wild-type API-5 
3’UTR (black bar) or mutant API-5 3’UTR (white bar) reporter constructs. 
Data presented as Mean±SE from at least three independent experiments. ** 












































Figure 3.3.5.(2) miR-224 negatively regulates API-5 expression. miR-224 
expression (normalized against RNU48) (Top) and endogenous API-5 mRNA 
expression (normalized against β-actin) (bottom) in control or miR-224 
precursor and miR-224 inhibitor transfected cells. Cells were initially 
transfected with either Control or miR-224 precursors. Twenty-four hours later, 
the same cells were transfected with either Control or miR-224 inhibitors.  
miR-224 and API-5 RNA levels were measured at various time-points after 
the 2nd transfection. Data are represented as Mean ± S.E. from at least three 
independent experiments. *** denotes P<0.001. 
(Published data) 
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precursor transfected HCT116 cells compared to the control cells (P<0.001) 
across time points examined, consistent with previous reports that miRNAs 
can also down-regulate gene expression at the transcript level (45).  When 
miR-224 inhibitor was transfected into miR-224 over-expressing cells, the 
API-5 transcript levels significantly increased (P<0.001) at the 2 time points 
examined suggesting that the miR-224 inhibitor was able to rescue the 
inhibition of API-5 expression by miR-224. This observation that miR-224 
decreased API-5 expression corroborates with our earlier observation that 
miR-224 increases apoptotic cell death and strongly suggests that miR-224 
exerts this effect through regulating the expression of API-5. 
3.3.6 Inhibition of miR-224 in THLE3 cells up-regulates API-5 expression and 
reduces apoptotic cell death. 
Thus far, we observed that miR-224 is over-expressed in the majority of 
HCC patients examined and demonstrated experimentally that the over-
expression of miR-224 in HCT116 cells increased apoptosis and reduced 
expression of the apoptosis inhibitor, API-5 gene.  We proceeded to evaluate 
the functional consequences of inhibiting the endogenous expression of miR-
224 in an immortalized primary liver cell-line, THLE-3.  The introduction of 
miR-224 inhibitor into THLE-3 cells was found to significantly inhibit the 
endogenous expression of miR-224 in these cells (P<0.001) (Figure 3.3.6(A), 
left) and significantly increased the expression of the API-5 gene (Figure 
3.3.6A, right).  Inhibiting endogenous miR-224 expression in the THLE-3 
primary liver cells was also found to protect these cells from UV-induced 





















Figure 3.3.6 Knock-down of miR-224 in THLE3 cells decreased the 
number of apoptotic cells.  (A) miR-224 (Left) and API-5 (Right) expression 
in THLE-3 cells transfected with either Control or miR-224 inhibitor. (B) 
Relative apoptosis of THLE-3 cells transfected with either Control or miR-224 
inhibitor.  Results show data from at least 3 independent experiments, 





































































3.3.7 API-5 mRNA expression was inversely correlated with miR-224 
expression in HCC patients  
We proceeded to examine if there is any correlation between miR-224 
and API-5 expression in HCC patients to evaluate the clinical significance of 
our observations.  As evident in Figure 3.3.7, a statistically significant inverse 
correlation was observed between miR-224 and API-5 expression in HCC 
patients (Pearson Coefficient r=−0.471, R2=0.221 at p< 0.05), demonstrating 
API5 as a clinically relevant target of miR-224, in HCC context. 
 
3.3.8 miR-224 targets SMAD4 to affect cell proliferation 
 To identify the cellular target through which miR-224 acts to increase 
cell proliferation, we employed the similar hypothesis driven approach. As 
shown by Table 3.3.5, a total of four non-redundant genes were identified to 
be involved in either cell proliferation (GO008283), growth (GO004007) or 
cell growth (GO0016049) (Boxed in blue). SMAD4 was the only putative 
target appeared in all three categories and a highly probable target through 
which miR-224 positively regulates cell proliferation. SMAD4 is the central 
mediator for Transforming Growth Factor beta (TGF-β) pathway which 
negatively regulates cell proliferation. Hypothetically, the possible down-
regulation of SMAD4 by miR-224 over-expression will de-repress the TGF-β 







Figure 3.3.7 API-5 transcript expression level is inversely correlated with 
miR-224 expression in HCC patients.  Scatter plot of the mean fold change 
of API-5 transcript versus that of miR-224 expression. Each spot represents 
data from one patient presented in log10 scale and a linear regression line is 
depicted as a solid line. Statistically significant inverse correlation was 







 3.3.8.(1) miR-224 specifically interacts with the putative miR-224 
binding site along SMAD4 3’UTR to negatively regulate reporter gene 
expression. 
To elucidate whether miR-224 directly targets SMAD4, we first 
identified two putative miR-224 binding sites along SMAD4 3’UTR with 
miRanda prediction program (www.microRNA.org). We subsequently cloned 
the 1310 bp long wildtype SMAD4 3’UTR as well as a mutant SMAD4 
3’UTR in which the putative miR-224 binding sites were mutated to abolish 
miR-224 binding, downstream of the β-galactosidase reporter gene driven by 
MRP1 promoter. As evident in Figure 3.3.8.(1), when miR-224 precursors 
were introduced, cells carrying the wildtype SMAD4 3’UTR reporter 
construct showed significantly reduced β-galactosidase activity (p<0.01) 
compared to the cells carrying the mutant SMAD4 3’UTR reporter construct 
in which the miR-224 bindings were abolished. However, no significant 
difference in reporter gene activity was observed between cells carrying the 
wildtype or mutant SMAD4 3’UTR reporter construct, when Control Oligos 
were introduced. This data suggested that miR-224 specifically interacted with 
the putative binding sites along the SMAD4 3’UTR to negatively regulate 



















Figure 3.3.8.(1) miR-224 interacts with putative binding sites on SMAD4 
3’UTR. (A) Schematic diagram of the constructs utilized to validate that the 
miR-224 targets the 3’UTR region of SMAD4. The wildtype SMAD4 3’UTR 
carrying the predicted miR-224 binding sites (Upper panel in the box) or the 
mutant SMAD4 3’UTR carrying the mutated miR-224 binding sites (Lower 
panels with the mutation residues in BOLD) were cloned downstream β-
galactosidase reporter gene driven by MRP1 promoter. (B) Effect of miR-224 
on SMAD4 3’UTR examined through normalized β-galactosidase activity in 
cells co-transfected with Control oligos or miR-224 precursor and wildtype 
SMAD4 3’UTR (Black bar) or mutant SMAD4 3’UTR reporter construct 
(White bar). Data presented as Mean±S.E from at least three independent 
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3.3.8.(2) miR-224 negatively regulates endogeneous SMAD4 
expression. 
To evaluate if miR-224 can affect the endogenous expression of 
SMAD4, we manipulated the endogeneous miR-224 expression using specific 
miR-224 precursors and inhibitors.  As shown in Figure 3.3.8.(2), SMAD4 
expression was significantly lower (p<0.001, lower panel) in HCT116 cells 
transfected with miR-224 precursor to over-express miR-224 (p<0.001, top 
panel), compared to the Control Oligos transfected cells. When miR-224 
inhibitor was co-transfected with miR-224 precursors, the over-expression of 
miR-224 was partially rescued (p<0.001, top panel) and the SMAD4 transcript 
level was significant increased (p<0.01) compared to that of the miR-224 
precursor transfected cells, suggesting that the miR-224 inhibitor was able to 
rescue the inhibition of SMAD4 expression by miR-224.  
3.3.8.(3) SMAD4 inhibition  phenocopies miR-224 over-expression. 
To ascertain that SMAD4 is indeed a target through which miR-224 
affects cell proliferation, we inhibited SMAD4 expression with siRNA which 
specifically targets SMAD4 (si-SMAD4) and examined its effect on cell 
proliferation. As shown in Figure 3.3.8.(3)B, SMAD4 inhibition increased cell 
proliferation (rightmost lane), phenocopying the effect of overexpression of 
miR-224 (middle lane).  Figure 3.3.8.(3)A shows the expression of miR-224 
and SMAD4 when miR-224 precursor and si-SMAD4 were introduced into 
the cells. Taken together, our data demonstrated that miR-224 regulates cell 




Figure 3.3.8.(2) miR-224 negatively regulates SMAD4 transcript 
expression. Relative miR-224 expression (normalized against RNU48) (Top) 
and relative SMAD4 transcript expression (normalized against β-actin) 
(bottom) measured with RT-qPCR in HCT116 cells transfected with Control 
Oligos or miR-224 precursor or co-transfected with both miR-224 precursor 
and inhibitor.  Data are represented as Mean ± S.E. from at least three 











































































Figure 3.3.8.(3) Cells whose SMAD4 expression is inhibited shows similar 
proliferation phenotype as cells over-expressing miR-224. (A) Expression 
of miR-224 and SMAD4 after the introduction of either miR-224 precursors or 
siRNA against SMAD4, measured with RT-qPCR (left panel) and Western 
blot analysis (right panel). (B) Relative cell proliferation of HepG2 cells 
transfected with Control oligos, miR-224 precursor or siRNA against SMAD4 
measured using the BrdU proliferation assay. Data presented as Mean ± SE 
































3.3.9 SMAD4 mRNA expression was inversely correlated with miR-224 
expression in HCC patients  
We proceeded to evaluate the clinical significance of our observations 
that miR-224 negatively regulates SMAD4 by carrying out a correlation 
analysis between miR-224 and SMAD4 transcript expression in 100 HCC 
patients. As evident in Figure 3.3.9, a statistically significant inverse 
correlation was observed between miR-224 and SMAD4 expression in HCC 
patients (Pearson Coefficient r=−0.350, R2=0.122 at p< 0.001), demonstrating 





 Figure 3.3.9 SMAD4 transcript expression level is inversely correlated 
with miR-224 expression in HCC patients.  Scatter plot of the mean fold 
change of SMAD4 transcript versus that of miR-224 expression. Each spot 
represents data from one patient presented in log2 scale and a linear regression 
line is depicted as a solid line. Statistically significant inverse correlation was 
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CHAPTER 4: DISCUSSION 
4.1 miRNA deregulation in hepatocellular carcinoma 
 Like other cancers, aberrant gene expression features significantly in 
human hepatocellular carcinoma [260]. At the time when this project started, 
miRNAs, the largest class of gene regulators at the post-transcriptional and 
translational level, were found to be significantly deregulated in a number of 
human blood cancers [44] and solid tumors [74]. However, comprehensive 
profiling of miRNA expression in human HCC was still very limited. 
Therefore, we aim to identify significant miRNA deregulation by profiling the 
miRNA expression in local HCC patients. As described in Section 3.1 in the 
Results, we profiled tumor versus paired adjacent non-tumorous tissues from 
100 HCC patients and identified 66 significantly differentially expressed 
miRNAs associated with HCC. As shown by Table 3.1, 36 of these 66 
miRNAs have been previously reported to be differentially expressed in HCC. 
We observed 97 % (35 out of 36 miRNAs) consistency between our data and 
the previously reported data, demonstrating the reliability and accuracy of our 
miRNA profiling revealing true HCC information that is not confounded by 
the patients selected. In addition, we have also identified 30 novel miRNA 
deregulations in HCC with majority of these miRNAs absent from the miRNA 
profiling in previously reported studies. Hence, our work reaffirms current 
knowledge on miRNA deregulation in HCC and added new targets and 




These 66 significantly differentially expressed miRNAs in HCC were 
not randomly distributed in the genome but rather clustered based on the 
genomic loci or their functional miRNA family. These miRNA clusters show 
evidence of coordinated expression in our HCC samples, suggesting these 
deregulated miRNAs may be coordinately regulated based on either genomic 
loci or family-defining seed sequences.  
In Section 3.2.1 to 3.3.3, we have provided some experimental 
evidence to partly support the above hypothesis. We observed significant 
down-regulation of members of let-7 family of miRNAs (let-7a, let-7b and let-
7c) in HCC tumors and this let-7 down-regulation was significantly inversely 
correlated with expression status of HBV viral X protein (HBx) in HCC 
patients. To ascertain whether HBx plays a more direct role in down-
regulating let-7, we transiently introduced HBx in HepG2 cells and observed 
direct down-regulation of let-7 miRNAs. As the focus of this project is to 
understand the functional relevance of the observed miRNA deregulation in 
HCC, we did not further characterize the exact mechanism of how HBx down-
regulates let-7. As these let-7 miRNAs reside on different genomic loci, we 
speculate that HBx may down-regulate let-7 by targeting the let-7 specific 
family-defining seed sequence at the stage of miRNA processing.  LIN28B is 
identified and characterized in HCC [261] and functions to block let-7 
precursors from being processed into mature miRNAs by inducing terminal 
uridylation and degradation of let-7 precursors [262]. LIN28B is frequently 
over-expressed in HCC and may explain for the reduced let-7 expression in 
HCC tumors. High LIN28B expression and low let-7 expression are associated 
with poor clinical prognosis [263]. It would be interesting to explore if HBx 
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acts through LIN28 to negatively regulate let-7 maturation. The identification 
of cellular factors which are responsible for regulating families of miRNAs 
may represent novel targets through which novel strategies can be devised to 
the reverse the coordinated deregulation of such miRNAs. 
In addition of the deregulation of miRNA families, we also found that 
32 out of these 66 deregulated miRNAs reside in miRNA clusters in the 
human genome. 16 of these 32 clustered miRNAs (50 %) showed evidence of 
coordinated expression at 7 genomic clusters (Figure 3.1 and Table 3.1), 
suggesting common mechanisms of co-regulation at these genomic loci. 
Possible mechanisms may include genomic copy number variation, epigenetic 
status changes or transcriptional activation/repression. 
Like many other cancers, genomic instability features significantly in 
HCC [264]. As many as 50 % miRNA genes are located in cancer-associated 
genomic regions or fragile sites [39]. Therefore, genomic DNA copy number 
variation represents a potentially important mechanism to regulate miRNA 
expression in HCC. Recent studies have provided evidence for DNA copy 
number variation at miRNA genomic loci in ovarian cancer, breast cancer and 
melanoma [265] and genomic amplification at Chr13q31 was reported to be 
responsible for miR-17-92 up-regulation in malignant lymphoma patients 
[266]. Members of miR-17-92 cluster were also found to be up-regulated in 
our profiling for HCC patients and genomic amplification may also be the 
reason behind our observation. Ding et al. reported genomic amplifications or 
deletions at miRNA loci of 22 out of the 129 miRNAs screened in HCC 
patient tissues. 75 % of these 22 miRNAs (16 miRNAs) showed concordant 
changes in expression [267]. Three of these miRNAs (miR-21, miR-151 and 
104 
 
miR-423) were reported to be associated with genomic amplification at the 
respective loci by up to 56 % and these miRNAs were also observed to be up-
regulated in our study. Hence, copy number variation at the miRNA genomic 
loci may represent a common mechanism for miRNA deregulation in human 
cancers including HCC. 
Epigenetic changes represent another mechanism for miRNA 
regulation. DNA methylation and histone modification can result in 
chromosomal remodeling which activates or represses transcription. Datta et 
al. reported differential miRNA expression in HCC cells after treatment with 
DNA methylation inhibitor (5-azacytidine) and histone deacetylase inhibitor 
(trichostatin A) and miR-1-1 is silenced through promoter DNA methylation 
in HCC patient samples [268]. miR-34a, which was up-regulated in tumors of 
HCC in our study, was shown to be up-regulated upon trichostatin A treatment, 
suggesting the involvement of histone acetylation in regulating miR-34a. 
Additional evidence has been provided by Furuta et al. who have 
demonstrated that miR-124 and miR-203 are epigenetically silenced through 
promoter methylation in HCC [269]. As epigenetic modification is heavily 
implicated in HCC [270], epigenetic changes may account for some of the 
aberrantly expressed miRNAs identified in HCC patients from our study.  
Further studies on epigenetic regulation of miRNAs, especially on the role of 
histone modification, will improve our understanding of this critical 
mechanism of miRNA regulation. Since epigenetic changes can be reversed 
with drug treatment, it might provide a novel therapy for HCC treatment. 
Similar to their gene counterparts, miRNAs are tightly regulated at the 
level of transcription. V-myc myelocytomatosis viral oncogene homolog 
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(MYC) oncogene has been shown to transcriptionally regulate a number of 
cellular miRNAs. MYC positively regulates miR-17-92 cluster [271] and miR-
9 [272] and negatively regulates miR-29a/b [273]. This may partly explain the 
aberrant pattern of such miRNA expression in HCC where MYC is frequently 
over-activated. Regulation of miRNA expression by another important cellular 
transcription factor nuclear factor kappa-B (NF-κB) has been reported for let-
7i [274],  miR-29a/b [273] and miR-143 [275], all of which were differentially 
expressed in HCC. In addition, miRNAs are also under the regulation of 
cellular signaling pathways. Tumor growth factor beta (TGF-β) signaling 
pathway is implicated in up-regulation of miR-224 in mouse granulosa cells 
[240] and miR-181b in HCC [276] while miR-34c is regulated by MAPK 
signaling pathway [277]. As more data emerges on transcriptional regulation 
of miRNAs, we can then better integrate miRNAs into existing cellular 
pathways that are dominated by protein-coding genes and further understand 
its role in aberrant miRNA expression in human cancer. 
Hence, aberrantly expressed miRNAs in HCC may be due to one or 
more of the interdependent mechanisms mentioned above. Much effort is 
needed to understand the exact mechanisms of these observed miRNA 
deregulation in HCC which will in turn offer valuable insights into their 
possible therapeutic intervention to revert the functional impact of their 
deregulation in liver cells. 
4.2 miRNA deregulation impacts on important cellular pathways  
The identification of miRNA deregulation is only the first step to 




Figure 4.2.1 Schematic diagram illustrating the deregulated miRNAs 
impacting on important cellular processes. HBx mediated down-regulation 
of let-7a increases cell proliferation via releasing the inhibition on STAT3. 
miR-224 up-regulation increases cell proliferation via targeting SMAD4 and 
increases cell apoptosis via targeting API5.  
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our project started, the functional relevance of such miRNA deregulation with 
respect to their roles in deregulating crucial cellular pathways remains largely 
unknown and the relevant cellular targets of these deregulated miRNAs 
remain even more elusive. In Section 3.2 and 3.3 in Results, we have 
functionally characterized let-7 (significantly down-regulated miRNAs) and 
miR-224 (significantly up-regulated miRNA) to gain an understanding of the 
role of their deregulation in HCC. 
4.2.1 HBx-Let-7-STAT3 pathway in HCC 
Hepatitis B virus protein X (HBx) plays an important role in 
hepatocellular carcinogenesis. Our current understanding of the role of HBx 
focuses on its ability to deregulate cellular gene expression at the transcription 
level through its interaction with cellular factors to affect either cellular signal 
transduction pathways or gene transcription. In this study, we provided 
evidence that HBx can also deregulate cellular gene expression at the post-
transcriptional level through deregulating cellular miRNAs such as let-7.  It is 
not uncommon for viruses to evolve mechanisms to suppress RNA 
interference, which is an important antiviral defense.  HIV-1 was recently 
reported to globally suppress host microRNA expression [278]. The Epstein-
Barr virus latent membrane protein 1 was reported to activate miRNA-155 
transcription [279]. This is the first study to demonstrate that the hepatitis B 
viral protein, HBx also plays a role in deregulating cellular miRNAs.   
Let-7, the first miRNA identified in humans, was reported to target a 
number of important cellular oncogenes such as MYC[76], RAS[75] and 
HMGA2[280].  In this study, we identified and experimentally validated 
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another direct cellular target of let-7, STAT3, which is an important member 
of the JAK/STAT pathway.  STAT3 was reported to be involved in many 
cellular processes including cell growth, survival, metastasis, angiogenesis and 
immune suppression, all of which favor tumor formation and progression 
[281]. STAT3 was also known to play critical role in liver regeneration and 
over-activation of STAT3 may play a role in contributing to HCC [282, 283]. 
In fact, constitutive activation of STAT3 alone is sufficient to transform 
normal mouse fibroblast [284]. Hence, STAT3 expression and activity are 
highly regulated via different mechanisms at different levels under 
physiological conditions. Mechanisms of STAT3 inhibition includes inhibition 
of Jak kinase activity through the activation of SOCS1 and SOCS3, also 
known as suppressor of cytokine signaling proteins [285]  and protein 
inhibitors of activated STAT3 (PIAS) [286], or through the modulation of 
specific phosphatases such as protein phosphatase 2A (PP2A) [287].  The 
identification that let-7 microRNAs targets STAT3 reveals an additional level 
of regulation that STAT3 is subjected to, whereby modulation of its 
transcript/protein abundance is carried out by microRNAs.  miRanda predicted 
a total of 122 putative miRNA binding sites along the 3’UTR of STAT3 (data 
not shown) suggesting that the STAT3 may be highly regulated not only at 
several different levels mentioned above but also at the post-transcriptional 
/translational level by several different miRNAs including let-7. Over-
activation of STAT3 is frequently observed in solid tumors including breast, 
ovary and prostate tumors [281] where let-7 is also frequently under-
represented [138]. However, STAT3 seems to be only one of several let-7 
cellular targets through which let-7 acts to negatively regulate cell 
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proliferation since completely inhibiting STAT3 alone does not completely 
inhibit cell proliferation (Figure 3.2.5.(3)).  This is not surprising as let-7 was 
also reported to target MYC [76] and RAS [41], both of which are important 
factors involved in cell proliferation.  The fact that let-7 can target MYC, RAS, 
STAT3 and probably other proliferation factors yet to be discovered further 
demonstrates the role of let-7 as a master regulator of cell proliferation, whose 
loss of function will result in the deregulation of crucial cellular processes, 
leading to tumorigenesis. Unfortunately, we could not observe a statistically 
significant correlation between let-7a and STAT3 expression in the 20 HCC 
patients we examined (data not shown). This might be due to the fact that 
STAT3 regulation is very complex and additional HCC patient samples may 
need to be examined to better stratify the samples and reveal any potential 
correlation. 
Although the down-regulation of let-7 promoted cell proliferation 
(Figure 3.2.4) and HBx was found to down-regulate let-7 expression (Figure 
3.2.6.(1)), HBx expressing cells does not seem to show increased cell 
proliferation compared to control cells under normal conditions (Figure 
3.2.6.(2)). This is probably due to the fact that HBx is also known to promote 
cell apoptosis in HepG2 cells [288].  To dissect the effect of HBx on cell 
proliferation from cell death, we proceeded to inhibit cell death by treating the 
cells with a general caspase inhibitor. When cell apoptosis is inhibited, HBx 
cells showed significantly higher cell proliferation than the control cells 
(Figure 3.2.6.(3)).  Thus, our results strongly suggest that HBx can 
concurrently impact on both cell death and cell proliferation and HBx-
mediated let-7 down-regulation functions to support cell proliferation in HBx 
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cells.  These data are consistent with previous reports that HBx is a pleiotropic 
viral protein involved in both cell proliferation [259] and death [251].  In the 
multi-stage, multi-hit process of tumorigenesis, HBx may function as an 
opportunistic factor that can potentially help to promote tumor formation 
partially through its down-regulation of let-7 miRNAs in those cells where cell 
apoptosis are impaired. This could perhaps explain why different research 
groups observe different phenotypes in HBx-expressing cells [251, 259, 288] 
and mice [289, 290] since the predominant phenotype of HBx depends on 
other factors that make up the microenvironment in which the function of HBx 
is evaluated. Our study focuses on the role of full length HBx protein while 
Zhang et al recently demonstrated that a natural mutant form of carboxyl 
terminal truncated HBx may have a different effect on cellular proliferation 
[291]. This raises the possibility that HBx protein may have different 
functional domains to execute its pleiotropic effect on multiple cellular 
functions. 
In summary, our work is the first report highlighting the role of the 
hepatitis viral protein HBx, in regulating cellular microRNAs expression. The 
HBx-let-7-STAT3 pathway identified in our study represents a clinically 
relevant pathway in which the pleiotropic HBx viral protein contributes to 
HCC and offers a new perspective in understanding the complexity of HCC. 
 
4.2.2 miR-224 up-regulation in HCC impacts on multiple pathways 
 In addition to HBx mediated let-7 down-regulation, we also 
functionally characterized miR-224 up-regulation in HCC in our study. As 
shown in Figure 3.3.1, miR-224 expression is kept at a very low level in 
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normal liver samples, probably due to the fact that miR-224 resides in 
ChrXq28 where transcription is quiescent. miR-224 expression is significantly 
elevated in the non-tumor tissues from HCC patients and further increased in 
HCC tumor tissues. The fact that miR-224 expression increases as liver 
disease progresses makes it a possible biomarker for liver status. Further work 
is needed to evaluate the feasibility of miR-224 as a liver biomarker. 
 Functional characterization of miR-224 reveals that miR-224 is 
capable of increasing both cell proliferation and apoptosis through targeting 
different cellular genes (Figure 3.3.3 and Figure 3.3.4). miR-224 increases cell 
proliferation by targeting SMAD4, the central mediator of TGFβ pathway. 
TGFβ is an important protein regulating cell proliferation and cell 
differentiation by acting as an anti-proliferative factor. SMAD4 functions to 
transduce the signal from activated TGFβ receptor by binding to the activated 
SMAD2/3 and facilitating the translocation of the activated complex into the 
nucleus where anti-proliferation genes such as p21 and p15 are activated [292]. 
A number of tumor types have been reported to be associated with SMAD4 
knockout mouse models [292], implicating dysfunctional TGFβ/SMAD 
pathway in carcinogenesis. We have demonstrated that miR-224 is able to 
interact with the putative miR-224 binding sites on SMAD4 3’UTR to 
negatively regulate the endogenous level of SMAD4 (Figure 3.3.8), promoting 
cell proliferation by possibly controlling TGFβ induced growth arrest. Hence, 
our data supported Yang et al’s hypothesis that miRNAs play roles in TGF-
β/SMAD-pathway-induced tumor-suppressive effects [292]. 
 Over-expression of miR-224 also sensitizes cells to undergo apoptosis 
by targeting API5, an apoptosis inhibitor. API5 was previously reported to act 
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downstream E2F and inhibit E2F-dependent apoptosis without affecting E2F-
dependent transcription [293].  The observation that miR-224 is over-
expressed in the tumors of HCC patients and that it plays a role in sensitizing 
cells to apoptosis via the inhibition of API5 expression seems to contradict 
conventional wisdom that apoptosis is reduced during carcinogenesis.  
Nonetheless, similar to miR-224, oncoproteins such as MYC and E1A, were 
found to sensitize cells to apoptosis upon minor insults that normal cells can 
usually resist e.g. serum depletion, DNA damaging agents, hypoxia, etc [294, 
295].  Oncogenic changes that promote apoptosis are thought to provide the 
selective pressure for cells to override apoptosis during the multistage process 
of carcinogenesis [294] resulting in a resistant population of cells that 
accumulate heritable genetic mutations [296] during its increased lifespan thus 
facilitating oncogenic transformation.  The dual role of miR-224 to influence 
both cell proliferation and cell death simultaneously may thus potentially 
hasten this selection process favoring cells that accumulate sufficient heritable 
genetic mutations to override apoptosis during the multistage of 
carcinogenesis. Sassen et al. has previously proposed that a single miRNA can 
potentially regulate opposing cellular activities such as cell proliferation and 
apoptosis [297] and miR-224 represents the first such miRNA identified. 
4.2.3 miRNA network forms part of the HCC microenvironment 
 The main challenge to understand miRNA function is to identify 
relevant cellular targets through which these miRNAs act to regulate cellular 
processes. In this study, we have contributed to the understanding of let-7 in 
negatively regulating cell proliferation by the identification of STAT3 as a let-
7 specific target. In addition, we have also identified API5 and SMAD4 as 
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relevant direct targets through which miR-224 positively regulate apoptosis 
and cell proliferation, respectively. However, we may be presenting only the 
tip of the iceberg as each miRNA is predicted to regulate hundreds of cellular 
targets. Indeed, let-7 is also known to regulate development [27] and miR-224 
over-expression is also recently found to increase cell migration, invasion [240] 
and anchorage independent cell growth [298]. This highlights the fact that we 
are still far from complete understanding of even a single miRNA. 
 Moreover, we have adopted a common but simplified approach to 
study either let-7 down-regulation or miR-224 up-regulation in isolation. In 
reality, an HCC tumor with low let-7 expression is also frequently found to 
over-express miR-224. Taken our limited knowledge on let-7 and miR-224, 
we may speculate that the tumor cells with low let-7 and high miR-224 
expression may be proliferating fast, less differentiated, more invasive and 
rapidly adapting to override apoptosis. The understanding of such complex 
network formed by multiple deregulated miRNAs is necessary to the role of 
such miRNA network in the real context of HCC. If we extrapolate this 
miRNA network from let-7 and miR-224 to the 66 significantly differentially 
expressed miRNAs in HCC, the exact combination of deregulated miRNAs in 
each of the HCC tumor samples may represent a unique signature of the 
specific tumor microenvironment associated with each individual HCC tumor, 
providing valuable information for personalized treatment. This hypothesis 
would require system biology approach to integrate a large dataset which 
comprises data from collective effort to characterize each miRNA.  
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4.3 miRNAs are potential diagnostic and therapeutic targets for 
HCC. 
Current classification of HCC replies exclusively to clinical parameters 
and miRNA profile can be used to improve our ability to classify HCC and 
stratify prognosis. MiRNA expression signatures have been shown to be able 
to differentiate liver samples based on histology (hepatocellular adenoma from 
HCC), etiology (alcohol induced HCC from HBV associated HCC) and cancer 
gene mutation (β-catenin and hepatocyte nuclear factor 1α) [131].  Recently, a 
signature of 20 miRNAs has been shown to associate with HCC metastasis 
and correlates with overall survival [242]. Furthermore, high miR-221 levels 
in HCC were associated with tumor multifocality and reduced time to 
recurrence after surgery [226] and high miR-222 level negatively correlates 
with disease free survival [137]. MiRNA profiling, in combination with 
existing clinical parameters, may provide additional information on HCC 
classification and prognostic risk stratification and help oncologists make 
better informed decisions.  
The easily detectable, serum bound miRNAs are good candidates to 
screen for specific biomarkers to improve existing screening strategies for 
early HCC detection. Significant differences in blood miRNA expression can 
be detected and associated with well-controlled liver tumorigenesis in a mouse 
model [243]. In human HCC, miR-500 is reported to be elevated in HCC 
patients and returned to normal after surgical resection [244]. MiR-500 and 
others represents potential diagnostic markers for HCC detection.  
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As miRNAs play an important role in HCC, they represent promising 
therapeutic targets for novel treatment strategies for HCC patients. Exciting 
data have emerged in the use of antagomirs which are chemically modified 
oligonucleotides to specifically and effectively knock down miRNA 
expression. Systemic delivery of antagomirs against miR-122 has resulted 
remarkably specific and stable down-regulation of miR-122 in the liver up to 
20 days [245]. As miR-122 promotes HCV replication, knock-down of miR-
122 may provide novel approach to manage HCV load in HCV-associated 
HCC. Recently Kota et al demonstrated the efficacy of the systemic delivery 
of miR-26a in an adeno-associated virus vector to protect disease progression 
without toxicity in a mouse liver cancer model [246], opening new door to 
miRNA replacement therapy. 
 
4.4 Conclusions and perspectives 
 In conclusion, we identified a miRNA signature consisting of 66 
significantly differentially expressed miRNAs between HCC tumors versus 
paired adjacent non-tumor tissues from 100 HCC patients. We subsequently 
functionally characterized let-7a down-regulation and miR-224 up-regulation. 
We identified that HBx is responsible for reduced let-7a expression and 
STAT3 as a direct cellular target through which let-7a negatively regulates 
cell proliferation. HBx-let-7-STAT3 pathway supports cell proliferation in 
HBx-expressing cells. On the other hand, miR-224 over-expression increases 
cell proliferation by targeting SMAD4 and sensitizes cells to apoptotic cell 
death by targeting API5.  
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 We believe that the study of miRNA deregulation in HCC will 
continue to grow in the characterization of the various deregulated miRNAs in 
terms of the impact on various cellular functions and target identification. Our 
study concentrates on the HBV-associated HCC as our patient samples are 
mostly HBV positive. Similar studies should also be performed on other types 
of HCC with different etiology (e.g. HCV associated or alcohol induced HCC) 
to provide a complete picture of miRNA deregulation in HCC. Integrating 
individual miRNA to form complex miRNA regulatory networks will further 
improve our understanding of the role of miRNA deregulation in HCC and 
facilitate novel treatment strategies. The understanding of the exact 
mechanisms for crucial miRNA deregulations will also provide clues for its 
therapeutic intervention. We hope, in the near future, that we can better 
comprehend the complex nature of HCC from the miRNA perspective. We 
can integrate this new information with the existing knowledge of HCC to 
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Profiling MicroRNA Expression in Hepatocellular Carcinoma
Reveals MicroRNA-224 Up-regulation and Apoptosis
Inhibitor-5 as a MicroRNA-224-specific Target*□S
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Like other cancers, aberrant gene regulation features sig-
nificantly in hepatocellular carcinoma (HCC). MicroRNAs
(miRNAs) were recently found to regulate gene expression at
the post-transcriptional/translational levels. The expression
profiles of 157miRNAs were examined in 19 HCC patients, and
19 up-regulated and 3 down-regulatedmiRNAswere found to
be associated with HCC. Putative gene targets of these 22
miRNAs were predicted in silico and were significantly
enriched in 34 biological pathways, most of which are fre-
quently dysregulated during carcinogenesis. Further character-
ization of microRNA-224 (miR-224), the most significantly up-
regulated miRNA in HCC patients, revealed that miR-224
increases apoptotic cell death aswell as proliferation and targets
apoptosis inhibitor-5 (API-5) to inhibitAPI-5 transcript expres-
sion. Significantly, miR-224 expression was found to be
inversely correlatedwithAPI-5 expression inHCCpatients (p<
0.05). Hence, our findings define a true in vivo target ofmiR-224
and reaffirm the important role of miRNAs in the dysregulation
of cellular processes that may ultimately lead to tumorigenesis.
Hepatocellular carcinoma (HCC)5 is among the top 10 most
prevalent cancers worldwide (1), accounting for 600,000
deaths annually (2). The overall 5-year survival rate for HCC
patients is less than 5% (3). Chemotherapeutic interventions are
ineffective, and surgical resection/liver transplantation is the
only treatment modality to confer survival benefit in HCC
patients. Late clinical presentations have also led to poor prog-
nosis for HCC patients. It is thus necessary to elucidate the
molecular mechanisms underlying HCC and identify novel
therapeutic targets and biomarkers for the early detection of
HCC.
Like other cancers, aberrant gene regulation features signif-
icantly in HCC. Several reports on gene expression profiling of
HCC patients have identified numerous pathways (e.g. prolifer-
ation, cell cycle regulation, apoptosis, angiogenesis, etc.) that
may be dysregulated during hepatocarcinogenesis (see review
in Ref. 4). Recently, an increasing number of reports have
described a new class of small noncoding RNAs that are impli-
cated in the regulation of gene expression at the post-transcrip-
tional and translational level. These regulators are termed
microRNAs (miRNAs), and their dysregulation may have
implications in carcinogenesis.
miRNAs represent a class of noncoding RNAs whose pro-
cessed products are 22 nucleotides in length and regulate
gene expression in plants and animals (5). To date, more than
500 miRNAs are predicted to be expressed in humans (6, 7).
These miRNAs are estimated to regulate the expression of
5000 human genes or 30% of all human proteins (8). It is
likely that the interaction between miRNAs and their numer-
ous mRNA targets may represent an important level of gene
regulatory control in the cell (5).
The importance of miRNAs in cancer is highlighted by the
observation that50% of miRNA genes are located in cancer-
associated genomic regions or fragile sites (9–11). Importantly,
miRNAexpression is frequently dysregulated in several cancers
including B-cell chronic lymphocytic leukemia (9, 12), Burkitt
lymphoma (13), colorectal cancer (14), lung cancer (15, 16), and
hepatocellular carcinoma (17). Additionally, differential
expression of miRNAs have been found to be associated with
post-operative survival in lung cancer patients (15) and are
diagnostic and prognosticmarkers of lung cancer (16).miRNAs
have been implicated to play both tumor suppressor and onco-
genic roles (18).
Althoughmuch is known about the profiles ofmiRNAs in the
various tissues/developmental stages, embryonic stem cell dif-
* This work was supported by a National Medical Research Council of Singa-
pore block grant through the National Cancer Centre (to C. G. L.), an indi-
vidual grant from the National Medical Research Council, and a grant from
theBioMedical ResearchCouncil (toC.G. L.). The costs of publicationof this
article were defrayed in part by the payment of page charges. This article
must therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1–S3 and Table S1.
1 These authors contributed equally to this work.
2 Present address: Institute of Molecular and Cell Biology, Singapore.
3 Present address: Bioinformatics Center, National Yang-Ming University, Tai-
pei, 112, Taiwan.
4 To whom correspondence should be addressed: Division of Medical Sci-
ences, National Cancer Center, Level 6, Lab 5, 11 Hospital Dr., Singapore
169610, Singapore. Tel.: 65-6436-8353; Fax: 65-6372-0161; E-mail:
bchleec@nus.edu.sg.
5 The abbreviations used are: HCC, hepatocellular carcinoma; miRNA,
microRNA; RQ, relative quantity; GO, gene ontology; BrdUrd, bromode-
oxyuridine; UTR, untranslated region; -gal, -galactosidase; MRP1, multi-
drug resistance-associated protein 1; EGFP, enhanced green fluorescence
protein; PE, phycoerythrin.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 283, NO. 19, pp. 13205–13215, May 9, 2008
© 2008 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
MAY 9, 2008•VOLUME 283•NUMBER 19 JOURNAL OF BIOLOGICAL CHEMISTRY 13205











Supplemental Material can be found at:
ferentiation, brain development, hematopoietic lineage differ-
entiation, as well as their deregulation in various cancers, less is
known about the function of each of thesemiRNAs or their true
cellular targets. Numerous algorithms have been developed to
predict the putative cellular targets of these miRNAs including
PicTar (19), miRBase Targets (7), and TargetScan (8). Some of
the cellular targets that have been experimentally validated for
the variousmiRNAs are HoxB8 (miR-196) (20), Hand2 (miR-1)
(21), E2F1 (miR-17–5p andmiR-20a) (22), Hox-A11 (miR-181)
(23), LATS2 (miR-372/3) (24), Rb1 (miR-106a), TGFBR2 (miR-
20a) (25), as well as IRAK1 and TRAF6 (miR-146) (26).
Here, we characterized the expression profiles of 157
miRNAs in 19 HCC patients and identified a set of significantly
differentially expressedmiRNAs associated withHCC.We also
functionally characterized one of the differentially expressed
miRNAs and identified its gene target.
EXPERIMENTAL PROCEDURES
Samples—Paired tumorous and adjacent nontumorous liver
tissues from 19 hepatocellular carcinoma patients were
obtained from the National Cancer Centre of the Singapore
Tissue Repository with prior approval from the National Can-
cer Centre Institutional Review Board.
miRNA Extraction and Expression Profiling—The Mir-
VanaTMmiRNA isolation kit (Ambion,Austin, TX)was used to
isolate total RNA including low molecular weight RNA from
patient samples and cell lines according to the manufacturer’s
protocol. Expression of 157 verified human microRNAs was
analyzed using the TaqMan MicroRNA assay human panel
early access kit (Applied Biosystems), according to the manu-
facturer’s instructions as previously described (27). Briefly,
patient RNA samples were used as template for reverse tran-
scription. Together with the high capacity cDNA archive kit,
RNase inhibitors, and miRNA-specific reverse transcription
primers (Applied Biosystems), the reverse transcription reac-
tions were carried out in a 96-well plate format. Real time PCR
was then performed with the reverse transcription products,
TaqMan 2Universal PCRMaster Mix without UNGAmper-
ase (Applied Biosystems), miRNA-specific TaqMan probes,
and primers (Applied Biosystems) on an Applied Biosystems
7500 Fast Real Time PCR systemwith an initial denaturation at
95 °C, followed by 40 cycles at 95 °C for 15 s and 60 °C for 1min.
The threshold cycle (CT) was then determined and defined as
the fractional cycle number at which the fluorescence detected
passes a fixed threshold. The Applied Biosystems 7500 Fast
software was used to analyze theCT values of differentmiRNAs
normalized to an endogenous control (let-7a or U6). The nor-
malized values (dCT) from tumorous tissue were then com-
pared with its paired nontumorous tissue, yielding miRNA dif-
ferential expression profiles.
In SilicoAnalyses ofmiRNAExpressionData, Identification of
Putative miRNA Targets, and Categorization of Biological Pro-
cesses of These Putative miRNA Targets—Relative quantitation
of the expression of miRNA was determined using the 2Ct
method (28), and the results were expressed as log2 of the rela-
tive quantity (RQ) of the targetmiRNAnormalized against hsa-
let-7a (log2RQ). Differentially expressed miRNAs were identi-
fied by significant analysis of microarrays (29), with the false
discovery rate threshold set at 5%. Clustering and visualiza-
tion of the normalized data were performed with Cluster and
TreeView (30), using average linkage and Pearson’s correlation
as a measurement for similarity. Computational identification
of the putative miRNA targets was performed using PicTar
(19), miRBase Targets Version 3.0 (7), and TargetScan Release
3.0 (8). A gene was considered to be a putative target of a given
miRNA only if it was predicted by at least two of the three
methods. Categorization of the biological processes of the puta-
tive miRNA gene target was performed with gene ontology
(GO) using the Database for Annotation, Visualization, and
Integrated Discovery GoCharts module (31), at level 5
annotations.
Validation of the Expression of miR-224 in Tumors of HCC
Patients—Northern blot analysis was performed to validate
miR-224 overexpression in the tumors ofHCCpatients. Briefly,
1 g of total RNA (HCT116 cells transfected with Pre-miRTM
miR-224 precursor) or 2g of lowmolecular weight RNA from
both the tumor and adjacent nontumorous tissues of a few of
the same HCC patients that were previously profiled was sepa-
rated on a 15% denaturing polyacrylamide gel and electro-
blotted onto a nylon membrane (Schleicher & Schuell GmbH;
Dassel, Germany) at 300mA for 30min. ThemiRNA-224 probe
(5-TAAACGGAACCACTAGTGACTTG-3 (17)) and U6-
probe (5-ATGTGCTGCCGAAGCGAGCAC-3) were end-
labeled with Redivue [-32P]ATP (Amersham Biosciences)
using T4 Polynucleotide Kinase (New England Biolabs,
Ipswich, MA) and purified using the nucleotide removal kit
according to themanufacturer’s instructions (Qiagen). Hybrid-
ization was performed using Express Hybridization solution
(Clontech, Mountain View, CA) at 42 °C for 16 h, and the blots
were exposed to Hyperfilm MP (Amersham Biosciences).
Growth and Viability of HCT116 Cells Transfected with
miR-224—The human colon cancer cell line, HCT116, was
grown in McCoy’s medium supplemented with 10% fetal calf
serum at 37 °C in a humidified atmosphere of 5% CO2. To
determine the effect of miR-224 on growth and viability prop-
erties of HCT116 cells, 4  105 cells were transfected with
either 30 nM of Pre-miRTM miR-224 precursor molecule (miR-
224 precursor) or 30 nM of Pre-miRTMmiRNA Precursor Mol-
ecules-Negative Control 1 (Control) (AM17110) (Ambion)
using siPORTTM amine transfection agent (Ambion) following
the manufacturer’s protocol. The time when transfection com-
menced was considered as time 0. Sixteen hours after incuba-
tion in medium containing siPORTTM amine transfection
agent, these transfected cells were transferred into normal
growth medium. Viable cells were determined through trypan
blue dye exclusion. The growth properties of these cells were
expressed as percentages of viable cells at the respective time
points relative to time 0. Viability of these cells was expressed as
the percentages of viable cells relative to the total number of
cells (both dead and alive) at each individual time point. The
results were obtained by counting cells from the same experi-
ment twice in three independent experiments.
Apoptotic and Cell Proliferation Properties of HCT116 Cells
Transfected with miR-224—HCT116 cells were transfected
using siPORTTM amine transfection agent with either 60 nM
control or 30 nMmiR-224 precursor and 30 nM control or 30 nM
miR-224 Is Up-regulated in HCC and Targets the API-5 Gene
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miR-224 precursor and 30 nM anti-miRTM miR-224 inhibitor
(miR-224 inhibitor; AM17000, Ambion). Apoptosis assay was
performed 48 h post-transfection using the Annexin V-PE apo-
ptosis detection kit I (BD Biosciences) according to the manu-
facturer’s protocols and analyzed using a FACSCalibur flow
cytometer (BD Biosciences). Apoptotic cells were represented
by high PE-Annexin V and low 7-amino-actinomycin fluores-
cence signals. Cell proliferation assays were performed 24 h
post-transfection using the BrdUrd cell proliferation assay kit
(Calbiochem, San Diego, CA) following the manufacturer’s
protocol. BrdUrd incorporation measured as absorbance at
A450 in a SpectroMAX PLUS microplate reader (Molecular
Devices, Sunnyvale, CA) 48 h after it was added to the cells.
Apoptotic Properties of Primary Liver Cell Line Immortalized
with SV40 T-antigen, THLE-3, Transfected with miR-224
Inhibitor—To evaluate whethermiR-224 influence the apopto-
tic potential of a primary liver cell line transformed with SV40
T-antigen, THLE-3 cells were transfected in collagen-coated
plates with either 60 nM control or 60 nM miR-224 inhibitor
using siPORTTM amine transfection agent. The transfected
cells were then treated with 20 J/m2 UV 24 h post-transfec-
tion, and apoptosis assay was performed 48 h after transfection.
Generation of the miR-224 Target, API-5 3-UTR-Reporter
Construct—To experimentally validate whether theAPI-5 gene
is an in vivo target of miR-224, the 3-UTR of the API-5 gene
was amplified from nontumorous human liver tissue using
primers API5primerF1 and API5primerR1 as shown in supple-
mental Fig. S1. The 3-UTR was then cloned downstream to a
-galactosidase (-gal) reporter gene driven by the humanmul-
tidrug resistance-associated protein 1 (MRP1) promoter in a
construct that also contained the enhanced green fluorescence
protein (EGFP) gene for normalization of transfection effi-
ciency (32) (see Fig. 3B). The humanMRP1 promoter was cho-
sen over the constitutive human cytomegalovirus promoter,
because the MRP1 promoter is 30 times weaker than the
cytomegalovirus promoter (data not shown), which will facili-
tate themeasurement of subtler changes in reporter gene activ-
ity. A mutant pAPI5-3UTR-MUT was also generated by PCR
mutagenesis using primers as shown in supplemental Fig. S1.
Three point mutations were generated on each of the three
miR-224 target recognition sites/seed as shown in Fig. 3C.
These mutant recognition sites were verified in silico not to
bind to any of the known human miRNAs using miRBase
(Release 8.1, May 2006). The mutant construct generated was
confirmed by sequencing.
Characterization of the Effect of miR224 on API-5 3-UTR-
Reporter Construct—HCT116 cells were transfected in 6-well
plates by using siPORTTM amine transfection agent (Ambion,
Austin, TX) according to the manufacturer’s instructions with
either 1.0g of the-gal reporter construct containing thewild
type 2035-bp 3-UTR sequence of human API-5 (termed
pAPI5-3UTR-WT) or -gal reporter construct containing the
mutant 3-UTR sequence of human API-5 (termed pAPI5-
3UTR-MUT) and co-transfected with either 30 nM of miR-224
precursor (Ambion) or 30 nM of control (Ambion). -Gal
reporter gene activity was assayed kinetically using chlorophe-
nol red--D-galactopyranoside as substrate and measured at
1-min intervals over 60 min at 570 nm in a SpectraMAX PLUS
microplate reader (Molecular Devices) with crude lysate from
the transfected cells harvested 24 h post-transfection. To nor-
malize for differences in transfection efficiencies, Western blot
analyses were performed using 0.02 g/ml mouse anti-EGFP
(Roche Applied Science) and 1:100,000 horseradish peroxi-
dase-conjugated goat anti-mouse (Pierce) secondary antibod-
ies. -Gal activity was then normalized against EGFP expres-
sion levels. The data was also normalized against differences in
basal -gal activity when either the pAPI5-3UTR-WT or
pAPI5-3UTR-MT construct, but not miR-224 precursor or
Control, was transfected.
Quantitation of the API-5 mRNA Levels in Patient Samples
and HCT116/THLE-3 Cells Transfected with miR-224—Re-
verse transcription real time PCR was performed to quantitate
the API-5 transcript levels in patient samples and transfected
HCT116/THLE-3 cells. cDNAwas synthesized from total RNA
using a high capacity cDNA archive kit (Applied Biosystems)
according to the manufacturer’s instructions. Real time PCR
was performed in an Applied Biosystems 7500 real time PCR
system using the QuantiTectTM SYBRGreen PCR kit (Qiagen).
Amplification reactions included cDNA template (25 ng),
API-5 primers (forward, 5-TAGTGGGTTTGGAGAAGTTC-
3; reverse, 5-TCACTTGATAGGCATCTTTATG-3) (0.25
pmol/l), and 2 PCR Master Mix (5 l; Qiagen) in a total
volume of 10 l. Amplification conditions include an initial
denaturation at 95 °C for 15 min, followed by 40 cycles at 95 °C
for 30 s, 55 °C for 30 s, and 72 °C for 30 s. SYBR Green fluores-
cence was measured after each extension step.
Statistical Analysis of Experimental Data—Student’s t test was
performed to analyze the significance of differences between sam-
ple means obtained from at least three experiments.
RESULTS
miRNA Expression Profiling Identifies Dysregulation of
miRNAs That Are Associated with HCC—In this study, the
expression profiles of 157 mature miRNAs were determined in
19 HCC tumors and adjacent nontumorous liver tissues using
the TaqMan MicroRNA assays human panel early access kit
(Applied Biosystems) and normalized against hsa-let-7a as rec-
ommended by the manufacturer. Similar results were obtained
when the same data set was also normalized against U6 RNA
levels (data not shown) (27). Of the 157miRNAs, 133 exhibited
differential expression in at least 50% of the HCC patients, and
these are presented in Fig. 1A as a TreeView Heat Map. From
the TreeView Heat Map, there seem to be clusters of 20
miRNAs (red box) and 14 miRNAs (green box) that were up-
regulated and down-regulated, respectively, in the tumors of
HCC patients. The trends of differential expression of some of
these miRNAs (miR-199a, miR-200a, miR-125a, and miR-224)
were consistent with those observed in the only other previous
report onmiRNA expression inHCC (17). Significance analysis
of microarrays (21) was then utilized to identify miRNAs that
displayed significant differential expression between the tumor
and adjacent nontumorous liver tissues of HCC patients (sup-
plemental Fig. S2). When the false discovery rate was set to
5%, only 19 miRNAs were found to be significantly up-regu-
lated, whereas three were determined to be significantly down-
regulated, with themean fold change of themost highly up-reg-
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ulated miRNA (miR-224) being log2RQ 3.50 and that for the
most down-regulated miRNA (miR-139) being log2RQ 
3.26 (Fig. 1B). Two of the three significantly down-regulated
miRNAs (miR-145 and miR-214) reside in the cluster of down-
regulated miRNAs (green box), whereas 14 of the 19 up-regu-
lated miRNAs (red box) reside in the cluster of up-regulated
miRNAs shown in Fig. 1A.
Majority of the Predicted Targets of These 22 Differentially
Regulated miRNAs Reside in Pathways Reported to Be Dysregu-
lated during Carcinogenesis—An in silico strategy was
employed to obtain a glimpse of the potential roles of these 22
differentially expressed miRNAs in HCC carcinogenesis. Puta-
tive gene targets of all 22miRNAs (Fig. 1B)were predicted using
PicTar (19), miRBase Targets Version 3.0 (7), and TargetScan
Release 3.0 (8), and only gene targets predicted by at least two of
the three algorithms (supplemental Fig. S3) were further ana-
lyzed to reduce the chance of false positives (19, 34, 35).
Between 12 and more than 500 gene targets were predicted for
each of the 19 miRNAs that were significantly up-regulated in
tumors of HCC patients (Fig. 1B, bottom left panel), whereas
147–173 gene targets were predicted for each of the three
miRNAs that were significantly down-regulated (Fig. 1B, bot-
tom right panel). The pathways that these predicted gene
targets reside were annotated using GO (36) and the Database
for Annotation, Visualization, and Integrated Discovery
(GoCharts module) (31) to determine biological pathways,
whichwere significantly over-represented. Based on ap value of
0.01, 48% (1148/2391) of the predicted nonoverlapping gene
targets of the miRNAs resided within 35 biological pathways







































Significantly Down-regulated in tumors (3)
FIGURE 1. Profiles ofmiRNA expression in HCCpatients.miRNA expressionwas examined between the HCC tumor and adjacent nontumorous liver tissues
from 19HCC patients as described under “Experimental Procedures.” A, hierarchical clustering of 133miRNAs that are differentially expressed in the tumors of
at least 50% of the 19 HCC patients. The different HCC patients are represented on the x axis, and the results are presented as themean fold change inmiRNA
expression of tumor versus adjacent nontumorous tissue in each patient. Red represents miRNAs that are overexpressed in the tumors, whereas green
representsmiRNAswhose expression is down-regulated in tumors. The green box shows a cluster ofmiRNAs that are down-regulated in HCC tumors, whereas
the red box display the cluster ofmiRNAswhose expression of are up-regulated in the tumor. B, top panel, hierarchical clustering of the 22 significantly up- and
down-regulatedmiRNAsobtainedusing significance analysis ofmicroarrayswith false discovery rate of5%. Bottom left panel, table of the 19miRNAs that are
significantly overexpressed in the tumors of HCC patients represented as mean fold change of tumor versus nontumorous tissue and expressed as log2RQ.
Bottom right panel, table of the three miRNAs that are significantly down-regulated in the tumors of HCC patients represented as mean fold change of tumor
versus nontumorous tissue and expressed as log2RQ.
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transcription, regulation of progression through cell cycle and
Wnt receptor signaling pathway (supplemental Table S1). 80%
of these 35 biological pathways have been reported to be impli-
cated in the carcinogenesis process (supplemental Table S1),
strongly suggesting that the miRNAs we observed to be differ-
entially expressed inHCCpatients target genes whose dysregu-
lation may play significant roles in carcinogenesis.
miR-224 Overexpression Decreases Cell Viability and Sensi-
tizes Cells to Apoptotic Cell Death—To gain further insights
into how dysregulation of these miRNAs may play a role in
carcinogenesis, we further characterizedmiR-224, themost up-
regulatedmiRNA (log2RQ 3.5 or fold change of 11.28) in our
study and the only miRNA that was also reported in another
study to be up-regulated in HCC patients. Northern blot anal-
ysis confirmed that miR-224 was up-regulated in the tumors of
HCC patients (Fig. 2A). The functional significance of
increased miR-224 expression in the cells was evaluated by
transfecting miR-224 precursor into the human colorectal
HCT116 cells, which exhibit low endogenous miR-224 expres-
sion (data not shown). miR-224 expression peaked 24 h post-
FIGURE 2. Functional characterization ofmiR-224. A, Northern blot analyses to validate the increasedmiR-224 expression in tumor tissues of representative
HCCpatients.P(number) represent the identity of thepatients corresponding to the samepatients in Fig. 1.Tdenotes tumor tissue from indicatedHCCpatients,
whereasNdenotes the paired nontumorous liver tissues.Control represent total RNA isolated fromHCT116 cells 72 h after transfectionwithmiR-224precursor
and hybridized with miR-224 probe. B, miR-224 expression in HCT116 cells. The left panel shows results from TaqMan MicroRNA individual assay for hsa-miR-
224 (Applied Biosystems) in HCT-116 cells after transfection with miR-224 and normalization against hsa-Let-7a for the various time points. The results are
expressed as the fold difference between miR-224 expression in miR-224 precursor transfected cells versus control transfected cells. The right panel shows
Northern blot Analyses of untransfected HCT116 cells or HCT116 cells carrying control or miR-224 precursor, 72 h after transfection. C, left panel, cell growth
expressed as percentage of viable cells at the respective time points relative to the transfection start time, time 0. miR-224 precursor transfected cells are
represented by squares, and control transfected cells are represented by triangles. Right panel, viability of cells expressed as the percentage of viable cells
relative to the total numberof cells at aparticular timepoint. The resultswereobtainedby counting cells from the sameexperiment twice in three independent
experiments.D, panel i, miRNA expression of cells transfectedwith control, miR-224 precursors, ormiR-224 precursors andmiR-224 inhibitors. Panel ii, relative
apoptosis of similarly treated cells, as assayed using PE-conjugated annexin V staining. Apoptotic cells were detected as high in PE-annexin V staining and low
in 7-amino-actinomycin (7-AAD) staining. The profiles shown are representative from three independent experiments. Panel iii, relative cell proliferation of
similarly treated cells assayedusing the BrdUrdproliferation assay kit. In B–D, data are fromat least three independent experiments and shownas themeans	
S.E. *, p 0.05; **, p 0.01; ***, denotes p 0.001.
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transfection, but its expression remained high (100-fold
higher than that of Control transfected cells) even at 168 h
post-transfection (Fig. 2B). Cell growth, viability, and apoptotic
profiles, some of the primary hallmarks of cancer (37), were
examined on miR-224 expressing cells. Cell growth remained
generally unaffected in cells transfected with either miR-224
precursor or Control (Fig. 2C, left panel), but cell viability was
significantly reduced (up to 20% reduced cell viability; p 0.05)
in cells transfected with miR-224 precursor compared with
cells transfected with Control (Fig. 2C, right panel). These data
suggest that miR-224 seems to affect the viability rather than
the growth of these cells.
Annexin V labeling was performed to delineate whether the
reduced viability of cells overexpressing miR-224 is due to
increased cell death through apoptosis. miR-224 precursor- or
control-transfected HCT116 cells were harvested 48 h post-
transfection, stained with PE-conjugated annexin V and 7-ami-
no-actinomycin, and analyzed on the flow cytometer. Apop-
totic cells are represented as cells with high PE-conjugated
annexin V fluorescence signals and low 7-amino-actinomycin
fluorescence signals. As shown in Fig. 2D (panel ii), 2-fold
greater apoptosis was observed in cells expressing miR-224
than in cells expressing the control precursors (p 0.001). Sig-
nificantly, when miR-224 inhibitor was introduced into cells
overexpressing miR-224, the miR-224 expression was signifi-
cantly reduced (p  0.001) (Fig. 2D, panel i), and significantly
less apoptosis (p 0.001) (Fig. 2D, panel ii) was observed, con-
sistent with cells not overexpressing miR-224. Hence, the
reduced cell viability observed in miR-224-expressing cells is
likely due to increased apoptosis of these cells in the presence of
miR-224 as evident from the increased apoptosis observed in
miR-224-overexpressing cells and the restoration of its normal
phenotype when miR-224 inhibitor was also introduced.
miR-224 Overexpression Increases Cell Proliferation—Curi-
ously, although miR-224 overexpression reduced cell viability
(Fig. 2C, right panel) and increased apoptosis (Fig. 2D, panel ii),
it does not seem to affect cell growth (Fig. 2C, left panel) as
measured by the percentage of viable cells at each time point
relative to time 0. We thus hypothesize that this observation
could be due to miR-224, also increasing cell proliferation in
addition to increasing cell apoptosis, thus resulting a similar
number of viable cells in miR-224-expressing cells compared
with control cells at any time point. The proliferation potential
of these cells was then examined using the BrdUrd incorpora-
tion assay. As shown in Fig. 2D (panel iii), transfection of miR-
224 precursor into these cells significantly increased the prolif-
eration potential of these cells (p  0.001), whereas the
co-transfection of themiR-224 inhibitor with themiR-224 pre-
cursors restored the cell proliferation potential to normal.
miR-224 Targets API-5—To elucidate the gene target that
miR-224 acts through to sensitize cells to apoptosis, we exam-
ined the putative targets of miR-224 more closely and short-
listed seven (H3F3B, API-5, ARMCX2, NUP153, FOSB,
TRIM9, and HOXD10) putative targets that ranked among the
top five in at least one in silico target prediction program and is
also identified by at least one other prediction program (Fig.
3A). These seven putative targets were found to be involved in
several biological processes that are significantly over-repre-
sented. FOSB and HOXD10 function as transcriptional regula-
tors. HOXD10 has also been implicated as a tumor suppressor
(38) and inhibitor of angiogenesis (39), whereasAPI-5 has been
shown to be an apoptosis regulator (40–42). Other significant
biological processes that involve these putative genes include
chromosome organization for H3F3B (43), microtubule bind-
ing for TRIM9 (33), and intracellular/nuclear transport for
NUP153 (44). Although the gene targets of miR-224 reside in
varied biological pathways that are true for anymiRNA (35), the
pathways of nearly all of the top sevenmiR-224 gene targets are
primarily those most associated with cancer, namely transcrip-
tion, cell cycle, or apoptosis regulation and nucleus/chromo-
somal organization. Of these seven top miR-224 gene targets,
API-5 seems to be the most appropriate candidate through
which miR-224 may act to increase apoptosis in cells because
API-5has previously been reported to be an anti-apoptotic gene
(40–42).
We proceeded to validate that API-5 was in fact a true gene
target ofmiR-224. ThreemiR-224-binding sites were identified
along the 2035-bp-ylong 3-UTR ofAPI-5 (miRBase release 8.1,
May 2006) (Fig. 3C). The entire wild type 3-UTR of API-5 as
well as a mutant form in which all three putative miR-224-
binding sites were mutated was then cloned downstream the
-gal reporter gene (Fig. 3B). The specific interaction between
miR-224 andAPI-5 3-UTR to inhibit reporter gene activitywas
evident in Fig. 3D. When miR-224 precursor was co-trans-
fected with wild type API-5 3-UTR reporter construct, sig-
nificantly reduced -gal activity was observed compared
with cells co-transfected with miR-224 precursor and
mutant API-5 3-UTR reporter construct (p 0.01). No sig-
nificant difference in -gal activity was observed between
HCT116 cells carrying either the wild type or mutant API-5
3-UTR reporter construct when co-transfected with control
precursor molecules (Fig. 3D).
To evaluate whether miR-224 can affect the endogenous
expression of API-5, HCT116 cells were initially transfected
with either miR-224 precursor or control. miR-224 inhibitor or
control were then introduced into these transfected cells 24 h
later, and reverse transcription real time PCRwas performed at
various time points after this second transfection. As shown in
Fig. 3E, API-5 expression was significantly lower in miR-224
precursor transfectedHCT116 cells compared with the control
cells (p  0.001) across time points examined, consistent with
previous reports that miRNAs can also down-regulate gene
expression at the transcript level (45).WhenmiR-224 inhibitor
was transfected into miR-224-overexpressing cells, the API-5
transcript levels significant increased (p  0.001) at the two
time points examined, suggesting that the miR-224 inhibitor
was able to rescue the inhibition of API-5 expression by miR-
224. This observation thatmiR-224 decreasedAPI-5 expression
corroborates with our earlier observation that miR-224
increases apoptotic cell death and strongly suggests that miR-
224 exerts this effect through regulating the expression of
API-5.
Inhibition of the Endogenous Expression of miR-224 Up-reg-
ulates API-5 Expression and Reduced Apoptotic Cell Death in
the Immortalized Primary Liver Cell Line, THLE-3—Thus far,
we observed that miR-224 is overexpressed in the majority of
miR-224 Is Up-regulated in HCC and Targets the API-5 Gene
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HCCpatients examined and demonstrated experimentally that
the overexpression of miR-224 in HCT116 cells resulted
increased apoptosis and reduced expression of the apoptosis
inhibitor, API-5 gene. We proceeded to evaluate the functional
consequences of inhibiting the endogenous expression of miR-
224 in an immortalized primary liver cell line, THLE-3. The
introduction of miR-224 inhibitor into THLE-3 cells was found
to significantly inhibit the endogenous expression of miR-224
in these cells (p  0.001) (Fig. 4A, top panel) and significantly
increased the expression of the API-5 gene (Fig. 4A, bottom
panel). Inhibiting endogenous miR-224 expression in the
THLE-3 primary liver cells was also found to protect these cells
from UV-induced apoptotic cell death (p 0.05) (Fig. 4B).
The Level of API-5 mRNA Expression Was Inversely Corre-
lated with miR-224 Expression in 18 HCC Patients—We pro-
ceeded to examine whether there is any correlation between
miR-224 and API-5 expression in HCC patients to evaluate the
clinical significance of our observations. As evident in Fig. 6, a
statistically significant inverse correlation was observed
betweenmiR-224 andAPI-5 expression inHCC patients (Pear-
son Coefficient r0.471, R2 0.221 at p 0.05).
DISCUSSION
MicroRNAs have recently been implicated to play important
roles in cancers because 50% of miRNA genes reside in can-
cer-associated genomic regions, and their expression has been
found to be dysregulated in various cancers. Thus far, only one
study examined miRNA profiles in HCC patients, and they
identified five miRNAs that were significantly down-regulated
(miR-199a, miR-199a*, miR-200a, miR-125a, and miR195) and
three that were significantly up-regulated (miR-224, miR-18,
and miR-p18) (17). miR-18 and miR-p18 were not examined in
this study,whereasmiR-199a,miR-199a*,miR-200a,miR-125a,
and miR-195 were also generally down-regulated in our study,
FIGURE 3. Identification and characterization of a gene target ofmiR-224. A, table showing the list of top seven putative targets ofmiR-224 determined in
silico using PicTar, miRBase, or TargetScan algorithms. These targets are ranked among the top five in at least one algorithm and are listed as a putative target
in at least one other algorithm. B, schematic diagramof the construct utilized to validate that the API-5 3-UTR is target ofmiR-224. The-gal reporter is driven
by theMRP1 promoter (32). The API-5 3-UTR (wild type ormutant) is cloned downstream the -gal reporter. EGFP driven by the cytomegalovirus promoter is
used to normalized for differences in transfection efficiencies. The construct also contain a pUC origin of replication (Ori) and an ampicillin resistance (Amp) for
growth and selection in bacterial cells. C, schematic representation of the 3-UTR of API-5 inwhich the predicted sequences of the threemiR-224-binding sites
is boxed. Thebases shadedgray represent sequences that havebeenmutated to abolishmiR-224binding to theAPI-5 3-UTR.Mutated sequenceswere verified
in siliconot tobind tomiR-224or anyof the knownhumanmiRNAs. Themutant construct generatedwas confirmedby sequencing.D, actionofmiR-224on the
3-UTR of API-5 examined through normalized -gal reporter activities in cells co-transfected with miR-224 precursors or control and wild type API-5 3-UTR
(black bar) or mutant API-5 3-UTR (white bar) reporter constructs. The results show data from at least three independent experiments. E, miRNA expression
(normalized against Let-7a) (top panel) and endogenousAPI-5mRNAexpression (normalized against-actin) (bottompanel) in control ormiR-224precursor or
miR-224 precursor and miR-224 inhibitor transfected cells. The cells were initially transfected with either control or miR-224 precursors. Twenty-four hours
later, the same cells were transfected with either control or miR-224 inhibitors. miR-224 and API-5 RNA levels were measured at various time points after the
second transfection. The results show data from at least three independent experiments. InD and E, the data are expressed as themeans	 S.E. *, p 0.05; **,
p 0.01; ***, p 0.001.
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although they were not statistically significant. Only miR-224
was also found to be significantly up-regulated in our study.
Our study identified 19 up-regulated and three down-regu-
lated miRNAs that may be associated with HCC. Interestingly,
four of the 19 significantly up-regulated miRNAs (miR-182,
miR-182*, miR-183, and miR-96) reside together on chromo-
some 7q32.2 in the intergenic region between two protein cod-
ing genes, namely the transcription factor  palindrome-bind-
ing protein, -pal (also known as nuclear respiratory factor 1)
and the ubiquitin-conjugating enzyme, E2H. The coordinate
up-regulation of these miRNAs that resides within the same
cluster suggests that this region of chromosome 7 may be
amplified. A search through the Comparative GenomeHybrid-
ization data base revealed that gain of chromosome 7 is com-
monly observed in HCC and other cancers including breast,
prostate, colorectal, gastro-esophageal, lung and bronchial,
head and neck, as well as aggressive lymphomas. Such coordi-
nate expression of several miRNA and/or genes was also
observed at the miR-17–92 cluster whose expression is up-reg-
ulated in lung cancer and plays a role in cell proliferation (46).
However, further examination of nuclear respiratory factor 1
and E2H transcript expression in these HCC patients revealed
that these genes were not significantly overexpressed in the
tumors of these patients (data not shown).
Although our study found that more miRNAs are up-reg-
ulated in HCC patients, another study that examined 334
tissues from patients with different cancers found that there
is a general trend of down-regulation of miRNA expression
(47). Nonetheless, a recent study that examined 540 samples
from patients with different cancers identified a solid tumor
miRNA signature that primarily comprises up-regulated
miRNAs (25).
Some of the miRNAs that we observed to be dysregulated in
HCCpatients exhibited similar trends of dysregulation in other
cancers. miR-96 and miR-183 were also found to be up-regu-
lated in colorectal cancer (27), whereas miR-21 and miR-155
were similarly overexpressed in breast, lung, and colon cancers
(25).miR-224was also up-regulated inHCCpatients in another
report (17), and miR-221 was also up-regulated in colon, pan-
creas, and stomach tumors (25). These observations suggest a
common miRNA regulation pathway shared by different solid
tumors.
FIGURE 4. Inhibiting endogenous miR-224 in THLE-3, an immortalized primary liver cell line, increased API-5 expression and decreased number of
apoptotic cells. A, miR-224 (top panel) and API-5 (bottom panel) expression in THLE-3 cells transfected with either control or miR-224 inhibitor. B, relative
apoptosis of THLE-3 cells transfected with either control or miR-224 inhibitor. The results show data from at least three independent experiments, expressed
as the means	 S.E. *, p 0.05; **, p 0.01; ***, p 0.001.
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The biological pathways that are affected through the dys-
regulation of these 22 miRNAs were further examined. Gene
targets for all 22 miRNAs were predicted in silico and GO/Da-
tabase for Annotation, Visualization, and Integrated Discovery
was employed to functionally annotate these gene targets. We
found that nearly 50%of the nonoverlapping gene targets reside
within 34 biological processes. 80% of these 34 biological pro-
cesses has been implicated in carcinogenesis (supplemental
Table S1) including proliferation (GO terms: regulation of
nucleobase, nucleoside, nucleotide, and nucleic acid metabo-
lism; regulation of progression through cell cycle; cell growth;
positive regulation of cellular metabolism); cell death (GO
term: apoptosis); metastasis (GO term: cell migration); and
Wnt (48) and Notch (49) signaling pathways.
To gain a better understanding of how dysregulation of these
miRNAs may play a role in carcinogenesis, we further charac-
terized miR-224, the most up-regulated miRNA in our study.
We observed that HCT116 cells overexpressing miR-224
exhibited similar rate of cell growth but significantly lower cell
viability than control cells (Fig. 2C). This decrease in cell viabil-
ity was found to be due to a significant increase of apoptosis in
miR-224-expressing cells that can be reversed by the addition of
miR-224 inhibitors (Fig. 2D, panel ii). Interestingly, miR-224-
overexpressing cells also significantly increase the proliferation
potential of the cells, which can be reversed by the addition of
miR-224 inhibitors (Fig. 2D, panel iii). The ability of a single
gene to be involved in both proliferation and apoptosis has been
previously demonstrated (e.g. myc) (50).
To elucidate the gene target of miR-224 that may play a role
in regulating apoptosis andhence account for the phenotypewe
observed, we shortlisted seven putative miR-224 gene targets
that are ranked highly by at least one prediction program (Fig.
3A). Of these seven putative targets, apoptosis inhibitor 5 (API-
5), also known asAAC-11, seems to be themost likely candidate
becauseAPI-5was reported as an anti-apoptotic gene (40–42).
Three potential miR-224-binding sites were identified at the
3-UTR of API-5 (Fig. 3C). Our results showed that miR-224
specifically interacted with the 3-UTR of API-5 to inhibit
reporter activity because no inhibition of reporter activity was
observed when themiR-224-binding sites inAPI-5 3-UTRwas
mutated (Fig. 3D). We further demonstrated that miR-224 can
inhibit endogenousAPI-5 expression (Fig. 3E), which is consist-
ent with our earlier observation that increasedmiR-224 expres-
sion leads to increased cell death (Fig. 2D) because API-5 is an
anti-apoptotic gene.
Earlier studies suggest that miRNA acts at the translational
level because only significant differences in the protein but not
the mRNA levels were observed (51). Our observations that
increased miR-224 reduced the endogenous API-5mRNA lev-
els in cells thus suggest that it is likely that miR-224 inhibit
API-5 expression at the post-transcriptional level by degrading
API-5 transcript, resulting in reduced steady-state API-5 tran-
script levels (Fig. 3E). Reduced API-5 levels will then sensitize
these cells to apoptosis (Fig. 2D).
To evaluate the functional consequences of inhibiting the
endogenous expression of miR-224 in primary liver cells, miR-
224 inhibitor was transfected into THLE-3 cells, an immortal-
ized primary liver cell line. Inhibiting miR-224 expression in
these primary liver cells significantly inhibited (p  0.001) the
endogenous expression of miR-224 in these cells (Fig. 4A, top
panel) and significantly increased the physiological expression
of the API-5 gene (Fig. 4A, bottom panel). Notably, reduced
physiological levels of miR-224 expression in the THLE-3 pri-
mary liver cells was also found to protect these cells from UV-
induced apoptotic cell death (p 0.05) (Fig. 4B).
Taken together, our data suggest that miR-224 influences
both the proliferation and apoptotic potential of cells. It has
been proposed that a single miRNA may regulate different
unrelated target genes to control opposing activities like cell
proliferation and apoptosis (52). miR-224 may thus represent
such amiRNA. The regulation of the cell proliferation potential
is likely to be mediated by a target gene of miR-224, which is
currently unknown, whereas the regulation of the apoptotic
potential is likely to be mediated via API-5, a known gene that
regulates apoptosis (Fig. 5). API-5 was previously reported to
act downstream E2F and inhibit E2F-dependent apoptosis
without affecting E2F-dependent transcription (42). We thus
hypothesize that miR-224 may influence E2F-dependent apo-
ptosis via API-5.
Notably, there is a significant inverse correlation between
miR-224 expression and API-5 expression in HCC patients
(p 0.05) (Fig. 6). The significant correlation betweenmiR-224
and API-5 in HCC patients lends credence to the experimental
observation that miR-224 negatively regulates API-5 expres-
sion and highlights the clinical relevance of this observation.
The observation thatmiR-224 is overexpressed in the tumors
of HCC patients and that it plays a role in sensitizing cells to
apoptosis via the inhibition of API-5 expression seems to con-
tradict conventional wisdom that apoptosis is reduced during
carcinogenesis. Nonetheless, similar to miR-224, oncoproteins
such as c-Myc and E1A were found to sensitize cells to apopto-
sis upon minor insults that normal cells can usually resist, for
example, serum depletion, DNA-damaging agents, hypoxia,
etc. (53, 54). Oncogenic changes that promote apoptosis are
thought to provide the selective pressure for cells to override
apoptosis during the multistage process of carcinogenesis (53),
resulting in a resistant population of cells that accumulate her-
itable genetic mutations (55) during its increased lifespan, thus
facilitating oncogenic transformation. The dual role ofmiR-224
to influence both cell proliferation and cell death simulta-
neously may thus potentially hasten this selection process
favoring cells that accumulate sufficient heritable genetic
mutations to override apoptosis during carcinogenesis.
In summary, we have identified 19 up-regulated and three









FIGURE 5.Hypothetical model of the role of miR-224.
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dicted putative gene targets of these differentially expressed
miRNAs in HCCwere found to belong to 34 significant biolog-
ical processes, most of which have been implicated in carcino-
genesis. Further characterization of one of these dysregulated
miRNAs revealed that miR-224, which is up-regulated in the
tumors of HCC patients, sensitizes cells to apoptosis through
the inhibition of API-5 at the mRNA levels and increases cell
proliferation. Significantly, miR-224 expression was found to
be inversely correlated with API-5 expression in HCC patients.
These findings reaffirm the important role of miRNAs in regu-
lating gene expression and suggest that dysregulation of the
expression of miRNAs may lead to dysregulated target gene
expression resulting in dysregulated cellular processes thatmay
ultimately lead to tumorigenesis.
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Abstract
MicroRNAs (miRs) are small non-coding RNAs regulating gene expression at the post-transcriptional and/or translational levels. miRs
play important roles in diverse biological processes, including development, cell differentiation, proliferation and apoptosis. Recent evi-
dence has shown that miR loci frequently map to cancer-associated genomic regions and deregulated miR expression profiles are asso-
ciated with many cancer types, implicating miRs in crucial processes that lead to tumourigenesis. Here, we review the current findings
about miRs and tumourigenesis, focusing on their involvement in the apoptosis pathway. A significant observation is that greater than
one-quarter of all known human miRs were reported to be deregulated in at least one cancer type. The expression of a subset of miRs
(e.g. miR-21 and miR-155) was found to be consistently up-regulated, whereas another subset of miRs (e.g. miR-143 and miR-145)
was consistently down-regulated across different cancer types suggesting their involvement in regulating common cellular processes
whose deregulation may lead to tumourigenesis. Several miRs were implicated to play roles in cell proliferation and apoptosis. Some
miRs, such as miR-29b and miR-15-16, influence only the apoptotic pathway, whereas others including let-7/miR-98 and miR-17-92
may play roles in both the apoptotic and cell-proliferation pathways. In conclusion, although our current understanding of the functions
of miRs is still fragmentary, taken together, this review highlights the complex and intricate roles that miRs play in the regulation of 
cellular processes. Perturbation of the expression of miRs may thus lead to tumourigenesis.
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Introduction
microRNAs (miRs) are a class of small non-coding RNAs whose
mature products are ~22 nucleotides long. They negatively regu-
late gene expression at the post-transcriptional and/or transla-
tional level. They were first discovered by Ambros and colleagues
in 1993 [1] in C.elegans and were shown to be abundantly
expressed in viruses [2], plants [3] and animals [4]. To date, there
are a total of 6396 miRs (miRBase Release 11. http://microrna.
sanger.ac.uk/sequences/), of which, 678 miRs are found in human
beings [5–7]. Many miRs show sequence and function conserva-
tion between distantly related organisms, suggesting that this
class of small RNAs is an integral part of essential cellular
processes [8]. For example, Lethal-7 (Let-7) was initially discov-
ered to be responsible for the developmental transition of L4 lavae
to the adult cell fates [9] in C.elegans. It was later found to be 
evolutionarily conserved, regulating development in Drosophila,
zebrafish, annelids, mollusks [8] and mouse [10] and possibly
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human beings, which comprised 12 members of the Let-7 family.
Their strong evolutionary conservation suggests that they are
likely to have an ancient origin [11] although they were identified
only recently. Their discovery has opened up a new dimension in
our understanding of gene regulation.
miR biogenesis
microRNAs are encoded in the genome and transcribed by RNA
polymerase II as primary transcripts that are called pri-miRs. Pri-
miRs are typically 3 to 4 kilobases long single-stranded RNAs with
5cap, 3 poly(A) tail and complicated secondary structure [12,
13]. The Pri-miRs are processed in the nucleus into one or more
precursor-miRs (pre-miRs) of ~70-nucleotide by microprocessor
complex comprising the nuclear RNase III, Drosha, and the dou-
ble-stranded RNA binding protein, Pasha/DGCR8 [13–15]. Pre-
miRs are then actively exported to the cytoplasm through
exportin-5 in association with RAN-GTPase [16, 17]. In the cyto-
plasm, another RNase III, known as Dicer, further processes the
pre-miR into ~22-nucleotide mature miR, which is double-
stranded (miR duplex). The miR duplex [18, 19] comprises a
strand (miR strand), which is incorporated into the multi-protein
RNA-induced silencing complex (miRISC) and a complementary
strand (miR* strand), which is degraded. Thermodynamic stability
of the strand probably determines the choice of strand to be incor-
porated into miRISC complex [20]. In mammalian system, the
functional miRISC carrying the mature miR can bind to the
3untranslated region (3UTR) of its target gene mRNA to result in
either mRNA degradation (for nearly perfect complementary base-
paring) or protein translation inhibition (for imperfect complemen-
tary base-paring). The mechanism of inhibition will depend on the
miR sequence, the target mRNA sequence and the exact compo-
sition of the miRISC protein complex [21, 22].
miR and cancer
The importance of microRNAs in cancer is highlighted by the
observation that ~50% of miRNA genes are located in cancer-
associated genomic regions or fragile sites [23, 24], which are fre-
quently amplified or deleted in tumourigenesis. Global repression
of microRNA processing machinery (Drosha, Pasha/DGCR8 and
Dicer1) promotes cellular transformation and miRNA processing-
impaired cells formed tumours with accelerated kinetics in mouse
model, implicating the role of mature miRs in cancer-related
processes [25]. Large-scale microRNA expression profiling of
human cancers have revealed that miRNA deregulation is fre-
quently associated with many cancer types including those origi-
nating from the blood [26–31], brain [32–34], thyroid [35–37],
breast [38], lung [39–41], tongue [42], nose and pharynx [43],
liver [44–47], the gastro-intestinal system (esophageal [48], 
gastric [49], pancreatic [50, 51] and colorectal cancers [52, 53])
as well as the genitourinary system (cervical [54], ovarian [55, 56]
and prostate [57, 58] cancers).
Table 1 summarizes our current knowledge on the profile of
miR expression in various human cancers. In these studies, miR
expression in tumours is compared against paired non-
tumourous tissues from cancer patients and significantly up- and
down-regulated miRs are indicated with red-box/up-arrow and
green-box/down-arrow, respectively. More than one-quarter of
known human miRs (175 out of 678 miRs) have been reported to
be significantly deregulated in at least one cancer type. However,
this may be a gross underestimation of the actual numbers of
deregulated miRs as the majority of the known miRs were only
identified in the previous 2 years and were not included in earlier
miR expression profiling studies. Nonetheless, this observation
suggests that microRNAs may represent one of the largest
classes of gene regulators implicated in cancer-related processes
although very little are known about them. Table 1 also highlights
some interesting patterns of miR expression profiles in cancers.
Of the cancer-implicated miRs, miR-21 is the most commonly
up-regulated miR in both solid and haematological tumours, con-
sistent with the report of Volinia et al. [58]. Besides miR-21, other
miRs including miR-155, miR-181b, miR-221 and miR-222 are
also frequently up-regulated in cancers of the blood, brain, thy-
roid and the gastro-intestinal (GI) systems, and to a lesser extent
in liver cancer, lung cancer and breast cancer. In contrast, the let-
7/miR-98 cluster is commonly down-regulated in tumours of the
thyroid, breast, lung, upper GI and the genitourinary system.
Similarly, miR-143 and miR-145 are frequently down-regulated in
the haematological tumours and solid tumours of the breast,
lung, prostate and the lower GI system. Such common deregula-
tion of miR expressions across various tumour types suggests
that these miRs may be involved in crucial cellular pathways that
are commonly deregulated in cancer development. Indeed, func-
tional studies have demonstrated that let-7/miR-98 negatively
regulate RAS [59] and v-myc myelocytomatosis viral oncogene
homologue (MYC) [60] whilst miR-21 negatively regulate phos-
phatase and tensin homologue (PTEN) [44] and programmed cell
death 4 (PDCD4) [61], which are proto-oncogenes or tumour
suppressors that regulate important cellular processes, including
cell growth, proliferation and apoptosis whose deregulation leads
to tumourigenesis. In addition to miRs that are commonly dereg-
ulated across different cancers, there are also miRs that seem to
be deregulated in only specific tumour types (Table 1). For exam-
ple, the miR-17-92 cluster and miR-93 are frequently reported to
be up-regulated mainly in cancers of the GI system. Interestingly,
a very large proportion of miRs (~81%) were found to be up-reg-
ulated in thyroid tumours, whereas a high percentage of miRs
(~70%) were reported to be down-regulated in prostate cancers.
These observations suggest that some tumour-specific mecha-
nisms may be in place to favour particular miR profiles depend-
ing on the tumour micro-environment. It is also worth noting that
miR-105, miR-144, miR-193 and miR-199b are seldom reported
to be deregulated in cancer, despite their relatively early discov-
ery, suggesting that these miRs probably play a role in cellular
14 © 2009 The Authors




















































































































































































































































































































































































































































































































miR-17-92 E2F1[68], TSP1/THBS1[70], CTGF[70], PTEN[62],
BIM/BCL2L11[62,69], RB2/RBL2[69], p21/CDKN1A[71]
miR-20a





















































































































Table 1: miRs that are significantly differentially expressed in human cancers and their validated in vivo targets.
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Upward pointing arrows in red boxes indicate that the miR is up-regulated in the cancer-type while downward pointing arrows in green
boxes indicate down-regulated miRs. Yellow boxes with both Upward- &downward-pointing arrows indicate that miR was reported to
be up-regulated in one study but down-regulated in another study.
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house-keeping processes and are less likely to be involved in
oncogenesis.
Although much is known about the aberrant miR expression
pattern associated with various cancers, much less is known
about the functional relevance of such miR deregulation or the 
in vivo miR targets. Table 1 also summarizes a total of 65 non-
overlapping experimentally validated direct cellular targets of miRs
that are reported to date [33, 43–45, 47, 55, 59–109]. Table S1
annotates these validated targets based on Gene Ontology (GO)
and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.
These 65 validated miR target genes show a significant enrich-
ment in the classical cancer-associated pathways such as tran-
scription, cell–cell adhesion and signalling, cell-cycle regulation,
cell proliferation and apoptosis, strongly suggesting that the
deregulation of these miR target genes may play significant roles
in carcinogenesis. However, as predicted by miR target prediction
algorithms (miRanda [6], PicTar [110] and TargetScan [111]),
each individual miR can potentially regulate hundreds of cellular
gene targets. But reports of the identification and characterization
of these in vivo miR targets remain few, which prevent our com-
prehensive understanding of the miR-regulated networks that
significantly impact cell differentiation, cell proliferation and apop-
tosis [112]. Current knowledge on a limited number of miRs or
miR clusters has revealed the complexity of miR-regulatory net-
works, and in this review, we will discuss the role of a few well-
studied miRs in tumourigenesis with a focus on its impact on the
apoptotic pathway.
miR and apoptosis
Apoptosis is the intrinsic cellular mechanism to eliminate cells
that are damaged or transformed. Deregulation of apoptosis is an
important step in cancer as it allows the genetically unstable cells
to survive and accumulate further mutations that eventually lead
to tumourigenesis. As cancer cells are mostly characterized by
increased cell proliferation and decreased cell death, cancer-
implicated genes have conventionally been classified into two
groups. One group, the oncogenes, up-regulates proliferation and
down-regulates apoptosis, whereas the other group, the tumour
suppressor genes, performs just the opposite function. Indeed,
pro-apoptotic genes such as p53 are frequently inactivated whilst
anti-apoptotic genes such as B-cell CLL/lymphoma 2 (BCL2) are
frequently over-activated in cancer progression. However, recent
evidence has shown that up-regulation of MYC and E2F onco-
genes can increase both cell proliferation and apoptosis [113,
114], suggesting the classification of cancer-related genes into
oncogenes or tumour suppressors may be an over-simplification.
Figure 1 summarizes our current knowledge of miRs implicated
in cell-proliferation and apoptosis, revealing that the miR-regula-
tory network is just as complicated as its protein-coding counter-
parts. Some miRs, such as miR-29b and miR-15-16, were found
to affect only the apoptotic pathway, whereas others including 
let-7/miR-98 and miR-17-92 play roles in both the apoptotic 
and cell-proliferation pathways (see review [114, 115]). In the fol-
lowing discussion, we will discuss some pro-apoptotic miRs,
anti-apoptotic miRs and miRs that regulate both proliferation 
and apoptosis.
The pro-apoptotic miRs targeting the BCL2 family
of genes
The miR-15-16 cluster induces apoptosis by targeting the
important anti-apoptotic factor BCL2 at the post-transcriptional
level [66]. It was proposed to function as a tumour suppressor
by keeping cell growth in check under normal physiological con-
ditions. Like many tumour suppressors, this miR cluster is
found to be frequently deleted in B-cell chronic lymphocytic
leukaemia (CLL), resulting in its down-regulation in more than
68% of the CLL cases [28]. The miR-15-16 cluter is also
reported to be down-regulated in pituitary adenoma [34] and
prostate carcinoma [57]. Hence in these cancers, miR-15-16
expression is preferentially down-regulated to favour cancer
development by inhibiting apoptosis (Fig.1). In a recent study,
which utilized expression microarray to investigate the effects of
miR-15a and miR-16-1 on the transcriptome and proteome of
MEG-01 leukaemic cells, genes (e.g. MCL1, ETS1 and JUN) that
directly or indirectly play a role in apoptosis and cell-cycle were
found to be significantly differentially expressed in these cells.
Another miR, miR-29b, which is down-regulated in lung and
prostate cancers (Table 1), was reported to also target myeloid
cell leukaemia sequence 1 (MCL1) [78], a member of the BCL2
family, implying that the function of miR-29b may be similar to
that of miR-15-16. Curiously, in some cancers, the expression of
these miRs (miR-15-16 and miR-29b) was reported to be up-
regulated instead. One possible explanation to these seemingly
contradictory observations may perhaps be that these miRs may
deregulate other cellular processes in addition to apoptosis in
these specific cancers.
The anti-apoptotic miR-21 targets PTEN 
and PDCD4
miR-21 is the most consistently up-regulated miR across many
cancer types (Table 1). miR-21 was first implicated as an anti-
apoptotic factor by the observation that knock-down of miR-21
increased apoptotic cell death in human glioblastoma cells [116]
and in the mouse model [117]. miR-21 directly targets PTEN
whose down-regulation will release its inhibition on protein
kinase B (PKB) resulting in significantly reduced apoptosis in
cancer cells (Fig.1). miR-21 also targets PDCD4 [61], a pro-apop-
totic gene frequently down-regulated in hepatocellular carci-
noma(HCC) [118]. Interestingly, miR-21 was also reported to be
up-regulated in HCC (Table 1). This suggests that miR-21 can
inhibit apoptosis through both PTEN and PDCD4. Recently, miR-21
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was reported to target important tumour suppressor genes
including tropomyosin 1 (TPM1) [72] and serpin peptidase
inhibitor, clade B (ovalbumin), member 5 (SERPINB5) [73] sug-
gesting that miR-21 may also play a role in tumour invasion and
metastasis. Hence, the oncogenic potential of miR-21 lies in its
ability to regulate multiple cancer-associated pathways probably
via multiple cellular targets, which may partially explain its fre-
quent up-regulation in cancer.
miR-210 decreases proapoptotic signalling in a
hypoxic environment
Hypoxia-regulated microRNAs such as miR-210 is induced in
response to low oxygen and play a role in cell survival by decreas-
ing caspase activation, the central components of apoptotic sig-
nalling [119]. As hypoxia is an important feature of tumour
microenvironment, it is of interest to note that miR-210 is also
Fig. 1 Diagrammatic representation of the roles of miRs in the regulation of cell proliferation and apoptosis. Red colour indicates a general up-regula-
tion of miRs in cancers and green colour indicates a general down-regulation of miRs in cancer.
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over-expressed in many major tumour types (Table 1), suggesting
that hypoxia may represent a contributing factor for microRNA
deregulation in certain cancers. A recent study by Camps et al. has
demonstrated that miR-210 is a good prognostic marker for
breast cancer [120].
Let-7/ miR-98 family and possible co-operation
with miR-21
Our understanding of the role of let-7/miR-98 family in cancer
development was facilitated by the identification of two proto-
oncogenes regulating cell proliferation and apoptosis, RAS [59]
and MYC [60], as direct targets of let-7/miR-98. Under normal
physiological conditions, Let-7 regulates cellular proliferation
by inhibiting RAS and MYC expression. However, in tumours,
let-7/miR-98 are frequently down-regulated resulting in
increased expression of cellular RAS and MYC and subsequent
elevation of cell proliferation as well as MYC-induced apoptosis
[114] (Fig.1). Increased apoptosis and proliferation seem to
contradict the conventional wisdom that apoptosis is reduced
during carcinogenesis. However, oncogenic changes that pro-
mote apoptosis are thought to provide the selective pressure for
the cells to override apoptosis during the multistage process of
carcinogenesis [121], resulting in the final cell population that
retain high proliferative but reduced apoptotic potential. It is
important to note that expression of miR-21 is frequently up-
regulated in let-7/miR-98 down-regulated tumours of the thyroid,
breast, lung, liver, esophagus and prostate (Table 1). This sug-
gests that miR-21 or other cellular factors may counter-balance
MYC-induced apoptosis in tumours in which let-7/miR-98
expression is down-regulated, whereas still maintaining a high
rate of cell proliferation.
miR-17-92 cluster highlights the complexity 
of miR regulatory networks
The miR-17-92 cluster, which modulates E2F1 expression, is
positively regulated by MYC [122]. Under normal physiological
conditions, miR-17-92 facilitates the tight regulation of MYC-
mediated cellular proliferation by inhibiting the MYC-induced
E2F1 expression. However, when miR-17-92 is over-expressed as
in the case of GI cancers, it can potentially become a very potent
oncogene targeting multiple cellular pathways to favour tumouri-
genesis by enhancing cell proliferation and inhibiting apoptosis.
As illustrated in Fig.1, miR-17-92 can increase MYC-enhanced
proliferation by targeting p21 [71] and consequently activating
the CyclinD1/CDK4 complex to release retinoblastoma (RB)’s
inhibition on E2F. In addition, miR-17-92 is also capable of down-
regulating RB [69] directly to drive cell proliferation. On the other
hand, miR-17-92 is also capable of minimizing MYC-induced
apoptosis by targeting BCL2-like 11 (BIM) and PTEN [62] to
increase the level of anti-apoptotic BCL2. Hence, miR-17-92 is
truly worthy of its reputation as the first non-coding oncogene,
oncomiR-1 [123]. This miR demonstrates the complexity of miR
regulatory network.
miR-224, the double-edged sword
miR-224 is up-regulated in HCC, pancreatic ductal adenoma and
various types of thyroid cancers (Table 1). We have demonstrated
that over-expression of miR-224 sensitizes cells to apoptosis
through API-5, an apoptosis inhibitor, and increase cell prolifera-
tion through yet an unknown mechanism [45]. Sassen et al. has
previously proposed that a single miR can potentially regulate
opposing cellular activities such as cell proliferation and apopto-
sis [124] and miR-224 represents the first such miR identified.
Similar to the MYC oncogene, which regulates both cell-prolifer-
ation and apoptosis, the dual role of miR-224 to influence both
cell proliferation and apoptosis can potentially hasten the selec-
tive process favouring cells that accumulate sufficient heritable
genetic mutations to override apoptosis during the multistage of
carcinogenesis.
Other miRs implicated in apoptosis
There are a number of other miRs that may potentially play roles
in regulating apoptosis in cancer. For example, miR-155 is fre-
quently over-expressed in many cancers and targets the tumour
protein p53 inducible nuclear protein 1 (TP53INP1) [91]. TP53INP1
was reported to be a positive regulator of p53-dependent apopto-
sis by enhancing Ser46 phosphorylation of p53 which in turn
induced p53-regulated apoptosis-inducing protein 1(p53AIP1)
expression and subsequent apoptotic cell death [125]. Hence,
over-expression of miR-155 in cancers will inhibit TP53INP1
expression and attenuate apoptotic cell death induced by
TP53INP1. In contrast, miR-127 was reported to target B-cell
CLL/lymphoma 6 (BCL6) [84] to potentially increase TP53-
dependent apoptosis by disrupting the negative regulatory feed-
back loop between BCL6 and TP53 [126, 127]. However, our
understanding of the rationale behind this deregulation in cancer
remains unclear.
Conclusion
One of the hallmarks of cancer is defects in the regulatory circuits
that control normal cell proliferation and homeostasis. Previously,
great efforts were focused on understanding the roles of protein-
coding genes in cancer. As discussed above, emerging research
are implicating miRNAs as a novel class of non-coding tumour
suppressors and oncogenes that play important roles in tumouri-
genesis. As we review the roles of miRNAs in apoptosis and 
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cancer, we begin to appreciate that miR’s role in tumourigenesis is
not merely either pro- or anti-apoptosis. Rather, it is likely that
coordination and perhaps synergism between several deregulated
miRs and their protein-coding counterparts facilitate a favourable
environment for cancer formation. Although current knowledge 
of miR function and targets is incomplete, it underscores the 
complexity of the roles of RNA in the regulation of cellular path-
ways. Continued effort in the detailed characterization of miR 
target and function is necessary to improve our understanding of
the role of miRs in tumourigenesis and facilitates the design of
appropriate therapies targeting this novel group of molecules.
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protein (HBx), associated with hepatocellular carcinoma (HCC),
has been implicated in the deregulation of cellular gene expres-
sion at the transcriptional level. To date, it remains unknown if
HBx regulates the expression of miRNAs which play important
roles in gene-regulation at the post-transcriptional and/or trans-
lational level.
Methods:miRNA microarrays were employed to compare the
expression of cellular miRNAs in HBx-versus control-HepG2 cells.
Reverse-transcription Taqman realtime-PCR was used to examine
let-7a expression in normal liver as well as paired HCC-tumor
and adjacent non-tumorous liver. Let-7a miRNA was functionally
characterized in cells with transiently altered let-7a expression.
The direct target of let-7a was identiﬁed in silico and validated
using 30UTR-reporter assay.
Results:HBx up-regulates 7 and down-regulates 11 miRNAs,
including the let-7 family. HBx expression was found to have a
signiﬁcant inverse correlation with the expression of the
highly-expressed members of the let-7 family in HCC patients,
highlighting the clinical relevance of our observations. Further
characterization of let-7a, the most highly expressed let-7 family
member, revealed that it negatively regulates cellular prolifera-
tion partly through targeting signal transducer and activator of
transcription 3 (STAT3). HBx-mediated down-regulation of let-
7a and up-regulation of STAT3 supports cell proliferation in
HBx cells.Journal of Hepatology 20
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Hepatocellular carcinoma (HCC) is the third leading cause of can-
cer related death worldwide, accounting for 700,000 deaths
annually [1]. As much as 80% of cases of HCC, mostly occurring
in countries where hepatitis B virus (HBV) is endemic such as
South-East Asia and Sub-Saharan Africa, are attributed to chronic
HBV infections [2]. It has been suggested that HBV promotes car-
cinogenesis through at least two major mechanisms: (1) Through
the integration of viral genomic fragments into the human
genome that can result in cis activation of proto-oncogenes or
cis-repression of tumor suppressor genes. (2) Additionally, viral
proteins can lead to trans-activation or trans-repression of
cellular genes/pathways that may eventually lead to oncogenic
transformation [2].
Hepatitis B virus x protein (HBx) is a 17 kDa protein that is
conserved among the mammalian hepadnaviruses and is impli-
cated to play an important role in hepatocarcinogenesis. The
HBx gene is the most common viral open reading frame inte-
grated into the host genome of HCC patients, and the HBx protein
is often found to be selectively over-expressed in HCC [3–5]. HBx
lacks a DNA binding domain and is widely believed to function as
a promiscuous trans-co-activator by interacting with various cel-
lular factors to regulate, at the level of transcription, a number of
cellular pathways such as JAK/STAT pathway [2,6], and many host
genes such as p53 tumor suppressor (TP53). The exact role of HBx
in HCC oncogenesis is not well understood and HBx protein has
been shown to display pleiotropic properties by impacting on
multiple, sometimes opposing pathways such as cell death and
cell proliferation. HBx has been shown in vitro to transform
immortalized murine hepatocyte cell lines [7–10], murine ﬁbro-10 vol. 53 j 57–66
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blasts [8], and rat ﬁbroblast cell lines [11]. In addition, Kim et al.
and Yu et al. have separately demonstrated that HBx can directly
cause HCC in mouse models [12,13]. On the contrary, several
other groups have found that HBx enhances cellular apoptosis
in vitro [14–18] while Lee et al. reported that HBx is not tumori-
genic in his line of transgenic mice [19]. Taken together, these
reports suggest that HBx has the potential to regulate many cel-
lular processes with seemingly opposite functions, and the pre-
dominant phenotype observed is dependent on other cellular
factors and the microenvironment in which the function of HBx
is evaluated. Although the role of HBx, in regulating gene expres-
sion through its interaction with transcription factors like TP53
[18], has long been established, it remains unknown if HBx regu-
lates gene expression through the regulation of microRNAs (miR-
NAs), a class of small non-coding RNAs.
Thus far, 700 miRNAs have been identiﬁed in the human
genome (miRBase Release 12.0). They function by binding to
the 30 untranslated region (30UTR) of their cellular targets to
cause mRNA degradation and/or protein translation inhibition,
both events resulting in a net reduction of functional target pro-
tein in the cell [20]. The miRNAs represent another important
level through which gene expression is regulated, hence they
play central roles in diverse cellular and developmental pro-
cesses, and deregulation of miRNA expression may lead to cancer
development [21]. Large-scale miRNA expression proﬁlings of
human cancers have revealed that miRNA deregulation is fre-
quently associated with many solid and liquid tumors including
human HCC [22–26], highlighting the role of miRNA in cellular
processes involved in malignant transformation. An example of
a miRNA implicated in carcinogenesis is the miRNA lethal-7
(let-7) which represents the ﬁrst miRNA identiﬁed in humans.
Let-7 was found to be frequently down-regulated in many human
cancers such as tumors of thyroid, breast, lung, esophagus, ovary,
prostate, and liver [27].
Since each miRNA can potentially regulate the expression of
numerous gene targets in the cell, HBx’s potential effect on cellu-
lar miRNAs may be a novel mechanism through which HBx dere-
gulates cellular gene expression, and may partially explain the
pleiotropic nature of this HBV viral protein. To investigate
whether the deregulation of gene expression by HBx also occurs
through the deregulation of cellular miRNA expression, we char-
acterized the expression proﬁles of 286 miRNAs in HBx-express-
ing compared to control-HepG2 cells using miRNA microarrays.
We identiﬁed a set of signiﬁcantly differentially expressed miR-
NAs that is regulated by HBx, including members of the let-7 fam-
ily. We demonstrated the inverse correlation between the
expression of HBx and that of the highly-expressed members of
the let-7 family including let-7a, let-7b, and let-7c in HCC patients,
highlighting the clinical relevance of our observations. We further
functionally characterized let-7a and identiﬁed its gene target.Materials and methods
Cell lines and HCC patient samples
The human hepatocellular carcinoma HepG2 and SNU-182 cells were cultured in
Dulbecco’s modiﬁed Eagle’s media (DMEM) supplemented with 10% fetal calf
serum (Bioindustries, Isreal) and 25 mM HEPES (Invitrogen, USA). The human
colorectal carcinoma HCT116 cells were cultured in modiﬁed McCoy’s 5A media
supplemented with 10% fetal calf serum (Bioindustries, Isreal). The cells were
incubated at 37 C in a humidiﬁed atmosphere with 5% CO2.58 Journal of Hepatology 20Paired tumorous and adjacent non-tumorous liver tissues from 20 hepatocel-
lular carcinoma patients were obtained from the National Cancer Centre of Singa-
pore Tissue Repository with prior approval from the National Cancer Centre (NCC)
Institutional Review Board (IRB) (NCC IRB No.: NC08–12). As it is ethically not
possible to obtain normal livers from healthy individuals, the ‘normal’ non-
tumorous portion of the livers from 20 colorectal cancer patients with liver
metastasis was obtained when these patients underwent surgery to remove the
colorectal metastatic tumor in the liver. These tissues were also obtained from
the National Cancer Centre of Singapore Tissue Repository with prior approval
from the National Cancer Centre (NCC) Institutional Review Board (IRB) (NCC
IRB No: NC05–022). The non-tumorous livers from colorectal cancer patients rep-
resent ‘normal’ liver in this study.
miRNA microarray
HepG2 cells were transduced with either HBx-expressing (HBx) or control (Con-
trol) recombinant adenovirus as previously described [18]. Cells were harvested
72 h post transduction for microarray analysis. Ambion mirVana™ Bioarrays were
used to examine the miRNA expression. Signiﬁcantly differentially expressed
miRNAs were identiﬁed with Volcano Plot analysis.
RT-qPCR and Western blot analysis
Let-7 expression was measured with Taqman microRNA assay. STAT3 transcript
expression was measured with SYBR RT-qPCR, and protein expression was mea-
sured with Western blot with speciﬁc antibodies.
Apoptosis and proliferation
Annexin V apoptosis assay and WST-1 cell proliferation assay were used to func-
tionally characterize cells with transiently altered let-7a expression.
Detailed description of the materials and methods used can be found in the
supplementary ﬁle.Results
Let-7 family of miRNAs is signiﬁcantly down-regulated in HBx-
expressing HepG2 cells
To evaluate if HBx deregulates the expression of cellular miRNAs,
the proﬁle of 286 human miRNAs was examined in HBx-express-
ing versus control-HepG2 cells, in three independent experi-
ments. The miRNA microarray data can be obtained from
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=tlmdlk-
myimcewhm&acc=GSE17474, Accession number: GSE17474.
Ninety miRNAs were found to exhibit signiﬁcant expression in
all three paired biological samples. These miRNAs are presented
in Fig. 1A in a Volcano plot which displays the logarithmic trans-
formation to the base 2 of the mean fold change of miRNA
expression in HBx versus control cells, against the negative loga-
rithm to the base 10 of the p-value of Student’s t test. Signiﬁ-
cantly differentially expressed miRNAs were identiﬁed as
absolute mean fold change of greater than 1.5 and p-value of
less than 0.01, and located in the two upper-lateral quadrants.
Seven miRNAs (miR-30c, miR-193b, miR-342, miR-199a, miR-
125a, miR-99b, and miR-191) were found to be signiﬁcantly
up-regulated while 11 miRNAs (miR-196a, miR-106a, miR-20a,
and let-7 family of miRNAs) were found to be signiﬁcantly
down-regulated in HBx-expressing cells compared to the control
cells (Fig. 1B). Notably, we observed that eight out of the nine
mature sequences of the human let-7 family were signiﬁcantly
down-regulated with the exception of let-7b which was also
down-regulated, but with a p-value of 0.07 (Fig. 1D). Fig. 1B


































 miR- 30c + 2.24 1.90E- 03 * * + 2.32 3.54E- 02 *
 miR- 199a + 1.55 5.00E- 03 * * + 3.41 4.33E- 02 *
let- 7a - 2.18 7.33E- 04 * * * - 1.98 2.54E- 02 *
let- 7b - 1.65 7.08E- 02 - 2.07 3.38E- 02 *
let- 7c - 2.70 1.53E- 03 * * - 1.95 3.48E- 02 *
let- 7d - 2.03 7.61E- 03 * * - 2.33 7.33E- 03 * *
let- 7e - 1.98 3.03E- 04 * * * - 2.25 2.33E- 02 *
let- 7f - 2.18 1.63E- 03 * * - 2.27 1.62E- 02 *
let- 7g - 1.80 6.53E- 05 * * * - 2.04 3.05E- 02 *
let- 7 i - 1.77 7.67E- 04 * * * - 2.28 8.90E- 03 * *


























































Fig. 1. Proﬁle of miRNAs deregulated by HBx in HepG2 cells. (A) Volcano plot showing 90 miRNAs that are signiﬁcantly expressed in HBx cells. miRNA microarray data
were collected by comparing the miRNA expression in HBx-expressing HepG2 cells (HBx cells) versus the control cells from three biological replicates. Y-Axis: log10(p-
value); X-axis: log2(ratio(HBx/control)). Differential expression of miRNAs in HBx cells versus control cells that are both biologically and statistically signiﬁcant are
indicated in the two upper-lateral quadrant with absolute fold change >1.5 and p-value <0.01. Green spots indicate miRNAs that are signiﬁcantly down-regulated while red
spots indicate miRNAs that are signiﬁcantly over-expressed in HBx cells. (B) Hierarchical clustering of miRNAs that are differentially expressed in HBx-expressing cells
using Euclidean correlation with average linkage. Up-regulated miRNAs are represented by red blocks while down-regulated miRNAs are shaded green. (C) Let-7 expression
normalized against RNU48, measured using reverse-transcription Taqman real-time PCR. Data are presented as mean ± SE from three independent experiments. (D)
Table showing the mean fold change and p-value of up-regulated miR-30c, miR-199a, and down-regulated let-7 miRNAs in HBx cells versus control cells from both the
miRNA microarray and RT Taqman real-time PCR. *p <0.05, **p <0.01 and ***p <0.001.
JOURNAL OF HEPATOLOGYHeat Map using unsupervised hierarchical clustering with Euclid-
ean distance and average linkage analysis. We chose to validate
the expression of two up-regulated miRNAs (miR-30c and miR-
199a) and all the members of the let-7 family, using reverse-tran-
scription Taqman real-time PCR. The data were normalized
against the endogenous control RNU48. The let-7 family of miR-
NAs showed greatly variable endogenous level of expression. The
expression of let-7a, let-7b, and let-7c was high whereas theJournal of Hepatology 20expression of let-7e and let-7i was very low (Fig. 1C). Nonethe-
less, all 9 mature miRNAs were validated to be signiﬁcantly
down-regulated in HBx-expressing cells. (Fig. 1C and D). To
ensure that the observed effect of HBx on let-7 is not cell line spe-
ciﬁc, we repeated the experiment in a second liver cell line, SNU-
182 [28]. As evident in Supplementary Fig. S2, the expression of
let-7a, let-7b, let-7c, let-7e, and let-7i was signiﬁcantly reduced
in HBx-expressing SNU-182 cells. Taken together, these results10 vol. 53 j 57–66 59
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show a distinct miRNA expression proﬁle, including the down-
regulation of the entire let-7 family of miRNAs, which is associ-
ated with HBx in HepG2 cells. Moreover, the down-regulation
of selected members of the let-7 miRNAs by HBx is reproducible
in SNU-182 cells.
HBx expression is inversely correlated with let-7a expression in
hepatocellular carcinoma patients
We proceeded to evaluate the clinical relevance of the observa-
tion that HBx negatively regulates members of the let-7 family,
by examining the correlation between the HBx protein expres-
sion and the various let-7 family members in 20 HBV-associated
HCC patients. Supplementary Fig. S3 shows the HBx status in the
20 HBV+ HCC patients, analyzed through Western blot analysis
with polyclonal rabbit-anti-HBx antibody generated from our
laboratory. The expression of miR-98 was undetectable in the
patients’ samples. With the exception of let-7e and let-7i, which
are expressed at very low levels in the HepG2 liver cell line, the
expression of the other members of the let-7 family generally
negatively correlates with the expression of the HBx protein in
HCC patients (Supplementary Fig. S4), although the correlation
is only statistically signiﬁcant (p <0.05) in the three most highly
expressed let-7 miRNAs (let-7a, let-7b, and let-7c) (Fig. 2A).
Further examination of let-7a revealed that let-7a expression is
signiﬁcantly lower in tumors compared to the adjacent
non-tumorous liver tissues of HCC patients (p <0.001), and both
HCC-tumors and adjacent non-tumorous liver tissues show
signiﬁcantly lower let-7a expression compared to normal liver
tissues (p <0.001 and p <0.01, respectively) (Fig. 2B). When the
HBV+ HCC patients were sub-grouped based on the relative HBx
status between tumor and non-tumor tissues, let-7a expression
was signiﬁcantly lower while HBx expression was signiﬁcantly
higher in the tumor compared to the non-tumorous liver tissues
in 16 HCC patients (p <0.001). In contrast, although not statisti-
cally signiﬁcant, let-7a expression was higher while HBx expres-
sion was lower in the tumor compared to the non-tumorous
tissues in the remaining four HCC patients (Fig. 2C). Hence, this
signiﬁcant negative correlation between the expression of
let-7a and the expression of the HBx protein in HCC patients
reafﬁrms the clinical relevance of our observations.
Let-7 negatively regulates cell proliferation
Let-7 miRNAs have been reported to play important roles in cell
differentiation and cell proliferation (see review [29]). To evalu-
ate the functional signiﬁcance of HBx-mediated let-7 down-regu-
lation, the level of cellular let-7 expression was altered by
exogenously introducing the let-7 precursor or let-7 inhibitor
into either HepG2 or SNU-182 cells. As the members of the let-
7 family of miRNAs have previously been shown to have similar
functions [30], let-7a was selected as a representative member of
the let-7 family of miRNAs since it is one of the most highly
expressed let-7 miRNA in our system, and consistently down-reg-
ulated by HBx in both HepG2 and SNU-182 cells (Fig. 1C, Supple-
mentary Fig. S2). A signiﬁcant 30% decrease (p <0.001) in cell
proliferation (Fig. 3B, left panel) was observed when let-7a pre-
cursor was introduced into HepG2 cells (Fig. 3A, left panel). Inver-
sely, when let-7a expression was inhibited by 50% through the
introduction of let-7a inhibitor (Fig. 3A, left panel), there was a
corresponding signiﬁcant increase (p <0.01) in cell proliferation60 Journal of Hepatology 20(Fig. 3B, left panel) in HepG2 cells. The expression of unrelated
miR-100 remained undisturbed, demonstrating the speciﬁcity of
the small oligos in perturbing endogenous let-7a level. Similar
resultswereobserved in theSNU-182cells (Fig. 3A, 3B, rightpanel).
Our data conﬁrmpreviousobservationsmadeby Johnsonet al. [30]
highlighting the role of let-7 in negatively regulating cell prolifer-
ation inHepG2 cells. No signiﬁcant difference in cell apoptosiswas
observed whether the cells were transfected with the Control Oli-
gos, the let-7a precursor or the let-7a inhibitor (data not shown),
conﬁrming the results from a previous study which showed that
under control conditions, let-7a does not affect apoptosis [31].
STAT3 is a direct cellular target of let-7
To elucidate the cellular targets through which let-7 affects cell
proliferation, we performed in silico analysis with different mi-
RNA target prediction algorithms to identify putative let-7 tar-
gets. Both miRanda [32,33] and PicTar [34] predicted STAT3,
the central mediator of JAK/STAT pathway, playing a role in cell
proliferation, as a putative let-7 target. Several studies have pre-
viously demonstrated the role of HBx in activating STAT3 [35,36].
Hence, we proceeded to investigate whether HBx can also regu-
late STAT3 expression through down-regulation of let-7 miRNAs.
One strong putative let-7 binding site was identiﬁed by miRanda
along STAT3 30UTR (http://www.microrna.org/microrna/
home.do). To validate whether let-7 directly targets STAT3, we
cloned the wild-type 30UTR of STAT3 as well as a mutant 30UTR
in which the putative let-7 binding site is mutated, downstream
of the b-galactosidase (b-gal) reporter gene (Fig. 4A). As shown in
Fig. 4B, introduction of let-7a into cells containing wild-type
STAT3 30UTR reporter construct, resulted in signiﬁcantly lower
(p <0.001) b-gal activity compared to cells carrying the mutant
STAT3 30UTR reporter construct in which the let-7 binding site
is mutated. No signiﬁcant difference was observed between cells
carrying wild-type or mutant STAT3 30UTR reporter construct
when Control Oligos were introduced (Fig. 4B). The endogenous
STAT3 transcript and protein expression were also signiﬁcantly
decreased (p <0.001) when let-7a precursor was introduced
(Fig. 4C). Conversely, when the let-7a inhibitor was introduced,
cells carrying the wild-type 30UTR of STAT3 displayed signiﬁ-
cantly higher (p <0.01) b-gal reporter activity compared to cells
carrying the 30UTR of STAT3 in which the let-7 binding site was
mutated (Fig. 4B). Similarly, the endogenous STAT3 transcript
and protein expression were also signiﬁcantly increased
(p <0.01) when let-7a inhibitor was introduced (Fig. 4C). As a
positive control, we concurrently examined whether the addition
of let-7a precursor or inhibitor into cells affected c-Myc, a previ-
ously validated cellular target of let-7a [37]. As indicated in
Fig. 4C (right panel), similar decrease and increase in c-myc pro-
tein expression was observed when let-7a precursor and inhibi-
tor, respectively, were introduced into the cells. Hence, these
data suggest that let-7a physically interacts with the 30UTR of
STAT3 to negatively regulate its cellular expression. To ascertain
that STAT3 is indeed a target through which let-7a affects cell
proliferation, we knocked down STAT3 with a siRNA that specif-
ically targets STAT3, and examined its effect on cell proliferation.
As shown in Fig. 4D, knock-down of STAT3 reduces cell prolifer-
ation (rightmost lane), phenocopying the effect of let-7a
over-expression (middle lane). Supplementary Fig. S5 shows the
level of expression of let-7a and STAT3 when let-7a precursor
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Fig. 2. HBx expression is inversely correlated with let-7a, let-7b, and let-7c expression in HCC patients. (A) Scatter plots showing the statistically signiﬁcant correlation
in the relative expression of HBx and let-7a (p <0.01), let-7b (p <0.05), and let-7c (p <0.01) in the tumor versus paired adjacent non-tumorous tissues of 20 HCC patients.
Each spot represents data from one HCC patient presented in the log2 scale, and the linear regression line is represented by the solid line. (B) Let-7a expression is lower in
HCC patient samples than in normal liver samples. Box plot of let-7a expression in the normal liver samples from 20 metastatic colorectal cancer patients (normal liver), the
adjacent non-tumorous liver (HCC non-tumor), and tumor tissues (HCC-tumor) from 20 HBV-associated HCC patients. (C) Let-7a expression is only signiﬁcantly reduced in
HCC-tumors where HBx is selectively over-expressed, compared to the paired adjacent non-tumor tissues. Box plot of let-7a expression in 20 normal liver samples (Normal
Liver), 16 HCC patients with higher HBx in tumor compared to the paired non-tumorous tissues, and 4 HCC patients with lower HBx in tumor than their paired non-
tumorous tissues. Representative Western blots of HBx versus B-actin are shown below the box plot to illustrate the HBx status between the two groups of HCC patients.
*p <0.05, **p <0.01 and ***p <0.001.
JOURNAL OF HEPATOLOGYexpression is also found to positively correlate with HBx expres-
sion in HCC patients (Supplementary Fig. S6). Taken together, our
data demonstrate that let-7a regulates cell proliferation at least
partially through its direct target, STAT3.
Down-regulation of let-7 by HBx supports cell proliferation in HBx-
expressing cells
To reafﬁrm the relationship between let-7a and STAT3 in HBx-
expressing cells, we examined the expression of let-7a and STAT3Journal of Hepatology 20in HepG2 cells transduced with Control or HBx recombinant ade-
noviruses respectively. As evident in Fig. 5A (left panel), let-7a
shows signiﬁcantly reduced expression (p <0.05) while STAT3
expression is signiﬁcantly increased at both the transcript
(p <0.01) and protein (p <0.05) level, in HBx-expressing cells
versus control cells. As HBx down-regulated let-7, and let-7
negatively regulates cell proliferation, we hypothesized that
HBx up-regulates cell proliferation through let-7a. Interestingly,
cell proliferation is not signiﬁcantly different in control- versus
HBx-infected cells (Fig. 5B, leftmost panel, 1st two bars).10 vol. 53 j 57–66 61
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B
Fig. 4. Characterization of STAT3 as a direct cellular target of let-7. (A) Schematic diagram of the constructs utilized to validate that the let-7 targets the 30UTR region of
STAT3. The wild-type STAT3 30UTR carrying the predicted let-7 binding site (left box) or the mutant STAT3 30UTR carrying the mutated let-7 binding site (right box with the
mutation residues in bold) were cloned downstream the b-galactosidase reporter gene driven by MRP1 promoter. (B) Effect of let-7a on STAT3 30UTR examined through
normalizedb-galactosidase activity in cells co-transfectedwithControl oligos, let-7aprecursor or let-7a inhibitor andwild-typeSTAT330UTR (blackbar) ormutant STAT330UTR
reporter construct (white bar). (C) Left panel: Graphdepicting relative fold change of let-7a expression (normalized against RNU48) (white bar), STAT3 transcript (grey bar) and
protein (black bar) expression (normalized against b-actin) in HepG2 cells transfected with Control oligos, let-7a precursor or let-7a inhibitor. Right panel: Representative
Western blot showing protein expression of c-Myc, and STAT3 against b-actin in cells transfectedwith Control oligos, let-7a precursor or let-7a inhibitor. (D) Cellswhose STAT3
expression is inhibited show similar proliferation phenotype as cells over-expressing let-7a. Relative cell proliferation of HepG2 cells transfected with Control oligos, let-7a
precursor or siRNAagainst STAT3measured using theWST-1 assay. Expression of let-7a and STAT3 after the introduction of either let-7a or siRNA against STAT3 can be found in






























































HepG2 SNU-182 HepG2 SNU-182
Fig. 3. Let-7 negatively regulates cell proliferation. (A) Relative let-7a (left two panels) and miR-100 (right two panels) expression normalized against RNU48, measured
using reverse-transcription Taqman real-time PCR, in HepG2 and SNU-182 cells transfected with Control oligos, let-7a precursor or let-7a inhibitor. (B) Relative cell
proliferation measured using the WST-1 assay in the same experimental setup. Data presented as mean ± SE from three independent experiments. *p <0.05, **p <0.01 and
***p <0.001.
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Fig. 5. HBx-expressing cells show increased cell proliferation upon treatment with apoptosis inhibitor. (A) Left panel: Relative expression of let-7a (white bar), STAT3
transcript (grey bar), and protein (black bar) in HBx-expressing HepG2 cells versus control cells. Right panel: Representative Western blotting showing protein expression
of STAT3, EGFP, and HBx against b-actin. (B) Relative cell proliferation measured with WST-1 assay (leftmost panel) and relative expression of let-7a and STAT3 (right two
panels) in HBx or control cells transfected with either Control Oligos or Let-7a precursors. (C) Left two panels: Relative cell apoptosis measured with Annexin V assay and
relative cell proliferation measured with WST-1 assay in HBx or control cells treated with control or apoptosis inhibitor, zVAD. Right two panels: Corresponding let-7a and
STAT3 expression under the same experimental conditions. Data presented are expressed as mean ± SE from three independent experiments. *p <0.05, **p <0.01 and
***p <0.001.
JOURNAL OF HEPATOLOGYNonetheless, when let-7a precursors were introduced, both let-7a
and STAT3 expression in the HBx cells was restored to a similar
level than in control cells (Fig. 5B, middle and rightmost panels).
Introduction of let-7a also results in the signiﬁcant inhibition of
cell proliferation in both control- and HBx-expressing cells
(Fig. 5B, leftmost panel), with the reduction of cell proliferation
in HBx-expressing cells being twice as much as that observed
in control cells (p <0.05). As HBx has long been known to be a
pleiotropic protein implicated in both cell death [18] and cell pro-
liferation [38], our data indirectly suggest that HBx’s effect on cell
apoptosis may negate its effect on cell proliferation.
To reafﬁrm that HBx’s role in cell proliferation is through its
down-regulation of let-7a, we limited the effect of HBx on apop-
tosis by treating the cells with a general apoptosis inhibitor,
zVAD, before assaying for cell proliferation. As shown in Fig. 5C,Journal of Hepatology 20when apoptosis was not inhibited, HBx-expressing cells showed
similar cell proliferation despite 50% more cell death, compared
to the control cells. HBx-expressing cells only showed signiﬁ-
cantly higher cell proliferation (30%, p <0.01) than the control
cells upon treatment with apoptosis inhibitor. The treatment
with control or apoptosis inhibitor did not affect HBx’s ability
to down-regulate let-7a and up-regulate STAT3 (Fig. 5C). The
above observations thus provide direct evidence that the pleio-
tropic HBx can inﬂuence both cell death and cell proliferation,
and HBx-mediated down-regulation of let-7 may function to sup-
port cell proliferation in HBx cells. Taken together, these data fur-
ther conﬁrm the pleiotropic nature of HBx protein and
demonstrate that HBx-mediated down-regulation of let-7 and
up-regulation of STAT3 play a role in maintaining cell prolifera-
tion in order to counter-balance its effect on cell apoptosis.10 vol. 53 j 57–66 63
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Discussion
The HBx protein plays an important role in hepatocellular carci-
nogenesis. Our current understanding of the role of HBx focuses
on its ability to deregulate cellular gene expression at the tran-
scription level through its interaction with many cellular factors
[6]. In this study, we provided evidence that HBx can also dereg-
ulate cellular gene expression at the post-transcriptional level
through the deregulation of cellular miRNAs. It is not uncommon
for viruses to develop mechanisms to suppress RNA interference,
which is an important antiviral defense. HIV-1 was recently
reported to globally suppress host microRNA expression [39].
The Epstein-Barr virus latent membrane protein 1 was reported
to activate miRNA-155 transcription [40]. This is the ﬁrst study
which demonstrates that the hepatitis B viral protein, HBx, also
plays a role in deregulating cellular miRNAs.
Of the 286 human miRNAs that were examined in this study,
HBx was found to signiﬁcantly up-regulate the expression of 7
miRNAs and down-regulate the expression of 11 cellular miRNAs
respectively (Fig. 1A and B). Many of these HBx-deregulated mi-
RNAs were also reported to be similarly deregulated in many
human diseases, and having functional impact on important cel-
lular pathways such as cell death and cell proliferation. Of the
seven up-regulated miRNAs, miR-125a is also up-regulated in
human thyroid papillary carcinoma [41] and type II diabetes in
a mouse model [42], and targets the tumor suppressor TP53
[43]. miR-199a was reported to be over-expressed in tumors of
human ovarian cancer [44], and to regulate NF-jB activity by tar-
geting IKKb [45]. HBx has been previously reported to play a role
in TP53 [46] and NK-jB pathways [47]. Our current data suggest
that HBx may also regulate these important cellular pathways
through the modulation of cellular miRNAs. Of the other HBx
up-regulated miRNAs, miR-99b, miR-191, and miR-342 are also
known to be up-regulated in myeloma [48], colorectal cancer
[49] and breast cancer [50], respectively, and miR-30c is required
for vertebrate hepatobiliary development [51]. However, further
studies are needed to understand the role of HBx in up-regulating
these miRNAs in the liver context. The 11 miRNAs that are down-
regulated by HBx belong to three families of miRNAs, implicated
in cell proliferation or apoptosis. miR-20a and miR-106a belong
to the miR-17 family which is comprised of six members (miR-
17, miR-20a/b, miR-106a/b, and miR-93) [52]. Five members of
this miR-17 family, with the exception of miR-20b, were exam-
ined in our microarray and they were all generally down-regu-
lated (data not shown). miR-20a is located in the well-known
oncogenic miR-17–92 cluster that is over-expressed in many
forms of cancer [27], and the repression of members of this clus-
ter such as miR-20a leads to increased apoptosis [53]. The down-
regulation of miR-106a predicted shortened disease free survival
in human colon cancer patients [54]. miR-196a was reported to
regulate cell proliferation and osteogenic differentiation in
human adipose tissue-derived mesenchymal stem cells [55]. Sig-
niﬁcantly, all nine mature sequences of human let-7 family of
miRNAs were validated to be down-regulated by HBx in human
liver HepG2 cells. Let-7 miRNAs are important regulators of
development, differentiation, and cell proliferation. Their down-
regulation was frequently observed in many cancer types includ-
ing HCC [27]. The global pattern of HBx-deregulated miRNAs can
potentially target many cellular genes and have an impact on a
number of cellular processes such as cell proliferation and apop-
tosis, partly explaining the pleiotropic nature of HBx protein.64 Journal of Hepatology 20As HBx is frequently over-expressed in the tumors of HBV-
associated HCC, HBx-mediated down-regulation of let-7 may be
one of the mechanisms responsible for the reduced presence of
let-7 in HCC [56]. This hypothesis was supported by the signiﬁ-
cant inverse correlation between HBx and let-7a, let-7b, and
let-7c expression in HCC patients. We further examined let-7a
expression in 20 normal liver samples from colorectal patients
who underwent surgery to remove their liver metastasis. We
found that let-7a expression was signiﬁcantly lower in both
tumor and non-tumorous liver tissues from HCC patients where
HBx expression is evident, compared to the normal liver tissues
from colorectal cancer patients (Fig. 2B). Moreover let-7a expres-
sion was signiﬁcantly lower in tumor compared to the adjacent
non-tumorous tissues in HBV+ HCC patients and its expression
was inversely correlated with the status of the HBx protein in
the paired tumor versus non-tumorous tissues (Fig. 2C). Taken
together, our data demonstrate the clinical relevance of the
observed HBx-mediated down-regulation of let-7 in the cell-line
studied. Due to practical difﬁculties in obtaining samples from
non-HBV-associated HCC patients, the role of let-7 in non-HBV-
associated HCC remains to be investigated. The exact mechanism
through which HBx down-regulates let-7 also remains unclear.
We hypothesize that HBx can either bind speciﬁc cellular tran-
scription factors to repress let-7 transcription or interact with
speciﬁc cellular factors to interfere with let-7 maturation. Lin28
was recently identiﬁed to negatively regulate let-7 maturation
[57], and it would be interesting to explore if HBx acts through
Lin28 to negatively regulate let-7 maturation.
Let-7, the ﬁrst miRNA identiﬁed in humans, was reported to
target a number of important cellular oncogenes such as MYC
[37], RAS [58], and HMGA2 [59]. In this study, we identiﬁed
and experimentally validated another direct cellular target of
let-7: STAT3, which is an important member of the JAK/STAT
pathway. STAT3 was reported to be involved in many cellular
processes including cell growth, survival, metastasis, angiogene-
sis, and immune suppression, all of which favors tumor formation
and progression [60]. STAT3 was also known to play critical role
in liver regeneration, and over-activation of STAT3 may play a
role in contributing to HCC [61,62]. In fact, constitutive activation
of STAT3 alone is sufﬁcient to transform normal mouse ﬁbro-
blasts [63]. Hence, STAT3 expression and activity are highly reg-
ulated via different mechanisms at different levels under
physiological conditions. Mechanisms of STAT3 inhibition include
inhibition of Jak kinase activity through the activation of SOCS1
and SOCS3, also known as suppressors of cytokine signaling pro-
teins [64] and protein inhibitors of activated STAT3 (PIAS) [65], or
through the modulation of speciﬁc phosphatases such as protein
phosphatase 2A (PP2A) [66]. The ﬁnding that let-7 microRNAs
target STAT3, reveals an additional level of regulation of STAT3
expression, through modulation of its transcript/protein abun-
dance, carried out by microRNAs. miRanda predicted a total of
122 putative miRNA binding sites along the 30UTR of STAT3 (data
not shown) suggesting that the STAT3 may be highly regulated
not only at several different levels mentioned above but also at
the post-transcriptional/translational level by several different
miRNAs including let-7. Over-activation of STAT3 is frequently
observed in solid tumors including breast, ovary, and prostate
tumors [60], where let-7 is also frequently under-represented
[27]. However, STAT3 seems to be only one of several let-7 cellu-
lar targets through which let-7 acts to negatively regulate cell
proliferation, since, completely inhibiting STAT3 alone, does not10 vol. 53 j 57–66
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completely inhibit cell proliferation (Suppl Fig. S5 and Fig. 4D).
This is not surprising, considering that let-7 was also reported
to target MYC [37] and RAS [41], both of which are important fac-
tors involved in cell proliferation. The fact that let-7 can target
MYC, RAS, STAT3, and probably other proliferation factors yet
to be discovered, further demonstrates the role of let-7 as a mas-
ter regulator of cell proliferation, whose loss of function will
result in the deregulation of crucial cellular processes, leading
to tumorigenesis. Unfortunately, we could not observe a statisti-
cally signiﬁcant correlation between let-7a and STAT3 expression
in the 20 HCC patients we examined (data not shown). This might
be due to the fact that STAT3 regulation is very complex and
additional HCC patient samples may need to be examined to bet-
ter stratify the samples and reveal any potential correlation.
Although the down-regulation of let-7 promoted cell prolifer-
ation (Fig. 3) and HBx was found to down-regulate let-7 expres-
sion (Figs. 1 and 5A), HBx-expressing cells do not seem to show
increased cell proliferation compared to control cells under nor-
mal conditions (Fig. 5B). This is not surprising as HBx is also
known to promote cell apoptosis in HepG2 cells [67]. To dissect
the effect of HBx on cell proliferation from cell death, we pro-
ceeded to inhibit cell death by treating the cells with a general
caspase inhibitor. When cell apoptosis is inhibited, HBx cells
showed signiﬁcantly higher cell proliferation than the control
cells (Fig. 5C). Thus, our results strongly suggest that HBx can
concurrently impact on both cell death and cell proliferation
and HBx-mediated let-7 down-regulation functions to support
cell proliferation in HBx cells. These data are consistent with pre-
vious reports showing that HBx is a pleiotropic viral protein
involved in both cell proliferation [38] and cell death [18]. In
the multi-stage, multi-hit process of tumorigenesis, HBx may
function as an opportunistic factor that can potentially help pro-
moting tumor formation partially through the down-regulation
of let-7 miRNAs in cells where cell apoptosis is impaired. This
could perhaps explain why different research groups observe dif-
ferent phenotypes in HBx-expressing cells [18,38,67] and mice
[12,19], since the predominant phenotype of HBx depends on
other factors that make up the microenvironment in which the
function of HBx is evaluated.
In summary, this is the ﬁrst report highlighting the role of the
hepatitis viral protein HBx, in regulating cellular microRNAs
expression. The HBx protein deregulates the expression of at least
18 cellular miRNAs, including the entire family of let-7 in HepG2
cells. Notably, a signiﬁcant inverse relationship between the
expression of the HBx protein and the expression of let-7a, let-
7b, and let-7c was observed in HCC patients highlighting the clin-
ical relevance of our observations. Let-7a was found to negatively
regulate cell proliferation, at least in part, by targeting STAT3.
HBx-mediated let-7 down-regulation supports cell proliferation
in HBx-expressing cells. Hence, HBx can deregulate cellular path-
ways through yet another mechanism by interfering with the
expression of cellular miRNAs. Our ﬁndings thus offer a new per-
spective in understanding both the pleiotropic nature of HBx viral
protein and its contribution to HCC.Conﬂicts of interest
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Role of miR‑224 in hepatocellular carcinoma: a tool 
for possible therapeutic intervention?
Hepatocellular carcinoma (HCC) is the third 
leading cause of cancer related death worldwide, 
with an annual global mortality of more than 
600,000 deaths [1,101]. The main etiological fac‑
tors associated with HCC, whose importance 
varies according to the geographical locations, 
include chronic hepatitis viral infection (hepa‑
titis B or C virus), long‑term exposure to afla‑
toxin B1, excessive alcohol consumption and 
obesity [101]. Despite years of extensive research, 
HCC is still poorly understood and very little 
progress has been made to improve the diagnosis 
and prognosis of HCC. Surgical resection and 
liver transplantation remain the only curative 
treatment modalities that consistently convey 
survival advantage to less than 10% of HCC 
patients, while conventional radiotherapy and 
chemotherapy are largely less successful modali‑
ties for treating HCC [2]. Recent advances in 
miRNA research have provided new insights 
in understanding HCC and presented promis‑
ing novel targets for early detection and better 
t reatment of HCC.
Since the discovery of the first miRNA in 
Caenorhabditis elegans by Ambros and colleagues 
in 1993 [3], this class of small noncoding RNAs 
have been found to be abundantly expressed in 
viruses [4], plants [5] and animals [6]. To date, 
more than 1000 human miRNAs have been 
annotated in miRBase (Release 16) [7–9]. They 
form the largest class of gene regulators at the 
post‑transcriptional/translational level and par‑
ticipate widely in many cellular processes. It is 
thus not surprising that miRNA deregulation 
has been reported to be associated with many 
human diseases including HCC. To date, a 
total of 14 publications have described miRNA 
de regulations in HCC through systematic profil‑
ing of miRNA expression in HCC tumors ver‑
sus either paired adjacent nontumor or unpaired 
normal liver tissues (Table 1) [10–23]. Unfortunately, 
as highlighted in a previous review [24], no single 
miRNA is consistently reported to be deregu‑
lated by all 14 studies and only a limited partial 
overlap exists in reported deregulated miRNAs 
from different studies. As shown in Table 1, the 
number of HCC patient samples profiled in 
these studies is relatively small, ranging from 
three to 104 patients, with ten studies having a 
sample size of fewer than 30 patients. As HCC is 
a highly heterogeneous disease with many etio‑
logic factors, the small sample size may partially 
account for the inconsistencies in the various 
reports. In addition, as different profiling meth‑
ods such as microarray, quantitative PCR, clon‑
ing and bead‑based microarray were employed 
in these 14 studies, the specificity and sensitivity 
associated with each of these profiling methods 
and the different number of mature miRNAs 
examined in each study may have also resulted 
in a slightly different set of miRNAs reported 
to be differentially expressed in HCC. A coor‑
dinated international effort which employs a 
consistent profiling strategy on a large sample 
set that sufficiently stratifies HCC patients based 
on eti ology and ethnicity would be needed to 
provide a more coherent overview of miRNA 
deregulation in HCC. 
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, characterized by high 
mortality rate and poor prognosis. Our understanding of the HCC pathology is still very much fragmented 
and little progress has been made to improve the clinical outcome of HCC patients. While recently discovered 
microRNA deregulation in HCC has added to the complexity of our understanding of HCC, it has also 
presented promising novel approaches to understand, diagnose and treat HCC. Here, we highlight one 
miRNA, miR‑224, which has been more consistently reported to be upregulated in HCC than other miRNAs. 
We will discuss the validated and predicted functional roles of this miRNA in HCC, speculate on the possible 
mechanism for its upregulation in HCC and explore the potential of miR‑224 as an exciting novel biomarker 
for the early detection of liver malignancies as well as a novel therapeutic target for HCC treatment.
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miRNAs which have been more consistently 
reported to be aberrantly expressed in multiple 
studies, irrespective of the nature of the patient 
samples or the profiling technologies, are most 
likely to be involved in the general mechanism of 
hepatocellular carcinogenesis. Table 1 summarizes 
the four upregulated miRNAs (miR‑21, miR‑221, 
miR‑222 and miR‑224) and two downregulated 
miRNAs (miR‑122 and miR‑199a) which have 
been consistently reported by at least six out of 
the 14 profiling studies. Indeed, these commonly 
deregulated miRNAs target crucial cancer‑impli‑
cated pathways. miR‑21 is the most commonly 
upregulated miRNA in both solid and hema‑
tological tumors [25], and inhibits cell apoptosis 
by targeting phosphatase and tensin homolog 
(PTEN) and programmed cell death protein 4 
(PDCD4) [26]. miR‑221/222 promote cell prolif‑
eration by targeting p27/CDKN1B to stimulate 
G1‑S transition [27] and inhibits cell apoptosis 
by targeting PTEN [28]. miR‑122 is the most 
abundant liver miRNA involved in liver homeo‑
stasis [29], and the loss of miR‑122 in HCC cor‑
relates with suppression of hepatic phenotype and 
gain of metastatic properties [30]. 
In this article, we will discuss the functional 
impact of miR‑224 upregulation in HCC, and 
speculate on the possible mechanism for its 
upregulation and its potential role as a promising 
 therapeutic and diagnostic target for HCC.
miR‑224 upregulation impacts 
multiple cellular pathways 
Each miRNA can potentially regulate hun‑
dreds of cellular targets and affect multiple 
cellular pathways. One way to gain insights 
into the functional role of miR‑224 is to exam‑
ine the cellular genes which miR‑224 targets. 
As most of miR‑224 direct cellular targets are 
unknown, in silico miRNA target prediction 
algorithms are the second best available option. 
miRecords, which is an online resource that 
compiles predicted miRNA targets produced 
by 11 established miRNA target prediction 
programs, was used to gain some insights into 
the putative targets that miR‑224 potentially 
regulate. A total of six of these 11 prediction 
programs, miRanda, mirTarget2, miTarget, 
PITA, RNAhybrid and TargetScan, predict 
targets for human miR‑224 [31]. A total of 
52 putative miR‑224 targets, mapping into 
39 gene ontology (GO) annotated functional 
processes, were predicted by at least five pre‑
diction programs (Table 2). These in silico pre‑
dictions suggest that miR‑224 can potentially 
affect many cellular processes associated with 
cancer, including transcription, cell differentia‑
tion, cell death, growth and cell proliferation. 
Interestingly, miR‑224 is predicted to affect 
both cell death and cell growth (Table 2). This 
seemingly opposing role of miR‑224 was also 
Table 1 . Recent publications on systematic profiling of miRNA deregulation in human hepatocellular carcinoma.






































Murakami et al. 2006 Microarray 25 180 6 - - - ↑ - ↓ [10]
Gramantieri et al. 2007 Microarray 17 238 28 - ↑ - - ↓ ↓ [11]
Meng et al. 2007 Microarray 3 - 15 ↑ ↑ ↑ - ↓ ↓ [12]
Huang et al. 2008 Microarray 10 331 33 ↑ ↑ - - - - [13]
Wang et al. 2008 qPCR 19 182 20 ↑ ↑ ↑ ↑ - - [14]
Jiang et al. 2008 qPCR 54 196 15 ↑ ↑ - - - ↓ [15]
Varnholt et al. 2008 qPCR 52 80 27 - - - - - - [16]
Ladeiro et al. 2008 qPCR 55 250 6 ↑ - ↑ ↑ ↓ - [17]
Connolly et al. 2008 MiRNA cloning 19 - 18 ↑ - - - ↓ - [18]
Su et al. 2009 Microarray 20 308 28 - - ↑ ↑ - ↓ [19]
Huang et al. 2009 Bead-based flow 20 114 30 - ↑ ↑ ↑ ↓ ↓ [20]
Ura et al. 2009 qPCR 26 188 29 ↑ ↑ ↑ - ↓ ↓ [21]
Pineau et al. 2010 Microarray 104 215 12 ↑ ↑ ↑ ↑ - - [22]
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observed experimentally where miR‑224 was 
found to increase both cell proliferation and 
apoptotic cell death [14,32]. One of the predicted 
miR‑224 targets in cell death process, apopto‑
sis inhibitor 5 (API5) (Table 2), has also been 
validated to be a direct cellular target through 
which miR‑224 sensitizes cells to apoptotic cell 
death in liver cells. The target through which 
miR‑224 influences cell proliferation remains 
unknown. The in silico prediction program sug‑
gests four nonredundant genes are involved in 
processes of cell growth and cell proliferation 
(Table 2). Of these four genes that are potential 
targets of miR‑224, SMAD family member 4 
(SMAD4) is the only putative miR‑224 target 
gene that is consistently highlighted. SMAD4, 
which is frequently dysregulated in cancer, is the 
central mediator for transforming growth factor 
b (TGF‑b) pathway and negatively regulates 
cell proliferation. Hypothetically, the possible 
downregulation of SMAD4 by miR‑224 over‑
expression will derepress the TGF‑b mediated 
inhibition on cell growth, resulting increased 
cell proliferation. This hypothesis is supported 
when Yao et al. reported that miR‑224 is regu‑
lated by TGF‑b/SMAD pathway and targets 
SMAD4 in mouse granulosa cells [33]. If this 
is true in human liver cells, it suggests the 
physiological role of miR‑224 in the negative 
feedback loop that controls TGF‑b signaling. 
miR‑224 overexpression in HCC will signifi‑
cantly deregulate the TGF‑b signalling  pathway 
and  facilitate unregulated proliferation.
The role of miR‑224 in increasing both cell 
proliferation and cell death may initially seem 
contradictory. However, similar to miR‑224, 
many other oncogenes including MYC and 
E1A were found to sensitize cells to apoptosis 
upon minor insults that normal cells can usu‑
ally resist [34,35]. Like these oncogenes, the dual 
role of miR‑224 to influence both cell prolif‑
eration and apoptosis may provide the selective 
pressure for cells to override apoptosis during 
the multistage process of tumorigenesis, result‑
ing in a resistant population of proliferating 
cells which may eventually accumulate enough 
genetic mutations for transformation to occur.
miR‑224 may also play an important role in 
metabolic processes and this is highlighted by 
the fact that 28 out of the 52 putative miR‑224 
targets are enriched in metabolic processes 
(Table 2). The Warburg effect of aerobic glyco‑
lysis is a key metabolic hallmark of cancer [36] 
and the activation of many oncogenes, such 
as RAS [37] and MYC [38], has been shown to 
drive changes in cell metabolism. Since in silico 
prediction has provided some useful clues in 
understanding the functional roles of miR‑224 
in the aspect of cell proliferation and cell 
apoptosis, it will be very exciting to examine 
miR‑224’s involvement in cancer metabolism, 
using a similar strategy. In addition, miR‑224 
overexpression is also recently found to increase 
cell migration, invasion [33] and anchorage inde‑
pendent cell growth [39]. Taken together, these 
data suggest that miR‑224 could be a potent 
oncogenic miRNA targeting multiple cancer‑
implicated pathways and the upregulation of 
miR‑224 in HCC seems to favor cellular trans‑
formation. It may be worthwhile to evaluate 
whether miR‑224 status correlates with clinical 
outcome for HCC patients.
Possible mechanisms for miR‑224 
upregulation in HCC
Like its gene counterpart, the regulation of 
miRNA expression is very complex. miRNA 
expression can be regulated at multiple levels 
including DNA amplification/deletion, epi‑
genetic modification, transcription, miRNA 
processing and decay. The expression of specific 
miRNAs such as let‑7 has also been shown to 
associated with specific etiological factors such 
as hepatitis B virus infection [40]. 
Although the mechanism for the upregula‑
tion of miR‑224 in HCC has yet to be elu‑
cidated, the genomic location of this miRNA 
may provide some clues about its regulation. 
As shown by Figure 1, miR‑224 resides in the 
same cluster as miR‑452 in the intron 6 of 
g‑aminobutyric acid receptor subunit epsilon 
(GABRE) gene, located near the end of q arm 
of chromosome X, in ChrXq28, a region known 
to be transcriptionally quiescent. As the inci‑
dence of HCC is more than twice as high in 
males than in females [101], the X‑linked nature 
of miR‑224 upregulation may partly explain 
this sex bias in HCC.
Although the ChrXq28 locus has been 
reported to be duplicated in a rare genetic 
disease affecting sexual development [41], it is 
unlikely to be the explanation for the upreg‑
ulation of miR‑224 expression in HCC since 
the duplication of ChrXq28 is rare and causes 
severe phenotypes such as mental retarda‑
tion and death before the age of 25 years [42]. 
Nonetheless, ChrXq28 is one of the best char‑
acterized human genomic regions hosting many 
cancer/testis (CT) antigen genes, a class of 
immunogenic proteins which are physiologically 
expressed only in the male germ cells but not in 
somatic cells. In many cancers (e.g., melanoma, 
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Table 2. Gene ontology term enrichment of 52 putative miR‑224 targets predicted by at least five 
prediction algorithms.
GO term GO ID Genes annotated to the GO term
Metabolic process† 0008152 ACSL4, AFF3, ATF2, BRPF3, BTRC, CASC3, DPYSL2, HMGCR, MAPK14, MED13L, NCOA6, 
NUAK1, POLR1D, POU3F2, PPAP2B, PRPF4B, RAD51L1, RUNX2, SDC4, SMAD4, SR140, 
TCERG1, TRIM9, UBE2D3, WTAP, YOD1, ZNF207, ZNF423


























Cell differentiation 0030154 ACSL4, DPYSL2, GGNBP2, MAP1B, NCOA6, POU3F2, RUNX2, SMAD4, ZNF423
Protein modification process 0006464 BRPF3, BTRC, MAPK14, NUAK1, PPAP2B, PRPF4B, SMAD4, UBE2D3, YOD1
Response to stress 0006950 CASC3, MAP1B, MAPK14, NCOA6, RAD51L1, SMAD4, UBE2D3, YOD1




0009653 BTRC, MAP1B, POU3F2, PPAP2B, SMAD4
Signal transduction 0007165 BTRC, DPYSL2, MAPK14, RAB10, SMAD4
Cell communication 0007154 BTRC, DPYSL2, MAP1B, POU3F2, SMAD4
Embryo development 0009790 ACSL4, MAP1B, NCOA6, PPAP2B, SMAD4
Cell death‡ 0008219 AMIGO2, API5, ITM2B, MAPK14, UBE2D3
Organelle organization 0006996 BRPF3, DIAPH3, H3F3B, MAP1B, SDC4
Reproduction 0000003 ACSL4, GGNBP2, HMGCR, PPAP2B
Response to 
endogenous stimulus
0009719 DPYSL2, H3F3B, MAP1B, NCOA6
DNA metabolic process 0006259 NCOA6, RAD51L1, UBE2D3
Protein transport 0015031 GGA3, RAB10, SMAD4
Response to 
external stimulus
0009605 ACSL4, MAP1B, MAPK14
Cytoskeleton organization 0007010 DIAPH3, MAP1B, SDC4
Lipid metabolic process 0006629 ACSL4, HMGCR, PPAP2B
Cell proliferation§ 0008283 BTRC, POU3F2, SMAD4
Growth§ 0040007 MAP1B, POU3F2, SMAD4
Cell cycle 0007049 BTRC, RAD51L1, WTAP
Behavior 0007610 ACSL4, MAPK14
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lung carcinoma and HCC), the somatic expres‑
sion of these CT antigens is de repressed mainly 
through epigenetic reprogramming including 
DNA methylation and chromatin remodeling 
[43]. A total of 19 CT antigens are mapped onto 
ChrXq28 region and two of these, MAGEA4 and 
MAGEA5, flank the miR‑224 locus (Figure 1). As 
tumors often express several CT antigens simul‑
taneously [43], it is possible that the expression 
of miR‑224 and CT antigens residing in the 
same chromosome region of ChrXq28 may be 
co ordinately upreg ulated through epigenetic 
reprogramming. Such coordinated regulation 
of expression was suggested by the limited 
expression data of miR‑224 and closeby genes 
at ChrXq28. Similar to miR‑224, GARBE 
(miR‑224 host gene) and MAGEA4 (~30 kbp 
away from miR‑224 locus) are also found to be 
upregulated in HCC [44,45], suggestive of coregu‑
lation between miR‑224 and neighboring genes. 
As CT antigens were reported to be upregulated 
epigenetically [43], it is thus likely that miR‑224 
is also upregulated epigenetically since it resides 
in the same chromosome region and seems to 
be coordinately upregulated in HCC although 
this remains to be experimentally validated. 
Nonetheless, with the availability of specific 
drugs targeting different epigenetic machiner‑
ies such as DNA methylase inhibitor (5‑aza‑2 ‑´
deoxycytidine), histone deacetylase inhibitor 
(trichostatin A) and histone methylase inhibi‑
tor (3‑deazaneplanocin A), the evaluation of the 
epigenetic regulation of miR‑224 can be readily 
assessed. The fact that miR‑224 may be coregu‑
lated with its host (GABRE)and neighboring 
genes (MAGEA4 and MAGEA5), since they 
reside close to one another in the same chro‑
mosome, suggests that further  characterization 
of this group of genes/miRNAs is warranted. 
miR‑224 was recently reported to be under the 
regulation of specific signaling pathways includ‑
ing the Src tyrosine kinase (Src) in mammary 
carcinoma cells [39], and the TGF‑b pathway 
in mouse granulosa cells [33], highlighting the 
involvement of different players in the regula‑
tion of miR‑224. We speculate that epigenetic 
reprogramming/chromatin remodeling pre‑
cedes the binding of these transcription factors 
at the miR‑224 locus to induce the expression 
of miR‑224.
Potential therapeutic strategies to 
target miR‑224 in HCC
As discussed earlier, miR‑224 was reported to 
affect cell proliferation [14], apoptosis [14], cell 
migration, invasion [33] and anchorage independ‑
ent cell growth [39], implicating this miRNA as 
an oncogenic miRNA capable of impacting 
multiple crucial cellular pathways. However, 
it remains unclear whether miR‑224 would be 
a good therapeutic target for the treatment of 
HCC. If so, promising new therapeutic strategies 
are being developed and can be quickly adapted 
to target miR‑224. 
The first strategy involves the liver‑specific 
delivery of short oligonucleotide‑based miR‑224 
inhibitors to block the action of mature miR‑224 
in deregulating cellular processes. Antisense 
miR‑224 inhibitors have been shown to effec‑
tively reverse phenotypes associated with 
miR‑224 overexpression in in vitro models [14] 
although it remains to be evaluated if these 
in vitro findings can be reproduced in animal 
models and human subjects. One attractive 
advantage of this strategy is the possibility of 
site‑specific delivery of such small oligo‑based 
miR‑224 inhibitors to liver cells through sys‑
temic intravenous administration. Zhu et al. has 
Table 2. Gene ontology term enrichment of 52 putative miR‑224 targets predicted by at least five 
prediction algorithms (cont.).
GO term GO ID Genes annotated to the GO term
Cell–cell signaling 0007267 DPYSL2, MAP1B
Ion transport 0006811 KCTD12, SLC4A4
Response to abiotic stimulus 0009628 MAP1B
Cellular amino acid and 
derivative metabolic process
0006519 YOD1
Response to biotic stimulus 0009607 YOD1
Translation 0006412 CASC3
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recently demonstrated the proof‑of‑concept for 
rapid site‑specific accumulation of engineered 
oligonucleotides in liver cells through such sys‑
temic administration [46]. If proven successful, 
this strategy may be useful to complement liver 
resection as a presurgical treatment to contain 
and manage HCC tumors.
If the expression of miR‑224 is regulated epige‑
netically, a second strategy would be to deliver spe‑
cific drugs that interfere with the chromatin struc‑
ture. Recently, targeting epigenetic machinery has 
emerged as an exciting new strategy for drug devel‑
opment, particularly for cancer and metabolic dis‑
eases. Vorinostat, a histone deacetylase inhibitor, 
is the first such drug approved by the US FDA 
in 2006 for the treatment of advanced cutaneous 
T‑cell lymphoma [47]. However, the limitation of 
current epigenetic drugs, such as vorinostat, is the 
nonspecific nature of these drugs, targeting a large 
number of cellular components such as all class I 
and II histone deacetylases. Knowledge on the 
exact mechanisms of the epigenetic processes will 
facilitate the identification of specific compounds 
that targets the individual component of the epi‑
genetic machinery. Finding a specific small mol‑
ecule epigenetic inhibitor drug may prove useful 
not only in neutralizing miR‑224 upregulation in 
HCC, it may also neutralize the aberrant activa‑
tion of other CT antigens in ChrXq28 and other 
regions of the genome that are also associated 
with HCC. Nonetheless, as these inhibitors are 
general inhibitors targeting the whole chromatin 
structure, there is a possibility of these inhibitors 
silencing other essential genes. Hence, further 
research has to be  performed to understand these 
drugs better.
The development of a relevant mouse model 
would facilitate the understanding of the onco‑
genic potential of miR‑224 in causing HCC as 
well as the evaluation of the above therapeutic 
strategies targeting miR‑224. 
miR‑224 may represent a useful 
novel biomarker for HCC or 
liver disease
Early detection of HCC has been difficult as 
the progression of HCC is largely asymptomatic. 
Currently, surveillance of HCC relies mainly 
on monitoring serum α‑fetoprotein levels and 
regular ultrasound or computed tomography 
examination [48]. A definitive diagnosis of HCC 
depends on histological analysis via a fine nee‑
dle biopsy. However, elevated α‑fetoprotein as 
a biomarker lacks specificity and the high‑cost 
ultrasound or computed tomography scan lacks 
affordability for a general screening applica‑
tion. A simple plasma‑based test which can rap‑
idly assess the liver status will be an important 
c ontribution to the HCC screening programs.
Although the development of miR‑224 as a 
therapeutic target for HCC may still be a far‑
fetched idea, there is great potential for miR‑224 
to be developed as a HCC or liver disease biomar‑
ker. Under normal physiological conditions, the 
expression of miR‑224 is very low or even unde‑
tectable [18] probably due to the transcriptional 
quiescent state of ChrXq28. However, as shown 
in Table 1, miR‑224 is one of the most consistently 
upregulated miRNAs in HCC. Interestingly, stud‑
ies which compare miR‑224 expression in HCC 
tumors with unpaired normal liver samples [17,19] 
tend to report much larger (27–30‑fold) changes 
than those that compare HCC tumors with paired 
adjacent nontumor samples (2.5–11‑fold) [10,14], 
suggesting that miR‑224 expression is not only 
upregulated in HCC, but it is also elevated in 
preneoplastic liver tissues which are frequently 
inflamed and/or cirrhotic. Murakami et al. found 
upregulation of miR‑224 in chronic hepatitis and 
liver cirrhosis [10]. Ladeiro et al. reported moder‑
ate elevation (~fivefold) in miR‑224 expression in 
benign tumors such as hepatocellular adenoma 
and miR‑224 expression was further elevated in 






Figure 1. Genomic locus of miR‑224. The top chromosomal map shows the location of miR-224 in ChrXq28 and the bottom map 
represents an enlargement of the 200-kb region in ChrXq28 showing the location of the miR-224/452 cluster, the host gene GABRE and 
the two flanking cancer/testis antigen genes (MAGEA4 and MAGEA5).
Chr: Chromosome.
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tumors of HCC (>20‑fold) [17]. Interestingly, the 
miR‑224 host gene, GABRE, was also reported 
to show a similar pattern of gradual upregulation 
corresponding to liver disease progression [44]. 
Taken together, these data suggest that miR‑224 
expression is gradually upregulated during liver 
disease progression, probably due to accumulated 
epigenetic changes in the genomic locus, making 
miR‑224 a useful potential biomarker to assess 
liver health status.
For miR‑224 to be developed as a potentially 
useful biomarker for HCC or liver disease, it 
must be readily detectable in a less invasive tis‑
sue like the blood/serum/plasma. miRNAs have 
recently been reported to be present in bodily 
fluid including blood serum making miRNAs 
attractive novel biomarkers [49]. The hypothesis 
is that miRNAs from damaged tissue such as 
necrotic tumor tissues are released into the blood 
serum which will facilitate its detection through 
a simple plasma‑based test. Of the four miR‑
NAs (miR‑21, miR‑221, miR‑222 and miR‑224) 
(Table 1) that are consistently upregulated in HCC, 
miR‑224 seems the most specific to HCC [50], 
although it was also found to be upregulated 
in thyroid tumors in one study [51]. As liver tis‑
sues are highly vascularised, miRNAs from liver 
damage would readily be released in the blood 
circulation facilitating its detection in the blood 
serum. Indeed, a recent study which examined the 
serum miRNA from 15 patients with clinically 
diagnosed HCC, ten with liver cirhosis and ten 
age‑matched healthy individuals, revealed higher 
levels of miR‑224 in the blood sera of patients 
with HCC (87‑fold) or liver cirrhosis (14‑fold) 
than the normal healthy patients [52]. To further 
develop miR‑224 as a useful biomarker, a larger 
study with appropriate stratification according to 
liver conditions (e.g., healthy liver, liver hepatitis, 
liver cirrhosis and hepatocellular adenoma) as well 
as grades of HCC is warranted, so that the levels 
of serum miR‑224 under the various liver health 
conditions can be determined to facilitate rapid 
clinical interpretation.
Conclusion
In summary, miR‑224 is one of the most consist‑
ently upregulated miRNAs in HCC that poten‑
tially affects crucial cancer implicated cellular 
processes such as cell proliferation, apoptosis and 
cell migration, making it an attractive target for 
HCC therapy. Notably, the detection of higher 
levels of miR‑224 in the serum of HCC patients 
and the observationthat miR‑224 upregulation 
seems to correspond to different stages of liver dis‑
ease progression suggests that miR‑224 may repre‑
sent a novel biomarker for liver disease and HCC.
Future perspective
This article summarizes the facts, inferences 
and speculations of miR‑224 in hepatocellular 
carcinogenesis. To evaluate if miR‑224 is indeed 
a useful therapeutic target for HCC, further 
research in both in vitro and in vivo models is 
needed to fully understand miR‑224 and its many 
targets. The effective design of a therapeutic strat‑
egy targeting miR‑224 would require our under‑
standing of the exact mechanism for miR‑224 
upregulation. Nonetheless, miR‑224 may repre‑
sent a useful attractive biomarker for HCC/liver 
disease since it is detected at higher levels in the 
serum of HCC patients compared with normal 
individuals and its expression seems to corre‑
late with the health status of the liver. Further 
research with appropriate stratification examin‑
ing the serum of individuals at different stages of 
liver disease or HCC is required to validate this 
observation. We hope that this article can offer 
some perspective and stimulate new ideas in our 
quest to understand miR‑224 in HCC.
Executive summary
miR‑224 upregulation impacts on multiple cellular pathways 
  miR-224 is reported by multiple studies as one of the more consistently upregulated miRNAs in hepatocellular carcinoma (HCC).
  miR-224 increases cell proliferation, apoptosis, migration, invasion and anchorage independent growth.
Possible mechanisms for miR‑224 upregulation in HCC
  miR-224 was reported to be induced by Src and the TGF-b pathway.
  There is indirect evidence that suggests that miR-224 may be epigenetically regulated.
Potential therapeutic strategies to target miR‑224 in HCC
  miR-224 upregulation in HCC can potentially be targeted through liver-specific delivery of small oligonucleotide-based inhibitors via 
systemic administration.
  If miR-224 is epigenetically regulated, drugs that specifically interfere with epigenetic modification may be useful.
miR‑224 may represent a useful novel biomarker for HCC or liver disease 
  miR-224 expression seems to correlate with the health status of the liver. 
  miR-224 can be detected in the serum and its levels have been found to be higher in the serum of HCC patients when compared with 
normal individuals, suggesting that miR-224 has the potential to be a useful, novel, less invasive biomarker for HCC.
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